image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
9325823b6b77f31a00e62d87ac177be3833e9b3543932fa147db8a5050d7cd74.png | simple | <table><tr><td></td><td>Group I</td><td>Group II</td></tr><tr><td>Chemotherapy cycles</td><td>5 (3-6) *</td><td>5 (1-6) *</td></tr><tr><td>>4 cycles</td><td>14 (87%) *</td><td>12 (80%) *</td></tr><tr><td>EBRT dose</td><td>40 (40-66) *</td><td>40 (40-66) *</td></tr><tr><td>Dose to point A</td><td>33 (5-52) *</td><td>34 (0-58) *</td></tr><tr><td>No UV brachytherapy</td><td>3 (19%) *</td><td>6 (40%) *</td></tr><tr><td>Total dose to point A</td><td>75 (60-93) *</td><td>66 (40-98) *</td></tr></table> |
be71ad524941a03803252be8bb566ed039437774937f261df6fd5f4a34c827b4.png | complex | <table><tr><td rowspan="2">Characteristics</td><td colspan="2">Unstandardized Coefficients</td><td>Standardized Coefficients</td><td rowspan="2">t</td><td rowspan="2">Sig.</td></tr><tr><td>B</td><td>Std. Error</td><td>Beta</td></tr><tr><td>SBP</td><td>−0.003</td><td>0.003</td><td>−0.104</td><td>− 0.946</td><td>0.348</td></tr><tr><td>PP</td><td>0.002</td><td>0.005</td><td>0.064</td><td>0.414</td><td>0.680</td></tr><tr><td>FH</td><td>0.073</td><td>0.076</td><td>0.066</td><td>0.970</td><td>0.336</td></tr><tr><td>AS</td><td>−0.012</td><td>0.019</td><td>−0.105</td><td>−0.630</td><td>0.531</td></tr><tr><td>AD</td><td>−0.046</td><td>0.042</td><td>−0.210</td><td>−1.100</td><td>0.276</td></tr><tr><td>APV</td><td>−0.019</td><td>0.002</td><td>−0.659</td><td>−8.097</td><td>< 0.0001</td></tr></table> |
b511eae88b72ecc85ca4a817274eb00b46a4098fb06c94419e9b72c03d7a72d4.png | simple | <table><tr><td>Author</td><td>Year</td><td>Population</td><td>Sample size</td><td>Method</td><td>Cut-off</td><td>miRNA</td><td>Survival analysis</td><td>Source of HR</td><td>Follow-up (month)</td></tr><tr><td>Luo</td><td>2015</td><td>China</td><td>88</td><td>qRT-PCR</td><td>Median</td><td>miR-26b</td><td>OS, RFS</td><td>Reported</td><td>mean 74 (5.12-98.5)</td></tr><tr><td>Safari</td><td>2015</td><td>Iran</td><td>40</td><td>qRT-PCR</td><td>Median</td><td>miR-20a</td><td>OS</td><td>DE</td><td>100</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>miR-10a</td><td>OS</td><td>DE</td><td></td></tr><tr><td>Wang C</td><td>2015</td><td>China</td><td>138</td><td>qRT-PCR</td><td>Median</td><td>miR-335</td><td>OS, RFS</td><td>Reported, DE</td><td>Mean 71(23-117)</td></tr><tr><td>Wang Q</td><td>2015</td><td>China</td><td>114</td><td>qRT-PCR</td><td>Median</td><td>miR-145</td><td>OS</td><td>Reported</td><td>median 47(11-69)</td></tr><tr><td>He</td><td>2014</td><td>China</td><td>73</td><td>qRT-PCR</td><td>ROC curve</td><td>miR-107</td><td>OS, DFS</td><td>DE</td><td>median 68.4</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>miR-130a</td><td>OS, DFS</td><td>DE</td><td></td></tr><tr><td>Liang</td><td>2014</td><td>China</td><td>335</td><td>qRT-PCR</td><td>X-tile algorithm</td><td>miR-215</td><td>DFS</td><td>Reported</td><td>60</td></tr><tr><td>Ma</td><td>2014</td><td>China</td><td>60</td><td>qRT-PCR</td><td>ROC curve</td><td>miR-205</td><td>OS</td><td>Reported</td><td>60</td></tr><tr><td>Park</td><td>2014</td><td>Korea</td><td>45</td><td>qRT-PCR</td><td>2.5-fold</td><td>miR-363-3p</td><td>OS</td><td>Reported</td><td>60</td></tr><tr><td>Wang</td><td>2014</td><td>China</td><td>54</td><td>qRT-PCR</td><td>Median</td><td>miR-31</td><td>OS</td><td>Reported</td><td>60</td></tr><tr><td>Yang</td><td>2014</td><td>China</td><td>133</td><td>qRT-PCR</td><td>Median</td><td>miR-126</td><td>OS</td><td>Reported</td><td>60</td></tr><tr><td>Luo</td><td>2013</td><td>China</td><td>60</td><td>qRT-PCR</td><td>Mean</td><td>miR-497</td><td>OS, DFS</td><td>Reported, DE</td><td>60</td></tr><tr><td>Shen</td><td>2013</td><td>China</td><td>126</td><td>qRT-PCR</td><td>Median</td><td>miR-224</td><td>OS</td><td>DE</td><td>median 51.9</td></tr><tr><td>Huang</td><td>2012</td><td>China</td><td>44</td><td>qRT-PCR</td><td>Mean</td><td>miR-125b</td><td>OS</td><td>Reported</td><td>mean 23.6 (2-70)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>miR-100</td><td>OS</td><td>Reported</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>miR-143</td><td>OS</td><td>DE</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>miR-145</td><td>OS</td><td>DE</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>miR-199a-5p</td><td>OS</td><td>DE</td><td></td></tr></table> |
cf9816f10a0f10d0b4b22938b0700c67c172d27ab89291dc70fb4e4c5033c63f.png | simple | <table><tr><td><i>Variables</i></td><td><i>Group 1 n (%)</i></td><td><i>Group 2 n (%)</i></td><td><i>p</i></td></tr><tr><td>Men</td><td>30 (88.2)</td><td>16 (69.6)</td><td>0.09</td></tr><tr><td>Age</td><td>65.94 ± 6.67</td><td>65.78 ± 9.29</td><td>0.9</td></tr><tr><td>Previous MI</td><td>9 (26.5)</td><td>6 (26.0)</td><td>0.97</td></tr><tr><td>Unstable angina</td><td>3 (8.8)</td><td>1 (4.3)</td><td>0.64</td></tr><tr><td>Previous CVA</td><td>11 (32.3)</td><td>5 (21.7)</td><td>0.48</td></tr><tr><td>Stroke</td><td>4 (11.8)</td><td>1 (4.3)</td><td>0.63</td></tr><tr><td>Hypertension</td><td>29 (85.3)</td><td>18 (78.3)</td><td>0.50</td></tr><tr><td>Diabetes</td><td>17 (50)</td><td>12 (52.2)</td><td>0.87</td></tr><tr><td>Hyperlipidaemia</td><td>19 (55.9)</td><td>9 (39.1)</td><td>0.21</td></tr><tr><td>Renal failure</td><td>4 (11.8)</td><td>1 (4.3)</td><td>0.63</td></tr><tr><td>Smoking</td><td>27 (79.4)</td><td>14 (60.9)</td><td>0.12</td></tr><tr><td>PAD</td><td>13 (38.2)</td><td>7 (30.4)</td><td>0.54</td></tr></table> |
955a9a17c4acf83f7f0eacfbb9643f3a34d3663b8e619facee62acc5ae4fa635.png | simple | <table><tr><td> </td><td>Mean (±SD) nuclear gray level</td></tr><tr><td>Normal urothelium (NU), global</td><td>106±15</td></tr><tr><td>NU, superficial epithelial layer</td><td>104±15</td></tr><tr><td>NU, intermediate cell layers</td><td>106±15</td></tr><tr><td>NU, basal cell layer</td><td>108±14</td></tr><tr><td>Urothelial carcinoma (UC), global</td><td>100±15</td></tr><tr><td>UC, nuclei not adjacent to the stroma</td><td>101±15</td></tr><tr><td>UC, nuclei adjacent to the stroma</td><td>99±16</td></tr></table> |
09cbfa80f1318dd589bb9ee2b36a35a214c12b0694351103f8adfbb23f829d4c.png | simple | <table><tr><td>Study Authors</td><td>Best Model/Main Finding</td><td>Subsequent Criticisms</td></tr><tr><td>Hubbell (2001)</td><td>ZSM</td><td>Goodness of fit only determined by graphical observation.</td></tr><tr><td>McGill (2003)</td><td>ZSM does not fit the data better than the lognormal</td><td>Used simulations to fit the ZSM</td></tr><tr><td>Volkov et al. (2003)</td><td>Derived an analytical solution for the ZSM and found the ZSM provided the best fit</td><td>Analytical equations did not represent the full solution as they applied solely to the mean number of species in a given class (Etienne and Olff 2004)</td></tr><tr><td>Vallade and Houchmandzadeh (2003)</td><td>Published a full analytical solution for the ZSM</td><td>Equations were later determined to be flawed (i.e., they applied the mean number of species in a given class) and were corrected by Etienne and Alonso (2005)</td></tr><tr><td>Alonso and McKane (2004)</td><td>Developed a different analytic solution</td><td>Rigorous fitting of the ZSM required likelihood methods</td></tr><tr><td>Etienne and Olff (2004)</td><td>Found slightly better support for the lognormal using a Bayesian approach</td><td></td></tr><tr><td>Etienne (2005)</td><td>Published the correct analytical solution and sampling formula. Two forms of the likelihood equations exist: (a) Ewens’ (1972) sampling formula of neutral alleles is used in the case of no dispersal limitation and (b) Etienne's (2005) formula in cases of dispersal limitation</td><td></td></tr><tr><td>Etienne and Alonso (2005)</td><td>Unified two different approaches to arrive at the full analytical solution: the genealogical approach (Etienne 2005) and master equation-based approach (e.g., Alonso and McKane 2004)</td><td></td></tr><tr><td>McGill et al. (2006)</td><td>Compared nine goodness-of-fit measures with the BCI data and found that for eight out of the nine measures the lognormal outperformed the ZSM</td><td></td></tr><tr><td>Jabot and Chave (2011)</td><td>Built on Etienne's (2005) maximum likelihood framework to develop a more robust test of neutrality incorporating the SAD of Hubbell's SINM and Shannon's index. The SAD of the BCI 50-ha plot did not significantly differ from neutrality; however, the SADs of smaller scale subplots from within the BCI plot were significantly non-neutral</td><td></td></tr><tr><td>Rosindell and Cornell (2013)</td><td>(a) The gamma and negative binomial distributions provided a better fit than the ZSM (b) The SENM predicts SADs which are more realistic than those from the SINM</td><td></td></tr></table> |
a8f3a470e456d15b1934bf777b49571b4ec3252ea1a635178311f730d8909409.png | complex | <table><tr><td>Function units</td><td>Known or possible role</td><td>References</td></tr><tr><td colspan="3">ULK1 complex</td></tr><tr><td>ULK1</td><td>Binds with ATG13, ATG101, and FIP200</td><td>[19, 20, 163]</td></tr><tr><td>ATG13</td><td>Bridges the interaction of ULK1 and FIP200; is required for the localization and stability of ULK1 and stimulates the kinase activity of ULK1</td><td>[164]</td></tr><tr><td>ATG101</td><td>Interacts with ULK1 in an ATG13-dependent manner; regulates the stability and basal phosphorylation of ATG13 and ULK1</td><td>[24, 25, 164]</td></tr><tr><td>FIP200</td><td>Scaffold protein, binds with ULK1 and ATG13; is required for proper localization, stability and kinase activity of ULK1</td><td>[19, 20, 29, 164, 165]</td></tr><tr><td colspan="3">PI3K complex III</td></tr><tr><td>Beclin 1</td><td>BH3-only protein; interacts with Bcl-2</td><td>[28, 29, 39]</td></tr><tr><td>ATG14L</td><td>Enhances Vps34 lipid kinase activity, upregulates autophagy</td><td>[28, 30]</td></tr><tr><td>hVps15</td><td>Ser/Thr protein kinase, is required for Vps34 membrane association</td><td>[166]</td></tr><tr><td>Vps34</td><td>PI3K, forms Phosphatidylinositol 3-phosphate (PI3P) for autophagy</td><td>[167, 168]</td></tr><tr><td colspan="3">ATG12 conjugation system</td></tr><tr><td>ATG5</td><td>Forms isopeptide bond with ATG12</td><td>[31, 169]</td></tr><tr><td>ATG12</td><td>Ubiquitin-like protein; forms isopeptide bond with Atg5 conjugation</td><td>[31, 169]</td></tr><tr><td>ATG7</td><td>E1-like activating enzyme, catalyzes ATG12–ATG5 and LC3-II-PE conjugation</td><td>[31]</td></tr><tr><td>ATG10</td><td>E2-like activating enzyme; catalyzes ATG12–ATG5</td><td>[31]</td></tr><tr><td>ATG16L1</td><td>Conjugates to ATG12-ATG5 complex</td><td>[170]</td></tr><tr><td colspan="3">LC3 conjugation system</td></tr><tr><td>LC3</td><td>Ubiquitin-like protein, conjugates to PE, an important marker of autophagy</td><td>[34, 171]</td></tr><tr><td>ATG4</td><td>Cysteine protease, regulates the level of free LC3-I</td><td>[31, 34]</td></tr><tr><td>ATG7</td><td>E1-like activating enzyme, catalyzes ATG12–ATG5 and LC3-II-PE conjugation</td><td>[31, 34]</td></tr><tr><td>ATG3</td><td>E2-like conjugating enzyme analog, catalyzes LC3-II-PE conjugation</td><td>[31, 34]</td></tr><tr><td colspan="3">Other essential proteins</td></tr><tr><td>WIPI-2</td><td>Mammalian homolog of yeast Atg18, a PI3P-binding protein, facilitates LC3 lipidation</td><td>[35, 172]</td></tr><tr><td>ATG2</td><td>Probably plays an essential role at late step of autophagosome formation</td><td>[29, 36]</td></tr><tr><td>ATG9</td><td>The only known transmembrane protein, may contribute to membrane recruitment</td><td>[37]</td></tr></table> |
76c213ed40563839fb96b14228b7a5c6a8f425fc6e81e136dc07996cada8090b.png | simple | <table><tr><td>Compound code</td><td>SiHa</td><td>B16F10</td><td>K562</td><td>Chang</td></tr><tr><td>1T</td><td>7.17 ± 0.3</td><td>5.16 ± 0.5</td><td>> 10.00</td><td>7.91 ± 0.4</td></tr><tr><td>2T</td><td>7.14 ± 0.5</td><td>7.63 ± 0.4</td><td>> 10.00</td><td>> 10.00</td></tr><tr><td>3T</td><td>> 10.00</td><td>> 10.00</td><td>> 10.00</td><td>> 10.00</td></tr><tr><td>4T</td><td>8.12 ± 0.4</td><td>> 10.00</td><td>> 10.00</td><td>> 10.00</td></tr><tr><td>5T</td><td>7.79 ± 0.5</td><td>7.14 ± 0.6</td><td>> 10.00</td><td>> 10.00</td></tr><tr><td>6T</td><td>4.79 ± 0.6</td><td>5.79 ± 0.4</td><td>> 10.00</td><td>> 10.00</td></tr><tr><td>7T</td><td>> 10.00</td><td>> 10.00</td><td>> 10.00</td><td>> 10.00</td></tr><tr><td>1C</td><td>4.21 ± 0.4</td><td>3.33 ± 0.3</td><td>> 10.00</td><td>6.21 ± 0.5</td></tr><tr><td>2C</td><td>6.20 ± 0.6</td><td>1.71 ± 0.3</td><td>> 10.00</td><td>8.03 ± 0.5</td></tr><tr><td>3C</td><td>5.10 ± 0.4</td><td>3.91 ± 0.3</td><td>6.14 ± 0.4</td><td>9.32 ± 0.6</td></tr><tr><td>4C</td><td>7.28 ± 0.5</td><td>5.91 ± 0.6</td><td>> 10.00</td><td>7.37 ± 0.4</td></tr><tr><td>5C</td><td>4.03 ± 0.5</td><td>2.09 ± 0.1</td><td>> 10.00</td><td>7.01 ± 0.1</td></tr><tr><td>6C</td><td>2.34 ± 0.2</td><td>0.70 ± 0.1</td><td>> 10.00</td><td>6.89 ± 0.3</td></tr><tr><td>7C</td><td>8.43 ± 0.3</td><td>> 10.00</td><td>6.86 ± 0.4</td><td>5.49 ± 0.4</td></tr><tr><td>Colchicine</td><td>2.5 ± 0.5</td><td>4.1 ± 0.1</td><td>1.3 ± 0.1</td><td>0.52 ± 0.1</td></tr><tr><td>Paclitaxel</td><td>364 ± 310*</td><td>9.57 ± 0.2</td><td>4.80 ± 0.4*</td><td>0.068 ± 0.02</td></tr><tr><td>Vinblastine</td><td>10.88 ± 0.8</td><td>55 ± 28*</td><td>0.006 ± 0.0</td><td>ND**</td></tr></table> |
eda4b2dfdbc60aa4126916705eb1b46251dc33ecba37378118a70853066acba9.png | complex | <table><tr><td rowspan="2">Factors of association<sup>a</sup></td><td colspan="3">All (n = 3458)</td><td colspan="3">Uganda (n = 491)</td></tr><tr><td>Adjusted OR</td><td>95 % CI</td><td>P value</td><td>Adjusted OR</td><td>95 % CI</td><td>P value</td></tr><tr><td>UC allocation by sleeping place (vs by people)</td><td>1.63</td><td>1.07–2.48</td><td>0.025</td><td>1.60</td><td>1.02–2.52</td><td>0.042</td></tr><tr><td colspan="7">Wealth quintile</td></tr><tr><td> Lowest</td><td>1.00</td><td></td><td rowspan="5"><0.001</td><td>1.00</td><td></td><td rowspan="5">0.172</td></tr><tr><td> Second</td><td>1.09</td><td>0.78–1.53</td><td>1.21</td><td>0.59–2.46</td></tr><tr><td> Middle</td><td>1.39</td><td>1.01–1.91</td><td>1.40</td><td>0.72–2.71</td></tr><tr><td> Fourth</td><td>1.66</td><td>1.19–2.31</td><td>1.48</td><td>0.76–2.91</td></tr><tr><td> Highest</td><td>1.91</td><td>1.37–2.64</td><td>2.79</td><td>1.20–6.53</td></tr><tr><td>Household of four people or more (vs three or less)</td><td>0.25</td><td>0.18–0.35</td><td><0.001</td><td>0.42</td><td>0.24–0.76</td><td>0.005</td></tr><tr><td>Household with any child under five (vs no child under five)</td><td>0.37</td><td>0.30–0.47</td><td><0.001</td><td>0.20</td><td>0.10–0.38</td><td><0.001</td></tr></table> |
d60f4ac02643a110bd4b1fac866e3136c338653990d4423d74081946f4aa8e55.png | complex | <table><tr><td rowspan="2" colspan="2">Stratified characteristics</td><td colspan="3">Cases [<i>n</i>(%)]</td><td colspan="4">Controls [<i>n</i>(%)]</td><td rowspan="2">AA</td><td colspan="2">AG</td><td colspan="2">GG</td></tr><tr><td>AA</td><td>AG</td><td>GG</td><td colspan="2">AA</td><td>AG</td><td>GG</td><td><i>p*</i></td><td><i>OR</i> (95%<i>CI</i>)*</td><td><i>P*</i></td><td><i>OR</i> (95%C/)*</td></tr><tr><td rowspan="2">Sex</td><td>male</td><td>393(73.6)</td><td>131(24.5)</td><td>10(1.9)</td><td colspan="2">338(65.5)</td><td>155(30.0)</td><td>23(4.5)</td><td>1.00</td><td>0.045</td><td>0.75(0.57-0.99)</td><td>0.011</td><td>0.36(0.16-0.80)</td></tr><tr><td>female</td><td>411(72.6)</td><td>144(25.4)</td><td>11(1.9)</td><td colspan="2">437(74.1)</td><td>138(23.4)</td><td>15(2.5)</td><td>1.00</td><td>0.590</td><td>1.08(0.81-1.44)</td><td>0.393</td><td>0.70(0.30-1.60)</td></tr><tr><td rowspan="2">Age(yr)</td><td>≤50</td><td>209(69.9)</td><td>86(28.8)</td><td>4(1.3)</td><td colspan="2">190(68.1)</td><td>82(29.4)</td><td>7(2.5)</td><td>1.00</td><td>0.645</td><td>0.91(0.62-1.34)</td><td>0.348</td><td>0.54(0.15-1.97)</td></tr><tr><td>>50</td><td>571(74.3)</td><td>181(23.5)</td><td>17(2.2)</td><td colspan="2">584(70.8)</td><td>210(25.5)</td><td>31(3.8)</td><td>1.00</td><td>0.341</td><td>0.89(0.71-1.13)</td><td>0.024</td><td>0.48(0.26-0.91)</td></tr><tr><td rowspan="3">BMI</td><td>normal</td><td>334(76.3)</td><td>97(22.1)</td><td>7(1.6)</td><td colspan="2">394(70.5)</td><td>146(26.1)</td><td>19(3.4)</td><td>1.00</td><td>0.070</td><td>0.76(0.56-1.02)</td><td>0.052</td><td>0.41(0.17-1.01)</td></tr><tr><td>overweight</td><td>325(70.8)</td><td>126(27.5)</td><td>8(1.7)</td><td colspan="2">285(69.7)</td><td>112(27.4)</td><td>12(2.9)</td><td>1.00</td><td>0.956</td><td>0.99(0.73-1.34)</td><td>0.372</td><td>0.66(0.26-1.65)</td></tr><tr><td>obesity</td><td>119(70.0)</td><td>47(27.6)</td><td>4(2.4)</td><td colspan="2">82(71.9)</td><td>25(21.9)</td><td>7(6.1)</td><td>1.00</td><td>0.566</td><td>1.19(0.66-2.13)</td><td>0.184</td><td>0.42(0.12-1.51)</td></tr></table> |
b53ca05ea83d03a4cc2343dc525cd20a8222cdec5a02441b862a86bce68f8648.png | simple | <table><tr><td>Set</td><td>Description</td><td>Min</td><td>Max</td><td>Mean</td><td>Median</td><td>St.dev.</td></tr><tr><td>1</td><td>Training Set (32 articles)</td><td>4</td><td>147</td><td>19</td><td>14</td><td>24</td></tr><tr><td>2</td><td>Test Set (50 articles – gold standard)</td><td>0</td><td>375</td><td>33</td><td>19</td><td>63</td></tr><tr><td>3</td><td>Test Set (507 articles – silver standard)</td><td>0</td><td>375</td><td>18</td><td>12</td><td>27</td></tr></table> |
6d0dacb451eb4eb04a56ca13b597b2c13d999df5b77d9e34a284196884e5a3bb.png | complex | <table><tr><td> </td><td>Intervention arm<i>n/N</i>(%, 95% CI)</td><td>Standard invitation arm<i>n/N</i>(%, 95% CI)</td></tr><tr><td colspan="3">Possible unintended consequences</td></tr><tr><td>Parents made an informed decision</td><td>28/54 (51.9, 26.7–76.1)</td><td>9/33 (27.3, 7.6–63.2)</td></tr><tr><td colspan="3">Acceptability</td></tr><tr><td>Incentives are a good idea</td><td>42/59 (71.2, 47.7–87.0)</td><td>25/35 (71.4, 45.0–88.4)</td></tr><tr><td colspan="3">Possible mechanisms of action</td></tr><tr><td>Very/quite motivated to return the form</td><td>105/200 (52.5, 35.0–69.4)</td><td>101/191 (52.9, 45.7–59.9)</td></tr><tr><td>Very easy/easy to remember to return the form</td><td>154/201 (76.6, 43.5–93.3)</td><td>133/193 (68.9, 63.6–73.8)</td></tr><tr><td>Returning the form is very/quite important</td><td>125/203 (61.6, 39.7–79.6)</td><td>131/194 (67.5, 59.1–74.9)</td></tr><tr><td>Gave consent form to parents the same day they received it from school</td><td>141/202 (69.8, 47.6–85.5)</td><td>111/193 (57.5, 52.3–62.5)</td></tr></table> |
e50fe4837121088489b3e196b989fcde01c48fbd724bc871ac66e1d52dbbfb51.png | simple | <table><tr><td>Cluster</td><td>n</td><td>%</td><td>Cluster group<sup>1</sup></td><td>Pulsotype</td><td>n</td><td>%</td><td>Pulsotype group<sup>1</sup></td></tr><tr><td>C1</td><td>6</td><td>3.2</td><td>Less common</td><td>C1a</td><td>3</td><td>1.6</td><td>Less common</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C1b</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C1c</td><td>2</td><td>1.0</td><td>Rare</td></tr><tr><td>C2</td><td>1</td><td>0.5</td><td>Rare</td><td>C2a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C3</td><td>18</td><td>9.7</td><td>Less common</td><td>C3a</td><td>17</td><td>9.2</td><td>Less common</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C3b</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C4</td><td>1</td><td>0.5</td><td>Rare</td><td>C4a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C5</td><td>1</td><td>0.5</td><td>Rare</td><td>C5a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C6</td><td>1</td><td>0.5</td><td>Rare</td><td>C6a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C7</td><td>1</td><td>0.5</td><td>Rare</td><td>C7a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C8</td><td>2</td><td>1.0</td><td>Rare</td><td>C8a</td><td>2</td><td>1.0</td><td>Rare</td></tr><tr><td>C9</td><td>1</td><td>0.5</td><td>Rare</td><td>C9a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C10</td><td>5</td><td>2.7</td><td>Less common</td><td>C10a</td><td>3</td><td>1.6</td><td>Less common</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C10b</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C10c</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C11</td><td>82</td><td>44.3</td><td>Common</td><td>C11a</td><td>79</td><td>42.7</td><td>Common</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C11b</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C11c</td><td>2</td><td>1.0</td><td>Rare</td></tr><tr><td>C12</td><td>1</td><td>0.5</td><td>Rare</td><td>C12a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C13</td><td>1</td><td>0.5</td><td>Rare</td><td>C13a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C14</td><td>1</td><td>0.5</td><td>Rare</td><td>C14a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C15</td><td>54</td><td>29.2</td><td>Common</td><td>C15a</td><td>8</td><td>4.3</td><td>Less common</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C15b</td><td>40</td><td>21.6</td><td>Common</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C15c</td><td>6</td><td>3.2</td><td>Less common</td></tr><tr><td>C16</td><td>1</td><td>0.5</td><td>Rare</td><td>C16a</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C17</td><td>7</td><td>3.8</td><td>Less common</td><td>C17a</td><td>3</td><td>1.6</td><td>Less common</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C17b</td><td>3</td><td>1.6</td><td>Less common</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>C17c</td><td>1</td><td>0.5</td><td>Rare</td></tr><tr><td>C18</td><td>1</td><td>0.5</td><td>Rare</td><td>C18a</td><td>1</td><td>0.5</td><td>Rare</td></tr></table> |
cc7ca857d0102b7ccbeed0d4a49174a671ac5fdeb86c059b2c24bd34ffcd966e.png | simple | <table><tr><td>Respiratory rate</td><td>Group I (Magnesium) mean ± SD</td><td>Group II (Control) mean ± SD</td><td><i>P</i>-value</td></tr><tr><td>After induction</td><td>23.8 ± 0.6</td><td>30.2 ± 1.3</td><td>0.001*</td></tr><tr><td>10 min.</td><td>23.8 ± 0.6</td><td>28.3 ± 1.3</td><td>0.001*</td></tr><tr><td>20 min.</td><td>24.2 ± 0.7</td><td>26.3 ± 1.0</td><td>0.002*</td></tr><tr><td>30 min.</td><td>23.3 ± 0.7</td><td>25.4 ± 1.0</td><td>0.002*</td></tr><tr><td>40 min.</td><td>22.4 ± 0.5</td><td>25.2 ± 1.3</td><td>0.012*</td></tr><tr><td>50 min.</td><td>22.5 ± 0.8</td><td>25.1 ± 1.3</td><td>0.054*</td></tr><tr><td>60 min.</td><td>22.5 ± 0.8</td><td>25.2 ± 1.3</td><td>0.034*</td></tr><tr><td>70 min.</td><td>24.5 ± 0.9</td><td>25.1 ± 1.5</td><td>0.280</td></tr><tr><td>80 min.</td><td>24.7 ± 1.0</td><td>24.8 ± 1.4</td><td>0.897</td></tr></table> |
ae93c7253fdea776b6480aeee8ddede36b22e2649108f10f1a9dea5f248743a5.png | simple | <table><tr><td>Elements</td><td>GP (genome proportion, %)</td></tr><tr><td>Retrotransposon</td><td>11.05</td></tr><tr><td> Copia</td><td>5.81</td></tr><tr><td> Gypsy</td><td>4.88</td></tr><tr><td> LINE/SINE</td><td>0.33</td></tr><tr><td> Unclassified LTR</td><td>0.03</td></tr><tr><td>Transposon</td><td>1.41</td></tr><tr><td> hAT</td><td>0.93</td></tr><tr><td> Mutator</td><td>0.27</td></tr><tr><td> DNA/CMC-EnSpm</td><td>0.10</td></tr><tr><td> Tc1-Mariner</td><td>0.11</td></tr><tr><td>rDNA</td><td>4.32</td></tr><tr><td>Satellite</td><td>12.93</td></tr><tr><td>Unclassified</td><td>1.02</td></tr><tr><td>Total</td><td>30.73</td></tr></table> |
3b03c2901e9a00e6c0a9b126293285ddf3d2906e264b56a0588feb91664835a9.png | complex | <table><tr><td rowspan="2">Characteristic</td><td colspan="2">Non-recurrent</td><td colspan="2">Metachronous metastasis</td><td rowspan="2">p-value<sup>1</sup></td></tr><tr><td>absolute</td><td><i>%</i></td><td>absolute</td><td><i>%</i></td></tr><tr><td>Total number</td><td>33</td><td> </td><td>12</td><td> </td><td> </td></tr><tr><td colspan="5">Age [years]</td><td>n.s.</td></tr><tr><td>Mean</td><td>65</td><td> </td><td>68</td><td> </td><td> </td></tr><tr><td>Median</td><td>67</td><td> </td><td>67</td><td> </td><td> </td></tr><tr><td colspan="5">Disease-free survival time [months]</td><td>0.000</td></tr><tr><td>Mean</td><td>78</td><td> </td><td>17</td><td> </td><td> </td></tr><tr><td>Median</td><td>77</td><td> </td><td>13</td><td> </td><td> </td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td><td> </td><td>n.s.</td></tr><tr><td>Female</td><td>14</td><td><i>42,4</i></td><td>8</td><td><i>66,7</i></td><td> </td></tr><tr><td>Male</td><td>19</td><td><i>57,6</i></td><td>4</td><td><i>33,3</i></td><td> </td></tr><tr><td colspan="5">UICC stage</td><td>n.s.</td></tr><tr><td>I</td><td>6</td><td><i>18,2</i></td><td>2</td><td><i>16,7</i></td><td> </td></tr><tr><td>II</td><td>18</td><td><i>54,5</i></td><td>8</td><td><i>66,7</i></td><td> </td></tr><tr><td>III</td><td>9</td><td><i>27,3</i></td><td>2</td><td><i>16,7</i></td><td> </td></tr><tr><td colspan="5">Location</td><td>n.s.</td></tr><tr><td>Colon</td><td>14</td><td><i>42,4</i></td><td>5</td><td><i>41,7</i></td><td> </td></tr><tr><td>Sigma</td><td>16</td><td><i>48,5</i></td><td>4</td><td><i>33,3</i></td><td> </td></tr><tr><td>Rectum</td><td>3</td><td><i>9,1</i></td><td>3</td><td><i>25</i></td><td> </td></tr></table> |
f8f470b8d043c2d1efbd0934e73dc9c808b680ddb12b2d61932154359665383c.png | simple | <table><tr><td></td><td>Cortical region</td></tr><tr><td>1</td><td>Banks of the superior temporal sulcus</td></tr><tr><td>2</td><td>Caudal anterior cingulate</td></tr><tr><td>3</td><td>Caudal middle frontal</td></tr><tr><td>4</td><td>Cuneus</td></tr><tr><td>5</td><td>Entorhinal</td></tr><tr><td>6</td><td>Frontal pole</td></tr><tr><td>7</td><td>Fusiform</td></tr><tr><td>8</td><td>Inferior parietal</td></tr><tr><td>9</td><td>Inferior temporal</td></tr><tr><td>10</td><td>Insula</td></tr><tr><td>11</td><td>Isthmus of the cingulate</td></tr><tr><td>12</td><td>Lateral occipital</td></tr><tr><td>13</td><td>Lateral orbitofrontal</td></tr><tr><td>14</td><td>Lingual</td></tr><tr><td>15</td><td>Medial orbitofrontal</td></tr><tr><td>16</td><td>Middle temporal</td></tr><tr><td>17</td><td>Parahippocampal</td></tr><tr><td>18</td><td>Paracentral</td></tr><tr><td>19</td><td><i>Pars opercularis</i></td></tr><tr><td>20</td><td><i>Pars orbitalis</i></td></tr><tr><td>21</td><td><i>Pars triangularis</i></td></tr><tr><td>22</td><td>Peri-calcarine</td></tr><tr><td>23</td><td>Postcentral</td></tr><tr><td>24</td><td>Posterior cingulate</td></tr><tr><td>25</td><td>Precentral</td></tr><tr><td>26</td><td>Precuneus</td></tr><tr><td>27</td><td>Rostral anterior cingulate</td></tr><tr><td>28</td><td>Rostral middle frontal</td></tr><tr><td>29</td><td>Superior frontal</td></tr><tr><td>30</td><td>Superior parietal</td></tr><tr><td>31</td><td>Superior temporal</td></tr><tr><td>32</td><td>Supra-marginal</td></tr><tr><td>33</td><td>Temporal pole</td></tr><tr><td>34</td><td>Transverse temporal</td></tr></table> |
8d1bd26cf951c3c0fc4d53cb529b0e98f356fb062c64cd402766e0fb20cf66a6.png | simple | <table><tr><td></td><td>Healthy weight</td><td>Increased weight</td></tr><tr><td>Persistent oligoarthritis</td><td>95 (90.5)</td><td>10 (9.5)</td></tr><tr><td>ERA</td><td>55 (68)</td><td>26 (32)</td></tr><tr><td>Poliarthritis RF (+)</td><td>46 (78)</td><td>13 (22)</td></tr><tr><td>Systemic</td><td>28 (90.5)</td><td>1 (9.5)</td></tr><tr><td>Undifferentiated</td><td>17 (81)</td><td>4 (19)</td></tr><tr><td>Psoriatic</td><td>16 (100)</td><td>0 (0)</td></tr><tr><td>Extended oligoarthritis</td><td>8 (89)</td><td>1 (11)</td></tr><tr><td>Poliarthritis RF (-)</td><td>4 (80)</td><td>1 (20)</td></tr></table> |
0dbb4fa02059ed85972ad7c7a67f6aa726822d082b692a244616f20ec31b0c52.png | complex | <table><tr><td>Function</td><td>Genes</td><td></td><td>Fold change</td></tr><tr><td rowspan="4">Intestinal peptides</td><td>GIP</td><td>Glucose inhibitory peptide</td><td>−1.72</td></tr><tr><td>GKN1</td><td>Gastrokine 1</td><td>−1.54</td></tr><tr><td>GKN2</td><td>Gastrokine 2</td><td>−1.51</td></tr><tr><td>VIP</td><td>Vasoactive intestinal polypeptide</td><td>1.30</td></tr><tr><td rowspan="8">Inflammation and oxidative stress</td><td>PTGS2</td><td>Prostaglandin-endoperoxide synthase – COX-2</td><td>1.20</td></tr><tr><td>DUSD1</td><td>Dual specificity phosphatase 1</td><td>1.37</td></tr><tr><td>S100A8</td><td>S100 calcium binding protein A8</td><td>1.59</td></tr><tr><td>S100A9</td><td>S100 calcium binding protein A9</td><td>1.51</td></tr><tr><td>IL1B</td><td>Interleukin 1 beta</td><td>1.21</td></tr><tr><td>GPX8</td><td>Glutathione peroxidase 8</td><td>1.21</td></tr><tr><td>FOS</td><td>Cellular oncogene c-Fos</td><td>1.55</td></tr><tr><td>JUN</td><td>Jun proto-oncogene</td><td>1.32</td></tr><tr><td rowspan="2">Transporters</td><td>SLC28A2</td><td>Sodium-coupled nucleoside transporter</td><td>−1.68</td></tr><tr><td>SLC2A3</td><td>Facilitated glucose transporter 3</td><td>1.25</td></tr><tr><td rowspan="5">Extracellular matrix</td><td>MUC5AC</td><td>Mucin 5 AC</td><td>−1.58</td></tr><tr><td>MUC2</td><td>Mucin 2</td><td>−1.32</td></tr><tr><td>MUC6</td><td>Mucin 6</td><td>1.21</td></tr><tr><td>MMP7</td><td>Metalloproteinase 7</td><td>1.27</td></tr><tr><td>VIL1</td><td>Villin 1</td><td>−1.22</td></tr><tr><td rowspan="6">Digestive functions</td><td>PGA5</td><td>Pepsinogen A</td><td>−1.97</td></tr><tr><td>LCT</td><td>Lactase</td><td>1.76</td></tr><tr><td>GLB1</td><td>β-galactosidase</td><td>−1.21</td></tr><tr><td>PNLIPRP2</td><td>Pancreatic lipase</td><td>1.30</td></tr><tr><td>PRSS1</td><td>Trypsin 1</td><td>1.24</td></tr><tr><td>ELA3A</td><td>Elastase</td><td>1.25</td></tr><tr><td rowspan="8">Immunity</td><td>GP2</td><td>Glycoprotein 2</td><td>1.38</td></tr><tr><td>HLA-A</td><td>Major histocompatibility complex class I A</td><td>2.63</td></tr><tr><td>HLA-C</td><td>Major histocompatibility complex class I C</td><td>−1.20</td></tr><tr><td>HLA-F</td><td>Major histocompatibility complex class I F</td><td>−1.28</td></tr><tr><td>HLA-DQA1</td><td>Major histocompatibility complex class II DQ alpha 1</td><td>1.38</td></tr><tr><td>HLA-DQB1</td><td>Major histocompatibility complex class II DQ beta 1</td><td>1.22</td></tr><tr><td>HLA-DRB1</td><td>Major histocompatibility complex class II DR beta 1</td><td>−1.35</td></tr><tr><td>HLA-DRB4</td><td>Major histocompatibility complex class II DR beta 4</td><td>1.39</td></tr><tr><td rowspan="3">Cholesterol homeostasis</td><td>LDLR</td><td>Low density lipoprotein receptor</td><td>1.30</td></tr><tr><td>APOD</td><td>Apolipoprotein D-III</td><td>1.20</td></tr><tr><td>APOA1</td><td>Apolipoprotein A-I</td><td>−1.37</td></tr></table> |
016a364daf9694349a8fd48831a90f749d1b448d5f0eca2dc9bd617b72bfc43d.png | complex | <table><tr><td rowspan="2" colspan="2"> </td><td colspan="2">Hospital plan for follow-up</td></tr><tr><td>General practitioner (n = 23)</td><td>Specialist health service (n = 66)</td></tr><tr><td rowspan="2">Hospital guidelines for follow-up</td><td>General practitioner (n = 11)</td><td>3</td><td>8</td></tr><tr><td>Specialist health service (n = 78)</td><td>20</td><td>58</td></tr></table> |
2ec57a24380e90e073a0e61ccf8b755f9f99ee9c696afe51804dbee11a8ef577.png | simple | <table><tr><td>Viral Systems</td><td>Copolymers</td><td>Genes</td><td>Targets</td><td>Administration</td><td>Observations</td><td>References</td></tr><tr><td>rAAV</td><td>Pluronic<sup>®</sup> F127</td><td>GM-CSF</td><td>solid tumors</td><td>in vivo intratumoral infusion (mouse)</td><td>higher efficiency by combining DC, local tumor irradiation and controlled supply of recombinant mGM-CSF with Pluronic<sup>®</sup></td><td>[77]</td></tr><tr><td></td><td>Pluronic<sup>®</sup> F68</td><td><i>lacZ</i></td><td>adipose tissue</td><td>in vivo inguinal (mouse)</td><td>increased transgene expression after 4 weeks</td><td>[78]</td></tr><tr><td></td><td>Pluronic<sup>®</sup> F127</td><td><i>lacZ</i></td><td>cartilage</td><td>in vitro hMSCs</td><td>controlled release of rAAV for high efficiencies over time and gene expression levels similar to those achieved by direct vector application</td><td>[80]</td></tr><tr><td></td><td>Pluronic<sup>®</sup> F68, Tetronic<sup>®</sup> 908</td><td>RFP, <i>lacZ</i>, and <i>SOX9</i></td><td>cartilage</td><td>in vitro hMSCs</td><td>encapsulation of rAAV in polymeric micelles for effective, durable, and safe modification of hMSCs; restoration of hMSC transduction in conditions of gene transfer inhibition; effective chondrogenesis</td><td>[79]</td></tr><tr><td></td><td>Pluronic<sup>®</sup> F68, Tetronic<sup>®</sup> 908</td><td><i>lacZ</i></td><td>cartilage</td><td>in vitro hOACs in situ human osteochondral model</td><td>micellar encapsulation for increased stability and bioactivity of rAAV; high levels of safe transgene expression in vitro and in experimental osteochondral defects in situ</td><td>[81]</td></tr><tr><td></td><td>Pluronic<sup>®</sup> F68, Tetronic<sup>®</sup> 908</td><td>TGF-β</td><td>cartilage</td><td>in vitro hOACs in situ human osteochondral model</td><td>increased levels of transgene expression compared with free vector treatment; high proteoglycan deposition and increased cell numbers in hOACs in vitro; high deposition of type-II collagen and reduced hypertrophy in osteochondral defects models in situ</td><td>[82]</td></tr><tr><td></td><td>Pluronic<sup>®</sup> F68, Tetronic<sup>®</sup> 908</td><td><i>lacZ</i></td><td>cartilage</td><td>in vitro hMSCs</td><td>high concentrations of rAAV; sustained levels of transgene expression over time</td><td>[92]</td></tr></table> |
abb84b20a5363129f363fd3103e4552de331181118568020bd747648a224b0a0.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Dispensation rate of generics</td><td rowspan="2"><i>P</i></td></tr><tr><td>Pre-adoption[% (drugs/total drugs)]</td><td>Post-adoption[% (drugs/total drugs)]</td></tr><tr><td>All drugs subjected to analysis</td><td>48.3 (447/926)</td><td>57.7 (604/1046)</td><td>< 0.001<sup>*</sup></td></tr><tr><td colspan="4">Drugs that have the same ingredients or different ingredients as the newly adopted generic drugs</td></tr><tr><td> Drugs with same ingredients</td><td>44.7 (135/302)</td><td>64.0 (217/339)</td><td>< 0.001<sup>*</sup></td></tr><tr><td> Drugs with different ingredients</td><td>50.0 (312/624)</td><td>54.7 (387/707)</td><td>0.094</td></tr><tr><td colspan="4">Priscribing facility</td></tr><tr><td> Gifu Municipal Hospital</td><td>47.5 (197/415)</td><td>66.5 (254/382)</td><td>< 0.001<sup>*</sup></td></tr><tr><td> Other hospitals/clinics</td><td>48.9 (250/511)</td><td>52.7 (350/664)</td><td>0.219</td></tr></table> |
1d1a3899d0bcccaedb7f9e201a558a015c01b89826561dca18ff8c79d07c3db8.png | complex | <table><tr><td>Descriptor</td><td colspan="3">P-values</td></tr><tr><td></td><td>Not ranked</td><td>30 Top-ranked</td><td>20 Top-ranked</td></tr><tr><td>C</td><td>1.2 e-1</td><td>5.8 e-1</td><td>5.6 e-1</td></tr><tr><td>D</td><td>5.1 e-3</td><td>2.6 e-1</td><td>2.4 e-1</td></tr><tr><td>Variance</td><td>9.0 e-2</td><td>3.4 e-1</td><td>5.7 e-1</td></tr></table> |
6c6b49749e59560aae0e3384be2f66c4931394f59f0edfc6dc9fcff258c8a0a5.png | simple | <table><tr><td>Migraine Triggers</td><td>N</td><td>%</td></tr><tr><td>Identified any Triggers</td><td>3416</td><td>82.9</td></tr><tr><td>Stress</td><td>2669</td><td>55.8</td></tr><tr><td>Environment (weather, etc...)</td><td>2870</td><td>60.0</td></tr><tr><td>Lack of Sleep</td><td>2484</td><td>51.9</td></tr><tr><td>Hormones/menstrual cycle</td><td>1792</td><td>37.4</td></tr><tr><td>Certain food drink</td><td>2138</td><td>44.7</td></tr><tr><td>Missing meals</td><td>1884</td><td>39.4</td></tr><tr><td>Certain smell</td><td>2046</td><td>42.7</td></tr><tr><td>Alcohol/drugs</td><td>1235</td><td>25.8</td></tr><tr><td>Physical Activity</td><td>1241</td><td>25.9</td></tr><tr><td>Sexual Activity</td><td>325</td><td>6.8</td></tr><tr><td>Other</td><td>739</td><td>15.4</td></tr><tr><td>Steps taken to avoid triggers</td><td>3033</td><td>63.4</td></tr></table> |
f8a7db21c7dc8394f828e2330eda1b4960b5981bcafe3306e2ae3c128f6da1a0.png | simple | <table><tr><td>Group</td><td>Cohesive fracture in tooth</td><td>Cohesive fracture in laminate</td><td>Adhesive</td><td>Mixed cohesive and adhesive</td></tr><tr><td>Control</td><td>5</td><td>1</td><td>0</td><td>5</td></tr><tr><td>SC</td><td>4</td><td>0</td><td>3</td><td>4</td></tr><tr><td>LC</td><td>1</td><td>0</td><td>5</td><td>4</td></tr><tr><td>Total</td><td>10</td><td>1</td><td>8</td><td>13</td></tr></table> |
f992cab970550d016d22f93f0d9c957163753309e6615bf128183bfa6eed929a.png | complex | <table><tr><td></td><td>Number</td><td>NLR</td><td>PNI</td></tr><tr><td>All cases</td><td>334</td><td>2.52 ± 2.06</td><td>51.03 ± 5.72</td></tr><tr><td colspan="4"> Age</td></tr><tr><td> ≦70</td><td>165</td><td>2.34 ± 1.91</td><td>52.20 ± 5.38*</td></tr><tr><td> >70</td><td>169</td><td>2.69 ± 2.18</td><td>49.59 ± 5.70*</td></tr><tr><td colspan="4">Smoking history</td></tr><tr><td> Never</td><td>122</td><td>2.27 ± 1.69</td><td>52.32 ± 5.00**<sup>,</sup> ***</td></tr><tr><td> Former</td><td>116</td><td>2.69 ± 2.41</td><td>49.70 ± 5.65**</td></tr><tr><td> Current</td><td>95</td><td>2.64 ± 1.99</td><td>50.97 ± 6.36***</td></tr><tr><td colspan="4">Histology</td></tr><tr><td> Adenocarcinoma</td><td>231</td><td>2.43 + 2.07</td><td>51.87 + 5.17****</td></tr><tr><td> Squamous cell carcinoma</td><td>69</td><td>2.80 + 2.30</td><td>48.22 + 6.49****</td></tr><tr><td> Large cell carcinoma</td><td>22</td><td>2.84 + 1.42</td><td>49.55 + 6.38</td></tr><tr><td> Adenosquamous carcinoma</td><td>6</td><td>2.01 + 0.61</td><td>52.49 + 2.39</td></tr><tr><td> Pleomorphic carcinoma</td><td>6</td><td>1.90 + 0.93</td><td>55.07 + 6.92</td></tr><tr><td colspan="4">Tumor differentiation</td></tr><tr><td> Well</td><td>118</td><td>2.39 + 2.12</td><td>51.82 + 4.70</td></tr><tr><td> Moderate</td><td>115</td><td>2.55 + 2.29</td><td>50.96 + 6.12</td></tr><tr><td> Poor</td><td>101</td><td>2.59 + 1.70</td><td>50.23 + 6.30</td></tr><tr><td colspan="4">Pathological stage</td></tr><tr><td> IA</td><td>144</td><td>2.40 + 2.13</td><td>51.74 + 5.33</td></tr><tr><td> IB</td><td>95</td><td>2.54 + 1.68</td><td>50.30 + 6.00</td></tr><tr><td> IIA+IIB</td><td>55</td><td>2.60 + 2.21</td><td>50.30 + 5.50</td></tr><tr><td> IIIA+IIIB</td><td>40</td><td>2.75 + 2.37</td><td>51.18 + 6.58</td></tr></table> |
20ef65b3b6feb5005d975a47ee70db392894106a57bc7c8170747af6d0fa5fbe.png | simple | <table><tr><td>PAMAM dendrimer generation (G)</td><td>Terminal amines (#)</td><td>Naked dendrimer molecular weight (kDa)</td><td>Gd-G5-doxorubicin dendrimer molecular weight (kDa)</td><td>Gd-DTPA conjugation (%)</td><td>Doxorubicin conjugation (%)</td><td>Molar relaxivity (mM<sup>-1</sup>s<sup>-1</sup>)</td></tr><tr><td>G5</td><td>128</td><td>29<sup>#</sup></td><td>85<sup>‡</sup></td><td>48.1</td><td>7.8</td><td>10.1<sup>&</sup></td></tr></table> |
00f05c068efae94b3a172e7462485e188f9a40fc7d8705002762340dbb2a94d4.png | complex | <table><tr><td rowspan="2">Temperature E (°C)</td><td rowspan="2">Dry weight of mycelial mat (mg/flask)</td><td rowspan="2">Protein content (mg/ml)</td><td colspan="3">Cellulase</td></tr><tr><td><sup>a</sup>FPase (FPU/ml)</td><td><sup>b</sup>CMCase (U/ml)</td><td><sup>c</sup>Β-glucosidase (U/ml)</td></tr><tr><td>25 °C</td><td>293</td><td>1.02</td><td>-nd-</td><td>4.56</td><td>0.62</td></tr><tr><td>30 °C</td><td>457</td><td>2.12</td><td>2.03</td><td>9.83</td><td>1.04</td></tr><tr><td>37 °C</td><td>457</td><td>2.12</td><td>1.62</td><td>6.24</td><td>0.99</td></tr></table> |
0c57c514d84f971261c621baca6d3b2d4b50a96c12045ffbaf39a751b2424e6c.png | complex | <table><tr><td>Group</td><td>Method</td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>False positives (%)</td><td>False negatives (%)</td></tr><tr><td rowspan="4"><i>Classical</i></td><td>Fisher</td><td>59.18</td><td>88.64</td><td>5.89</td><td>40.82</td></tr><tr><td>Sidak</td><td>18.37</td><td>97.73</td><td>0.11</td><td>81.63</td></tr><tr><td>Simes</td><td>46.94</td><td>97.73</td><td>1.33</td><td>53.06</td></tr><tr><td>FDR</td><td>24.49</td><td>97.73</td><td>0.13</td><td>75.51</td></tr><tr><td rowspan="5"><i>Updated Classical</i></td><td>TPM</td><td>63.04</td><td>92.86</td><td>4.93</td><td>36.96</td></tr><tr><td>GATES</td><td>24.49</td><td>98.00</td><td>0.17</td><td>75.51</td></tr><tr><td>WGATES</td><td>26.53</td><td>98.00</td><td>0.16</td><td>73.47</td></tr><tr><td>HYST</td><td>24.49</td><td>98.00</td><td>0.16</td><td>75.51</td></tr><tr><td>WHYST</td><td>24.49</td><td>98.00</td><td>0.16</td><td>75.51</td></tr><tr><td rowspan="2"><i>Novel</i></td><td>VEGAS</td><td>20.41</td><td>100.0</td><td>0.16</td><td>79.59</td></tr><tr><td>VEGAS [10%]</td><td>28.57</td><td>98.00</td><td>0.40</td><td>71.43</td></tr></table> |
38540e6f3bdda226803e67de5ebafb047f67dcb6d534c0378aa93934ef4c280a.png | complex | <table><tr><td></td><td colspan="3">2013–2014 Change</td><td colspan="3">2014–2015 Change</td></tr><tr><td>Runs Per Game</td><td>5.8</td><td>8.6</td><td>48%</td><td>8.6</td><td>9.4</td><td>9%</td></tr><tr><td>Batting Average</td><td>0.286</td><td>0.326</td><td>14%</td><td>0.326</td><td>0.324</td><td><1%</td></tr><tr><td>On-base Pct.</td><td>0.372</td><td>0.407</td><td>9%</td><td>0.407</td><td>0.419</td><td>3%</td></tr><tr><td>Slugging Pct.</td><td>0.390</td><td>0.468</td><td>20%</td><td>0.468</td><td>0.519</td><td>11%</td></tr><tr><td>Home Runs</td><td>11</td><td>25</td><td>127%</td><td>25</td><td>39</td><td>56%</td></tr><tr><td>Base-on-Balls</td><td>108</td><td>140</td><td>30%</td><td>140</td><td>171</td><td>22%</td></tr><tr><td>Strikeouts (K)</td><td>217</td><td>182</td><td>16%</td><td>182</td><td>219</td><td>(20%)</td></tr><tr><td>BB/K Ratio</td><td>0.50</td><td>0.77</td><td>54%</td><td>0.77</td><td>0.78</td><td>1%</td></tr></table> |
60ae1cfe7703b3b26f087433a8a403310d5235deca8351c30ba2c2b17f311ff5.png | simple | <table><tr><td> </td><td>Lean group</td><td>Obese group</td><td>Obese GDM group</td><td>P-value<sup>1</sup></td><td>Adjusted p-value<sup>2</sup></td></tr><tr><td>Weight [g]</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Birth</td><td>3,449 ± 332 [15]</td><td>3,651 ± 285 [13]</td><td>3,617 ± 333 [16]</td><td>0.201</td><td>0.169</td></tr><tr><td>Week-6</td><td>4,701 ± 330 [15]</td><td>4,963 ± 635 [13]</td><td>5,285 ± 517 [12]</td><td>0.017<sup>b</sup></td><td>0.170</td></tr><tr><td>Month-4</td><td>6,468 ± 522 [15]</td><td>6,929 ± 829 [11]</td><td>7,066 ± 732 [13]</td><td>0.071</td><td>0.211</td></tr><tr><td>Year-1</td><td>9,786 ± 915 [15]</td><td>10,356 ± 1273 [12]</td><td>10,392 ± 1212 [14]</td><td>0.286</td><td>0.549</td></tr><tr><td>Weight gain [g]</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Δ Week-6 - birth</td><td>1,265 (1,095-1,480) [15]</td><td>1,480 (775–1,690) [13]</td><td>1,550 (1,361-1,892) [12]</td><td>0.017<sup>b</sup></td><td>0.394</td></tr><tr><td>Δ Month-4 - week-6</td><td>1,734 (1,390-2,100) [15]</td><td>2,070 (1,840-2,300) [11]</td><td>1,848 (1,460-2,100) [11]</td><td>0.112</td><td>0.042<sup>a</sup></td></tr><tr><td>Δ Year-1 - month-4</td><td>3,318 ± 760 [15]</td><td>3,228 ± 801 [11]</td><td>3,329 ± 666 [13]</td><td>0.936</td><td>0.937</td></tr><tr><td>Δ Year-1 - birth</td><td>6,337 ± 996 [15]</td><td>6,665 ± 1,220 [12]</td><td>6,765 ± 1,102 [14]</td><td>0.554</td><td>0.722</td></tr><tr><td>Length [cm]</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Birth</td><td>51.8 ± 1.5 [15]</td><td>52.5 ± 1.4 [13]</td><td>52.3 ± 1.5 [16]</td><td>0.299</td><td>0.264</td></tr><tr><td>Week-6</td><td>55.6 ± 0.9 [15]</td><td>56.0 ± 1.8 [13]</td><td>56.4 ± 1.4 [12]</td><td>0.360</td><td>0.738</td></tr><tr><td>Month-4</td><td>63.3 ± 1.2 [15]</td><td>64.4 ± 2.0 [11]</td><td>63.7 ± 1.4 [13]</td><td>0.226</td><td>0.177</td></tr><tr><td>Year-1</td><td>76.5 ± 2.3 [15]</td><td>77.5 ± 2.6 [12]</td><td>76.7 ± 2.7 [14]</td><td>0.551</td><td>0.666</td></tr><tr><td>Ponderal index [g/cm<sup><i>3</i></sup>]</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Birth</td><td>6.65 ± 0.54 [15]</td><td>6.95 ± 0.48 [13]</td><td>6.81 ± 0.51 [16]</td><td>0.291</td><td>0.287</td></tr><tr><td>Week-6</td><td>8.45 ± 0.55 [15]</td><td>8.86 ± 1.03 [13]</td><td>9.36 ± 0.75 [12]</td><td>0.018<sup>b</sup></td><td>0.176</td></tr><tr><td>Month-4</td><td>10.21 ± 0.81 [15]</td><td>10.74 ± 1.06 [11]</td><td>11.04 ± 0.97 [13]</td><td>0.073</td><td>0.272</td></tr><tr><td>Year-1</td><td>12.80 ± 1.04 [15]</td><td>13.34 ± 1.38 [12]</td><td>13.52 ± 1.30 [14]</td><td>0.262</td><td>0.616</td></tr><tr><td>Head circumference [cm]</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Birth</td><td>34.0 (34.0-35.5) [15]</td><td>35.0 (34.5-36.5) [13]</td><td>35.5(34.0-36.0) [16]</td><td>0.072</td><td>0.410</td></tr><tr><td>Week-6</td><td>37.5 (37.0-38.8) [15]</td><td>38.3 (37.6-39.7) [13]</td><td>38.9 (37.7-40.0) [12]</td><td>0.023<sup>b</sup></td><td>0.096</td></tr><tr><td>Month-4</td><td>41.1 ± 1.2 [15]</td><td>42.1 ± 1.7 [11]</td><td>42.0 ± 1.3 [13]</td><td>0.132</td><td>0.184</td></tr><tr><td>Year-1</td><td>45.6 ± 1.4 [15]</td><td>47.0 ± 1.6 [12]</td><td>47.1 ± 1.7 [14]</td><td>0.072</td><td>0.105</td></tr><tr><td>Waist circumference [cm]</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Year-1</td><td>45.1 ± 2.4 [15]</td><td>45.6 ± 4.0 [12]</td><td>45.7 ± 3.0 [14]</td><td>0.859</td><td>0.897</td></tr></table> |
77a532df3cad4f730778fa6fc880b9a678ed208271397d3310c0040ffbb7e848.png | simple | <table><tr><td>Age MTfer</td><td>Mean age</td><td>Number</td></tr><tr><td>Posetive</td><td>50.75</td><td>4</td></tr><tr><td>Negative</td><td>40.60</td><td>42</td></tr><tr><td>Total</td><td>41.48</td><td>46</td></tr></table> |
b160c9b2cb2481f60d3caa55cffad960563b3619764dc8d1d2af11b352a7a990.png | simple | <table><tr><td>Health centre</td><td># fulltime professionals in labour ward</td><td>Midwives</td><td>Obstetric bed</td><td>Delivery couch</td><td># deliveries in the last month</td></tr><tr><td>Woreda 7</td><td>6</td><td>6</td><td>4</td><td>2</td><td>40</td></tr><tr><td>Bole 17</td><td>10</td><td>8</td><td>11</td><td>2</td><td>68</td></tr><tr><td>Woreda 9,NSLSC</td><td>5</td><td>3</td><td>10</td><td>1</td><td>52</td></tr><tr><td>Saris</td><td>8</td><td>3</td><td>8</td><td>4</td><td>53</td></tr><tr><td>Teklehaymanot</td><td>6</td><td>6</td><td>4</td><td>2</td><td>25</td></tr><tr><td>Kebena</td><td>6</td><td>6</td><td>5</td><td>2</td><td>18</td></tr><tr><td>Meshualekiya</td><td>5</td><td>5</td><td>6</td><td>2</td><td>27</td></tr><tr><td>Shiromeda</td><td>5</td><td>5</td><td>8</td><td>2</td><td>33</td></tr><tr><td>Entoto 1</td><td>9</td><td>4</td><td>8</td><td>3</td><td>67</td></tr><tr><td>Woreda 9, KKSC</td><td>12</td><td>6</td><td>7</td><td>2</td><td>122</td></tr><tr><td>Total</td><td>72</td><td>52</td><td>71</td><td>22</td><td>505</td></tr></table> |
d4de04d773343cb7da1a6ce66524bfeb61cd431da893a1d7666a333de8a77b7a.png | simple | <table><tr><td>microRNAs</td><td>Location on chromosome</td><td>WT</td><td>WT+UVR</td><td>Log Fold Change</td><td>Adjusted <i>p</i>-value</td><td>Total # of gene targets</td></tr><tr><td>miR-127-3p</td><td>chr12: 109592846-109592915 [+]</td><td>1.089</td><td>−0.401</td><td>−1.49</td><td>1.11E-06</td><td>12</td></tr><tr><td>miR-136-3p</td><td>chr12: 109595327-109595388 [+]</td><td>1.027</td><td>−0.48</td><td>−1.507</td><td>2.04E-06</td><td>32</td></tr><tr><td>miR-136-5p</td><td>chr12: 109595327-109595388 [+]</td><td>1.246</td><td>−0.431</td><td>−1.677</td><td>1.11E-06</td><td>275</td></tr><tr><td>miR-154-5p</td><td>chr12: 109738433-109738498 [+]</td><td>0.811</td><td>−0.283</td><td>−1.094</td><td>2.04E-06</td><td>201</td></tr><tr><td>miR-185-3p</td><td>chr16: 18327401-18327465 [−]</td><td>−0.853</td><td>0.225</td><td>1.078</td><td>3.10E-05</td><td>203</td></tr><tr><td>miR-196a-5p</td><td>chr11: 96265164-96265265 [+]</td><td>1.441</td><td>−1.405</td><td>−2.846</td><td>1.11E-06</td><td>137</td></tr><tr><td>miR-196b-5p</td><td>chr6: 52230081-52230165 [−]</td><td>1.223</td><td>−0.962</td><td>−2.185</td><td>1.11E-06</td><td>134</td></tr><tr><td>miR-206-3p</td><td>chr1: 20679010-20679082 [+]</td><td>0.602</td><td>−0.492</td><td>−1.094</td><td>2.41E-06</td><td>336</td></tr><tr><td>miR-31-3p</td><td>chr4: 88910557-88910662 [−]</td><td>−0.823</td><td>0.897</td><td>1.72</td><td>1.11E-06</td><td>100</td></tr><tr><td>miR-31-5p</td><td>chr4: 88910557-88910662 [−]</td><td>−1.07</td><td>0.962</td><td>2.031</td><td>1.11E-06</td><td>263</td></tr><tr><td>miR-335-5p</td><td>chr6: 30741299-30741396 [+]</td><td>1.152</td><td>−0.175</td><td>−1.327</td><td>1.80E-05</td><td>237</td></tr><tr><td>miR-376a-3p</td><td>chr12: 109723781-109723848 [+]</td><td>1.016</td><td>−0.382</td><td>−1.398</td><td>2.90E-05</td><td>24</td></tr><tr><td>miR-376b-5p</td><td>chr12: 109723458-109723539 [+]</td><td>0.945</td><td>−0.146</td><td>−1.091</td><td>2.04E-06</td><td>225</td></tr><tr><td>miR-377-3p</td><td>chr12: 109740510-109740577 [+]</td><td>0.919</td><td>−0.338</td><td>−1.256</td><td>2.04E-06</td><td>517</td></tr><tr><td>miR-379-5p</td><td>chr12: 109709060-109709125 [+]</td><td>1.172</td><td>−0.292</td><td>−1.464</td><td>1.11E-06</td><td>73</td></tr><tr><td>miR-411-5p</td><td>chr12: 109710175-109710256 [+]</td><td>1.091</td><td>−0.442</td><td>−1.533</td><td>1.43E-06</td><td>157</td></tr><tr><td>miR-434-3p</td><td>chr12: 109594506-109594599 [+]</td><td>0.954</td><td>−0.344</td><td>−1.298</td><td>5.37E-06</td><td>155</td></tr><tr><td>miR-434-5p</td><td>chr12: 109594506-109594599 [+]</td><td>1.08</td><td>−0.394</td><td>−1.475</td><td>2.04E-06</td><td>24</td></tr><tr><td>miR-511-3p</td><td>chr2: 14261003-14261081 [+]</td><td>0.795</td><td>−0.444</td><td>−1.239</td><td>2.04E-06</td><td>467</td></tr><tr><td>miR-5617-5p</td><td>chrX: 20863126-20863182 [−]</td><td>−1.015</td><td>0.138</td><td>1.152</td><td>3.75E-06</td><td>267</td></tr><tr><td>miR-691</td><td>chr16: 74341990-74342067 [−]</td><td>−0.897</td><td>0.242</td><td>1.139</td><td>2.06E-06</td><td>413</td></tr><tr><td>miR-709</td><td>chr8: 84086099-84086186 [+]</td><td>−1.091</td><td>0.249</td><td>1.34</td><td>2.32E-06</td><td>445</td></tr></table> |
e316383d52cb13e75e60b7aa8c12234aa36736eecd4c1e9cdb591a346f7d7e72.png | complex | <table><tr><td rowspan="2"></td><td>Group 1</td><td>Group 2</td><td rowspan="2">P values</td></tr><tr><td>NSRT</td><td>SRT</td></tr><tr><td rowspan="2">Number of retinal tears per eye</td><td>1.42 ± 0.8 (<i>r</i> = 1-5)</td><td>1.36 ± 0.5 (<i>r</i> = 1-2)</td><td rowspan="2">0.54</td></tr><tr><td>n (%)</td><td>n (%)</td></tr><tr><td colspan="4">Initial retinal tear location</td></tr><tr><td> Superotemporal</td><td>80 (45.5)</td><td>11 (40.7)</td><td>0.94</td></tr><tr><td> Inferotemporal</td><td>53 (30.1)</td><td>12 (44.5)</td><td>0.21</td></tr><tr><td> Superonasal</td><td>29 (16.5)</td><td>2 (7.4)</td><td>0.32</td></tr><tr><td> Inferonasal</td><td>14 (7.9)</td><td>2 (7.4)</td><td>0.92</td></tr><tr><td colspan="4">Retinal tear size</td></tr><tr><td> Small</td><td>108 (66.3)</td><td>11 (47.8)</td><td>0.27</td></tr><tr><td> Medium</td><td>44 (27)</td><td>9 (39.1)</td><td>0.45</td></tr><tr><td> Large</td><td>11 (6.7)</td><td>3 (13.1)</td><td>0.32</td></tr></table> |
4d7699d69ac1cf97c6afd2999d6f0c89a25de009533e166c4c48aff5270c9a0a.png | complex | <table><tr><td rowspan="2"></td><td>Total number of patients</td><td>Fibromyalgia+</td><td>Fibromyalgia-</td><td rowspan="2"><i>P</i></td></tr><tr><td>(n = 196)</td><td>(n = 42)</td><td>(n = 154)</td></tr><tr><td>Patients who received at least one TNFi</td><td>141 (71.9 %)</td><td>33 (78.6 %)</td><td>108 (70.1 %)</td><td>0.28</td></tr><tr><td> Number of TNFi treatments</td><td>1.84 (1.0)</td><td>2.36 (1.1)</td><td>1.68 (0.9)</td><td><0.01</td></tr><tr><td> Switchers*</td><td>9 (6.5 %)</td><td>5 (15.2 %)</td><td>4 (3.8 %)</td><td>0.03</td></tr><tr><td colspan="5">First TNFi</td></tr><tr><td> Mean duration of first TNFi treatment, years</td><td>3.0 (3.8)</td><td>1.7 (2.4)</td><td>3.5 (4.0)</td><td><0.01</td></tr><tr><td colspan="5"> Reason for TNFi discontinuation:</td></tr><tr><td> Inefficacy %</td><td>54 (69.2 %)</td><td>12 (54.6 %)</td><td>42 (75.0 %)</td><td>0.14</td></tr><tr><td> Toxicity %</td><td>4 (5.1 %)</td><td>2 (9.1 %)</td><td>2 (3.6 %)</td><td>0.76</td></tr><tr><td> Inefficacy + toxicity %</td><td>4 (5.1 %)</td><td>3 (13.6 %)</td><td>1 (1.8 %)</td><td>0.23</td></tr><tr><td> Others %</td><td>16 (20.5 %)</td><td>5 (22.7 %)</td><td>11 (19.6 %)</td><td>1.00</td></tr></table> |
51e5ae98603cf50052c2398224f2ab7d2dbd4d6027f6010a917327a5a3b6278c.png | simple | <table><tr><td>Categories and Themes and No. of participants disclosing the theme</td></tr><tr><td>Category 1: The experience of maladaptive coping responses and the perceived barriers to recovery</td></tr><tr><td>Isolating self from social support (6/8)</td></tr><tr><td>Using alcohol to gain temporary relief and to both avoid depression and associated emotions (5/8)</td></tr><tr><td>Lack of available psychological support or understanding of depression from others (4/8)</td></tr><tr><td>Not being listened to and the lack of collaboration in first experience of treatment (4/8)</td></tr><tr><td>Dealing with publicity and the continued expectations from elite sport (4/8)</td></tr><tr><td>Overtraining interpreted as self-harm (3/8)</td></tr><tr><td>Category 2: Adaptive processes and turning points in recovery</td></tr><tr><td>Separate from elite sport environment to understand depression and embark on self-discovery (6/8)</td></tr><tr><td>Channeling sporting will to win and personal agency toward a high level of commitment to recovery (6/8)</td></tr><tr><td>Experiencing acceptance and expressing real self in therapeutic relationship (5/8)</td></tr><tr><td>Support from significant other, recognizing depression and developing hope (4/8)</td></tr><tr><td>Category 3: The process of recovery and the transitions within the self</td></tr><tr><td>Being less defined by sport, broadening identity, and adopting self-care (5/8)</td></tr><tr><td>Developing intrinsic motivation an internal locus of evaluation and falling in love with sport again (5/8)</td></tr><tr><td>Coming out and gaining self-acceptance in sport and society as central to healing and recovery (4/8)</td></tr></table> |
70f605ae211c1ae5b5684184c2cc049f39ac80866b4fb3849c733024367563a9.png | complex | <table><tr><td>N= 29,157,460</td><td>%</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Male</td><td>49.9</td></tr><tr><td> Female</td><td>50.1</td></tr><tr><td colspan="2">Age</td></tr><tr><td> 6 to 11</td><td>7.4</td></tr><tr><td> 12 to 19</td><td>11.4</td></tr><tr><td> 20 to 39</td><td>30.9</td></tr><tr><td> 40 to 59</td><td>33.5</td></tr><tr><td> 60 to 79</td><td>16.8</td></tr><tr><td>Smoking Status</td><td> </td></tr><tr><td> Never smoked</td><td>52.6</td></tr><tr><td> Past smoker</td><td>27.1</td></tr><tr><td> Current smoker</td><td>20.3</td></tr><tr><td colspan="2">Education</td></tr><tr><td> Degree/diploma</td><td>49.6</td></tr><tr><td> <Degree/diploma</td><td>50.5</td></tr><tr><td colspan="2">Immigrant Status</td></tr><tr><td> Born in Canada</td><td>79.0</td></tr><tr><td> Not born in Canada</td><td>21.0</td></tr><tr><td>Aboriginal Status</td><td> </td></tr><tr><td> Non-Aboriginal</td><td>96.9</td></tr><tr><td> Aboriginal</td><td>3.10</td></tr><tr><td colspan="2">Income adequacy</td></tr><tr><td> Highest income</td><td>47.9</td></tr><tr><td> Middle income</td><td>31.9</td></tr><tr><td> Lowest income</td><td>20.3</td></tr><tr><td colspan="2">Dental insurance</td></tr><tr><td> Private coverage</td><td>62.3</td></tr><tr><td> Public coverage</td><td>5.8</td></tr><tr><td> Non-insured</td><td>31.9</td></tr><tr><td colspan="2">Self-reported oral health</td></tr><tr><td> Excellent/very good/good</td><td>84.5</td></tr><tr><td> Fair/poor</td><td>15.5</td></tr><tr><td colspan="2">Self-reported general health</td></tr><tr><td> Excellent/very good/good</td><td>91.9</td></tr><tr><td> Fair/poor</td><td>8.1</td></tr><tr><td colspan="2">Self-reported oral pain</td></tr><tr><td> Rarely/never</td><td>88.4</td></tr><tr><td> Often/sometimes</td><td>11.6</td></tr><tr><td colspan="2">Self-perceived unmet needs</td></tr><tr><td> No needs</td><td>67.0</td></tr><tr><td> Has at least one need</td><td>33.0</td></tr><tr><td colspan="2">Brushing frequency</td></tr><tr><td> >Once/day</td><td>72.0</td></tr><tr><td> Once/day</td><td>24.6</td></tr><tr><td> <Once/day or Never</td><td>3.4</td></tr><tr><td colspan="2">Flossing Frequency</td></tr><tr><td> >Once/day</td><td>8.6</td></tr><tr><td> Once/day</td><td>21.4</td></tr><tr><td> <Once/day</td><td>42.0</td></tr><tr><td> Never</td><td>28.1</td></tr><tr><td colspan="2">Avoided dental treatment due to cost</td></tr><tr><td> No</td><td>83.5</td></tr><tr><td> Yes</td><td>16.5</td></tr><tr><td colspan="2">Last Dental Visit</td></tr><tr><td> In the last year</td><td>74.5</td></tr><tr><td> More than one year ago</td><td>25.5</td></tr><tr><td colspan="2">Dental Visit Frequency</td></tr><tr><td> > Once a year</td><td>42.6</td></tr><tr><td> Once a year</td><td>31.7</td></tr><tr><td> < Once a year</td><td>9.2</td></tr><tr><td> Only for emergency</td><td>13.3</td></tr><tr><td> Never</td><td>3.2</td></tr><tr><td colspan="2">Work/School Days Lost</td></tr><tr><td> No</td><td>60.9</td></tr><tr><td> Yes</td><td>39.2</td></tr></table> |
38999d3bfc35f618983f749ff18e4cf937bba00d01b30f8f389c35dba05464dc.png | simple | <table><tr><td>Variable</td><td>CaseN(%)</td><td>ControlN(%)</td><td><i>χ</i><sup><i>2</i></sup></td><td><i>P</i></td></tr><tr><td>Hypertension</td><td></td><td></td><td>4.625</td><td>0.032</td></tr><tr><td> Yes</td><td>189 (12.8)</td><td>152 (10.3)</td><td></td><td></td></tr><tr><td> No</td><td>1285 (87.2)</td><td>1325 (89.7)</td><td></td><td></td></tr><tr><td>Diabetes mellitus</td><td></td><td></td><td>0.791</td><td>0.374</td></tr><tr><td> Yes</td><td>59 (4.0)</td><td>50 (3.4)</td><td></td><td></td></tr><tr><td> No</td><td>1410 (96.0)</td><td>1422 (96.6)</td><td></td><td></td></tr><tr><td>Benign tumor of breast</td><td></td><td></td><td>26.957</td><td><0.001</td></tr><tr><td> Yes</td><td>84 (5.9)</td><td>166 (11.3)</td><td></td><td></td></tr><tr><td> No</td><td>1339 (94.1)</td><td>1298 (88.7)</td><td></td><td></td></tr><tr><td>Galactophore Hyperplasia</td><td></td><td></td><td>14.52</td><td><0.001</td></tr><tr><td> Yes</td><td>252 (17.3)</td><td>336 (22.9)</td><td></td><td></td></tr><tr><td> No</td><td>1207 (82.7)</td><td>1130 (77.1)</td><td></td><td></td></tr><tr><td>Spillage of nipple</td><td></td><td></td><td>5.849</td><td>0.016</td></tr><tr><td> Yes</td><td>19 (1.3)</td><td>37 (2.5)</td><td></td><td></td></tr><tr><td> No</td><td>1433 (98.7)</td><td>1419 (97.5)</td><td></td><td></td></tr><tr><td>Inverted nipple</td><td></td><td></td><td>2.167</td><td>0.141</td></tr><tr><td> Yes</td><td>19 (1.3)</td><td>11 (0.8)</td><td></td><td></td></tr><tr><td> No</td><td>1432 (98.7)</td><td>1442 (99.2)</td><td></td><td></td></tr><tr><td>Multiple breasts</td><td></td><td></td><td>2.070</td><td>0.150</td></tr><tr><td> Yes</td><td>19 (1.3)</td><td>29 (2.0)</td><td></td><td></td></tr><tr><td> No</td><td>1430 (98.7)</td><td>1427 (98.0)</td><td></td><td></td></tr><tr><td>Family history of breast cancer</td><td></td><td></td><td>13.168</td><td><0.001</td></tr><tr><td> Yes</td><td>99 (6.7)</td><td>55 (3.7)</td><td></td><td></td></tr><tr><td> No</td><td>1382 (93.3)</td><td>1423 (96.3)</td><td></td><td></td></tr><tr><td>Family history of first-degree relatives</td><td></td><td></td><td>3.479</td><td>0.062</td></tr><tr><td> Yes</td><td>57 (4.0)</td><td>39 (2.7)</td><td></td><td></td></tr><tr><td> No</td><td>1375 (96.0)</td><td>1392 (97.3)</td><td></td><td></td></tr><tr><td>Family history of second-degree relatives</td><td></td><td></td><td>8.619</td><td>0.003</td></tr><tr><td> Yes</td><td>43 (3.0)</td><td>20 (1.4)</td><td></td><td></td></tr><tr><td> No</td><td>1384 (97.0)</td><td>1409 (98.6)</td><td></td><td></td></tr></table> |
43d17689665c61a9472bae578452b7f4926075e524b23fabd015e10d6e199363.png | simple | <table><tr><td>Target mRNA</td><td>Sequence(5’-3’)</td><td>Product size</td></tr><tr><td>(Accession number)</td><td> </td><td>(bp)</td></tr><tr><td>hOCT1/<i>SLC22A1</i></td><td>AATGGACCACATCGCTCAAAA</td><td> </td></tr><tr><td>(NM_003057)</td><td>CTTCGAGGGAAAGCATCTTTAAAT</td><td>68</td></tr><tr><td>hOCT2/<i>SLC22A2</i></td><td>GGACGGCTGGGTGTACGA</td><td> </td></tr><tr><td>(NM_003058)</td><td>GGAGTTGGCACATACCAGGTTAA</td><td>70</td></tr><tr><td>hOCT3/<i>SLC22A3</i></td><td>CATGCCTTGTCACTGCGTTCT</td><td> </td></tr><tr><td>(NM_021977)</td><td>ATGTAGCCACTGTGGTCCTCAA</td><td>63</td></tr><tr><td>hOCTN1/<i>SLC22A4</i></td><td>CCAGAGTGGGCAGCATCAT</td><td> </td></tr><tr><td>(NM_003059)</td><td>TAGGGCAGCATTCTGTTGTAAGC</td><td>67</td></tr><tr><td>hOCTN2/<i>SLC22A5</i></td><td>CCTTCTCTTCATGCAGCTGGTA</td><td> </td></tr><tr><td>(NM_003060)</td><td>CCCACCATCACCAGGACTGT</td><td>66</td></tr><tr><td>hMATE1/<i>SLC44A1</i></td><td>CAGTCACGCTGGCAATCG</td><td> </td></tr><tr><td>(NM_080546)</td><td>GGTGTCACAGGCAGAAGATAAGC</td><td>77</td></tr><tr><td>hMATE2/<i>SLC44A2</i></td><td>TCTGAGAGGAACTGGGAAGCA</td><td> </td></tr><tr><td>(NM_152908)</td><td>AGGCCGATGATGTAATATGTGATG</td><td>69</td></tr><tr><td>hPMAT/<i>SLC29A4</i></td><td>CAGCTTTCACGGATACTACATTGG</td><td> </td></tr><tr><td>(NM_001040661)</td><td>GCAAAGTAGATGGCGTGATAACG</td><td>67</td></tr><tr><td>hGAPDH</td><td>CCACATCGCTCAGACACCAT</td><td> </td></tr><tr><td>(NM_002046)</td><td>GCGCCCAATACGACCAAAT</td><td>66</td></tr></table> |
1fa3d284f971ff5d226b9070c8a0743a0a4003be02a1bd50abc6c097e32e641d.png | simple | <table><tr><td></td><td>Total</td><td>HPV awareness</td><td>Prevalence ratio</td><td>95% CI</td><td>P</td></tr><tr><td>Age at first sexual intercourse</td><td></td><td></td><td></td><td></td><td>0.307</td></tr><tr><td> ≤15</td><td>132</td><td>33.3%</td><td>1</td><td></td><td></td></tr><tr><td> > 15</td><td>169</td><td>39.1%</td><td>1.17</td><td>[0.86-1.59]</td><td></td></tr><tr><td>Number of lifetime sexual partners</td><td></td><td></td><td></td><td></td><td>0.238*</td></tr><tr><td> 1</td><td>120</td><td>37.5%</td><td>1</td><td></td><td></td></tr><tr><td> 2-3</td><td>116</td><td>28.5%</td><td>0.76</td><td>[0.52-1.10]</td><td></td></tr><tr><td> ≥4</td><td>65</td><td>49.2%</td><td>1.31</td><td>[0.94-1.84]</td><td></td></tr><tr><td>Previous STI<sup>1</sup></td><td></td><td></td><td></td><td></td><td>0.002</td></tr><tr><td> No</td><td>292</td><td>34.9%</td><td>1</td><td></td><td></td></tr><tr><td> Yes</td><td>9</td><td>88.9%</td><td>2.55</td><td>[1.93-3.36]</td><td></td></tr><tr><td>Abortion</td><td></td><td></td><td></td><td></td><td>0.603</td></tr><tr><td> No</td><td>282</td><td>36.2%</td><td>1</td><td></td><td></td></tr><tr><td> Yes</td><td>19</td><td>42.1%</td><td>1.16</td><td>[0.67-2.02]</td><td></td></tr><tr><td>Contraception</td><td></td><td></td><td></td><td></td><td>0.398</td></tr><tr><td> No</td><td>74</td><td>32.4%</td><td>1</td><td></td><td></td></tr><tr><td> Yes</td><td>227</td><td>37.9%</td><td>1.17</td><td>[0.81-1.69]</td><td></td></tr></table> |
e9a9165fdc7e7844850a29dd108f7ba82e024a1e1a6253161be07c48144c065b.png | complex | <table><tr><td>Item</td><td colspan="3">People with diabetes are advised to regularly check their feet and the inside of their shoes. People differ a lot with respect to the importance they attach to “good advice“ of this kind. How important is this advice for you personally?</td></tr><tr><td>Reply options</td><td>not important</td><td>a little important</td><td>important or very important</td></tr><tr><td>Tailored answer</td><td>OK, so this recommendation is not important for you. Maybe you are very aware of the inconvenience of daily foot care. You are right there; it takes some effort in the beginning. At the same time it helps a lot to prevent diabetic foot syndrome. A diabetic foot can be painful and can lead to amputation. There is a great benefit for the comparatively small effort of taking care of your feet. For many people the first step is the hardest. Once you get used to it, the effort does not seem so great anymore.</td><td>OK, so this recommendation is a little important for you. Maybe you are aware of the inconvenience of daily foot care. At the same time it helps a lot to prevent diabetic foot syndrome. A diabetic foot can be painful and can lead to amputation. There is a great benefit for the comparatively small effort of taking care of your feet. For many people the first step is the hardest. Once you get used to it, the effort does not seem so great anymore.</td><td>You are right, this recommendation is really important. Looking after your feet can be inconvenient but helps a lot to prevent diabetic foot syndrome. A diabetic foot can be painful and can lead to amputation. There is a great benefit for the comparatively small effort of taking care of your feet.</td></tr></table> |
90d730e968877e7213255a79c57e6ddc8e028e8277338c0585d03c06ca9124fc.png | simple | <table><tr><td>Area</td><td>Sex</td><td>Age (years)</td><td>No. at the 1st <sup>1)</sup></td><td>No. at the 2nd <sup>2)</sup></td><td>Seroconversion rate (%)</td></tr><tr><td>Trial</td><td>Male</td><td>2-5</td><td>1</td><td>0</td><td>0</td></tr><tr><td> </td><td> </td><td>>5</td><td>15</td><td>12</td><td>80.0</td></tr><tr><td> </td><td>Female</td><td>2-5</td><td>6</td><td>2</td><td>33.3</td></tr><tr><td> </td><td> </td><td>>5</td><td>15</td><td>9</td><td>60.0</td></tr><tr><td>Control</td><td>Male</td><td>2-5</td><td>2</td><td>1</td><td>50.0</td></tr><tr><td> </td><td> </td><td>>5</td><td>34</td><td>25</td><td>73.5</td></tr><tr><td> </td><td>Female</td><td>2-5</td><td>3</td><td>2</td><td>66.6</td></tr><tr><td> </td><td> </td><td>>5</td><td>20</td><td>16</td><td>80.0</td></tr></table> |
2e6975d45786a538f70efe68afab2678611cd031b59953bdea55a7694b4e32d7.png | simple | <table><tr><td>Parameter</td><td>Calcium Diphosphate</td><td>Chitin</td><td>Lactose H<sub>2</sub>O</td><td>Avicel PH 101</td><td>Starch 1500</td><td>PVP K30</td><td>Sorbitol</td></tr><tr><td><i>P<sub>Y</sub></i></td><td>250.1</td><td>122</td><td>150</td><td>62.5</td><td>75.1</td><td>35.7</td><td>48.4</td></tr><tr><td><i>D</i><sub>0</sub></td><td>0.36</td><td>0.12</td><td>0.38</td><td>0.23</td><td>0.33</td><td>0.27</td><td>0.39</td></tr><tr><td><i>D<sub>A</sub></i></td><td>0.49</td><td>0.52</td><td>0.69</td><td>0.44</td><td>0.48</td><td>0.72</td><td>0.79</td></tr><tr><td><i>D<sub>B</sub></i></td><td>0.13</td><td>0.31</td><td>0.31</td><td>0.21</td><td>0.15</td><td>0.46</td><td>0.4</td></tr></table> |
803cc49c44487c12db95d93fa7047eb784c7ff6051759838529a3240966b750b.png | simple | <table><tr><td></td><td></td><td>No ETOH Group (<i>n</i> = 1,445)</td><td>Low ETOH Group (<i>n</i> = 273)</td><td>High ETOH Group (<i>n</i> = 605)</td><td>Total (<i>n</i> = 2,323)</td><td><i>P</i> value<sup>#</sup></td></tr><tr><td>Severe head injury</td><td>%</td><td>66.5</td><td>68.5</td><td>59.8</td><td>64.85</td><td>0.016</td></tr><tr><td>Severe chest injury</td><td>%</td><td>56.9</td><td>54.8</td><td>48.5</td><td>54.64</td><td>0.023</td></tr><tr><td>Severe abdomen injury</td><td>%</td><td>25.3</td><td>28.1</td><td>28.8</td><td>26.44</td><td>NSS</td></tr><tr><td>Severe extremity injury</td><td>%</td><td>5.3</td><td>4.0</td><td>1.7</td><td>4.18</td><td>0.012</td></tr><tr><td>ISS</td><td>Mean (SE)</td><td>31.3 (0.3)</td><td>32.4 (0.7)</td><td>30.3 (0.5)</td><td>31.2 (0.3)</td><td>NSS*</td></tr><tr><td>Length of stay (days)</td><td>Mean (SE)</td><td>22.6 (0.7)</td><td>21.3 (1.4)</td><td>22.7 (1.4)</td><td>22.5 (0.6)</td><td>NSS*</td></tr><tr><td>Mortality</td><td>%</td><td>15.5</td><td>16.9</td><td>13.6</td><td>15.15</td><td>NSS</td></tr></table> |
14a169c34892d64c09fd9c2290c4a98362d52e9fe174b447afda8a1be4a64810.png | simple | <table><tr><td>Type</td><td>Method</td><td>Gold standard fusion genes detected</td><td>Sensitivity<sup>b</sup></td><td>Total fusion genes detected</td><td>Precision</td><td>F-score</td></tr><tr><td>SGS + TGS</td><td>IDP-fusion 2LR + 2SR<sup>a</sup></td><td>24</td><td>33.80%</td><td>35</td><td>68.57%</td><td>0.4528</td></tr><tr><td></td><td>IDP-fusion 2LR + 1SR</td><td>24</td><td>33.80%</td><td>37</td><td>64.86%</td><td>0.4444</td></tr><tr><td>SGS</td><td>TopHat-Fusion</td><td>16</td><td>22.54%</td><td>59</td><td>27.12%</td><td>0.2462</td></tr><tr><td></td><td>SOAPfuse</td><td>10</td><td>14.08%</td><td>39</td><td>25.64%</td><td>0.1818</td></tr><tr><td></td><td>TRUP</td><td>22</td><td>30.99%</td><td>63</td><td>34.92%</td><td>0.3284</td></tr><tr><td></td><td>FusionMap</td><td>20</td><td>28.17%</td><td>205</td><td>9.76%</td><td>0.1449</td></tr><tr><td></td><td>deFuse</td><td>27</td><td>38.03%</td><td>196</td><td>13.78%</td><td>0.2022</td></tr><tr><td></td><td>BreakFusion</td><td>15</td><td>21.13%</td><td>130</td><td>11.54%</td><td>0.1493</td></tr><tr><td>TGS</td><td>IsoSeq</td><td>15</td><td>21.13%</td><td>83</td><td>18.07%</td><td>0.1948</td></tr></table> |
c033adc7b1d2703410739fa081af70905485ea8fefbbc191979c9bc0e47dda03.png | simple | <table><tr><td>Patient ID</td><td>Sample ID</td><td>Gender</td><td>Age at test</td><td>Type of cancer</td><td>Sample type</td></tr><tr><td>1</td><td>F1311260008</td><td>Female</td><td>64</td><td>Lung cancer, SCC</td><td>FFPE</td></tr><tr><td>2</td><td>B1312160009</td><td>Female</td><td>61</td><td>Colon cancer</td><td>Blood</td></tr><tr><td>3</td><td>F1312230017</td><td>Male</td><td>54</td><td>Lung cancer, SCC</td><td>FFPE</td></tr><tr><td>4</td><td>F1401170002</td><td>Male</td><td>57</td><td>Rectal cancer</td><td>FFPE</td></tr><tr><td>5</td><td>F1401170004</td><td>Male</td><td>53</td><td>Lung adenocarcinoma</td><td>FFPE</td></tr><tr><td>6</td><td>F1402240017</td><td>Male</td><td>20</td><td>Neuroectodermal tumor</td><td>FFPE</td></tr><tr><td>7</td><td>F1410200833B1410200832</td><td>Female</td><td>52</td><td>Lung adenocarcinoma</td><td>FFPE</td></tr><tr><td>8</td><td>C1409280774B1409280773</td><td>Male</td><td>67</td><td>Lung adenocarcinoma</td><td>Pleural fluid</td></tr><tr><td>9</td><td>F1411100940B1411100938</td><td>Female</td><td>53</td><td>Breast cancer</td><td>FFPE</td></tr><tr><td>10</td><td>F1412241251B1412241250</td><td>Female</td><td>66</td><td>Lung adenocarcinoma</td><td>FFPE</td></tr></table> |
3423c7267310ce3c6284972137767b387bc2a39f134884e8fb53d0f572abd933.png | complex | <table><tr><td rowspan="2" colspan="2">Variables</td><td colspan="2">Watching porn videos</td><td colspan="2">Attending night clubs</td><td colspan="2">Sex with commercial sex workers</td></tr><tr><td>COR (95% CI)</td><td>AOR (95% CI)</td><td>COR (95% CI)</td><td>AOR (95% CI)</td><td>COR (95% CI)</td><td>AOR (95% CI)</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="2"></td><td>Male</td><td>4.8 (3.5 - 6.5)**</td><td>4.1 (2.9 - 5.8)**</td><td>3.9 (2.3 - 6.7)**</td><td>2.3 (1.3 - 4.3)**</td><td>NA</td><td>NA</td></tr><tr><td>female</td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td></td><td></td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="3"></td><td>18 – 20</td><td><sup>1</sup></td><td><sup>1</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>20 – 24</td><td>3.5 (1.4 - 9.0)**</td><td>1.3 (0.9 - 2.0)</td><td>_</td><td>_</td><td>_</td><td>_</td></tr><tr><td>> 24</td><td>2.2 (0.9 - 5.5)</td><td>3.0 (1.1 - 8.4)**</td><td>_</td><td>_</td><td>_</td><td>_</td></tr><tr><td rowspan="6">Year of study</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Year I</td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td></td><td></td></tr><tr><td>Year II</td><td>0.7 (0.5 - 0.9)</td><td>1.2 (0.8 - 1.8)</td><td>1.2 (0.4 - 3.5)</td><td>2.3 (0.6 - 9.2)</td><td>─</td><td>─</td></tr><tr><td>Year III</td><td>0.5(0.3 - 0.7)</td><td>1.6 (0.9 - 2.6)</td><td>2.2 (0.8 - 6.4)</td><td>3.4 (0.9 - 13.5)</td><td>─</td><td>─</td></tr><tr><td>Year IV</td><td>0.8 (0.4 - 1.3)</td><td>1.2 (0.6 - 2.5)</td><td>3.1 (1.1 - 9.2)**</td><td>3.7 (0.9 - 14.4)</td><td>─</td><td>─</td></tr><tr><td>Year V</td><td>0.9 (0.5 - 1.8)</td><td>1.3 (0.6 - 2.8)</td><td>1.7 (0.5 - 5.7)</td><td>2.8 (0.6 - 13.5)</td><td>─</td><td>─</td></tr><tr><td>Ethncity</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4"></td><td>Amhara</td><td>1.4 (0.9 - 2.1)</td><td>0.7 (0.4 - 1.2)</td><td>0.9 (0.5 - 1.7)</td><td>1.8 (0.8 - 3.7)</td><td>─</td><td>─</td></tr><tr><td>Oromo</td><td>0.9 (0.5 - 1.5)</td><td>1.3 (0.7 - 2.4)</td><td>1.4 (0.7 - 2.8)</td><td>1.95 (0.8 - 4.5)</td><td>─</td><td>─</td></tr><tr><td>Tigray</td><td>1.02 (0.6 - 1.9)</td><td>1.2 (0.6 - 2.3)</td><td>2.2 (1.1 - 4.4)**</td><td>5.6 (2.2 - 14.2)**</td><td>─</td><td>─</td></tr><tr><td>Other</td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td>─</td><td>─</td></tr><tr><td>Religion</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4"></td><td>Orthodox</td><td>─</td><td>─</td><td>1</td><td><sup>1</sup></td><td></td><td></td></tr><tr><td>Muslim</td><td>─</td><td>─</td><td>0.6 (0.3 - 1.3)</td><td>0.73 (0.3 - 1.8)</td><td>─</td><td>─</td></tr><tr><td>Protestant</td><td>─</td><td>─</td><td>0.6 (0.3 -1.3)</td><td>0.73 (0.3 - 1.9)</td><td>─</td><td>─</td></tr><tr><td>Other</td><td>─</td><td>─</td><td>3.1 (1.3 - 7.7)**</td><td>4.0 (1.0 - 16.1)</td><td>─</td><td>─</td></tr><tr><td>Chewing</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="3">khat</td><td>Never</td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td></tr><tr><td>Some times</td><td>4.1 (2.4 - 6.9)**</td><td>2.0 (1.1 - 3.6)**</td><td>9.8 (6.3 - 15.4)**</td><td>6.48 (3.9 - 10.9)**</td><td>0.3 (0.1 - 0.9)**</td><td>0.54(0.2 - 1.5)</td></tr><tr><td>Always</td><td>1.1 (0)</td><td>1.1 (0)</td><td>27.2 (10.8 - 68.3)</td><td>18.7 (6.4 - 53.9)**</td><td>0.3 (0.1 - 1.1)</td><td>0.38 (0.1 - 2.2)</td></tr><tr><td>Alcoholism</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="3"></td><td>Never</td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td><td><sup>1</sup></td></tr><tr><td>Always</td><td>1.2 (0.6 - 2.4)</td><td>0.61(0.3 - 1. 4)</td><td>9.3 (3.6 - 24)**</td><td>3.3 (1.1 - 10.1)**</td><td>0.3 (0.0 - 3.3)</td><td>0.8 (0.1 - 9.9)</td></tr><tr><td>Sometimes</td><td>6.4 (4.4 - 9.4)**</td><td>4.78 (3.2 - 7.2)**</td><td>15.8 (8.9 - 27.7)**</td><td>9.5 (5.2 - 17.5)**</td><td>0.2 (0.1 - 0.9)**</td><td>0.6 (0.1 - 2.3)</td></tr><tr><td>Attending</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="2">night clubs</td><td>Yes</td><td>4.2 (0.3 - 7.2)</td><td>0.9 (0.5 - 1.8)</td><td>NA</td><td>NA</td><td>4.2 (1.7 - 10.8)**</td><td>4.6 (1.8 - 1.8)**</td></tr><tr><td>No</td><td><sup>1</sup></td><td><sup>1</sup></td><td></td><td></td><td><sup>1</sup></td><td><sup>1</sup></td></tr></table> |
d1e928ca65e0040d812fb8d65feb8afec522418c2fee3111b9b029d18e4873e3.png | simple | <table><tr><td>Variable†</td><td></td><td>Odds ratio</td><td>95% CI‡</td></tr><tr><td>Pretreatment HCV RNA level§</td><td>Per 1 log increase</td><td>0.179</td><td>0.096–0.336</td></tr><tr><td>HCV genotype</td><td>1b = 1; non-1b = 0</td><td>0.324</td><td>0.151–0.695</td></tr><tr><td>IFN-α regimen</td><td>6-MU = 1; 3-MU = 0¶</td><td>2.310</td><td>1.070–4.990</td></tr><tr><td>Stage of fibrosis</td><td>F3–4 = 1; F0–2 = 0</td><td>0.408</td><td>0.104–0.892</td></tr></table> |
2b67a7f7eed8b69ea52051b1bf841a0b10d770d83edb6f8d583f74d14a0cd4f9.png | simple | <table><tr><td>Family</td><td>Millet Zhang gu</td><td>Millet Yugu1</td><td>Maize</td></tr><tr><td>AUX/IAA</td><td>29</td><td>29</td><td>52</td></tr><tr><td>GIF</td><td>3</td><td>3</td><td>3</td></tr><tr><td>MBF1</td><td>2</td><td>2</td><td>3</td></tr><tr><td>Med10</td><td>1</td><td>1</td><td>2</td></tr><tr><td>Med11</td><td>1</td><td>1</td><td>2</td></tr><tr><td>Med12</td><td>1</td><td>1</td><td>6</td></tr><tr><td>Med13_C</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Med14</td><td>2</td><td>2</td><td>1</td></tr><tr><td>Med17</td><td>1</td><td>1</td><td>2</td></tr><tr><td>Med18</td><td>1</td><td>1</td><td>0</td></tr><tr><td>Med20</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Med22</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Med31</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Med4</td><td>1</td><td>1</td><td>2</td></tr><tr><td>Med6</td><td>1</td><td>1</td><td>2</td></tr><tr><td>Med7</td><td>2</td><td>2</td><td>2</td></tr><tr><td>PC4</td><td>2</td><td>2</td><td>3</td></tr><tr><td>RB</td><td>2</td><td>2</td><td>5</td></tr><tr><td>Sigma54_activat</td><td>9</td><td>10</td><td>9</td></tr><tr><td>Spt20</td><td>2</td><td>2</td><td>1</td></tr><tr><td>TAZ</td><td>7</td><td>7</td><td>7</td></tr><tr><td>OFP</td><td>33</td><td>27</td><td>43</td></tr></table> |
b88eaea3279b4cef4e5cf7ba3a86579263455b6f8bce67d25527783b5e0b136b.png | complex | <table><tr><td>Variables</td><td colspan="2">Survival statusDead Censored</td><td>CHR (95%CI)</td><td>AHR (95%CI)</td></tr><tr><td colspan="5">Sex</td></tr><tr><td> Male</td><td>23</td><td>154</td><td>2.5 (1.3, 5.0)</td><td>1.3 (0.6, 3.0)</td></tr><tr><td> Female</td><td>15</td><td>198</td><td>1</td><td>1</td></tr><tr><td colspan="5">Age</td></tr><tr><td>< 1yer</td><td>3</td><td>8</td><td>4.9 (1.4, 17.0)</td><td>2.5 (0.6, 9.9)</td></tr><tr><td> 1-5 years</td><td>17</td><td>99</td><td>2.2(1.1, 4.3)</td><td>1.7(0.7, 3.7)</td></tr><tr><td> 5-15 years</td><td>18</td><td>245</td><td>1</td><td>1</td></tr><tr><td colspan="5">Residence</td></tr><tr><td> Urban</td><td>35</td><td>298</td><td>1</td><td>1</td></tr><tr><td> Rural</td><td>3</td><td>54</td><td>0.6(0.2, 2.0)</td><td>0.5(0.1, 1.7)</td></tr><tr><td colspan="5">OI at baseline</td></tr><tr><td> Yes</td><td>30</td><td>152</td><td>4.3 (2.0,9.0)</td><td>1.9 (0.8, 4.5)</td></tr><tr><td> No</td><td>8</td><td>200</td><td>1</td><td>1</td></tr><tr><td colspan="5">WHO clinical staging</td></tr><tr><td> Stage I and II</td><td>8</td><td>221</td><td>1</td><td>1</td></tr><tr><td> Stage III and IV</td><td>30</td><td>131</td><td>5.6 (2.6, 12.3)</td><td>2.6 (1.1, 6.6)<sup>**</sup></td></tr><tr><td colspan="5">CD4 count or percent</td></tr><tr><td> Below the threshold</td><td>33</td><td>2410</td><td>3.2 (1.2, 8.2)</td><td>5.2 (1.9, 14.1)<sup>**</sup></td></tr><tr><td> Above the threshold</td><td>5</td><td>112</td><td>1</td><td>1</td></tr><tr><td colspan="5">Hemoglobin level</td></tr><tr><td>< 10 g/dl</td><td>15</td><td>32</td><td>6.2 (3.2, 11.9)</td><td>3.2 (1.4, 7.4)<sup>**</sup></td></tr><tr><td>≥ 10 g/dl</td><td>23</td><td>320</td><td>1</td><td>1</td></tr><tr><td colspan="5">Underweight</td></tr><tr><td> Normal</td><td>10</td><td>242</td><td>1</td><td></td></tr><tr><td> Moderate (WAZ < − 2</td><td>13</td><td>66</td><td>4.2 (1.8, 9.6)</td><td>2.4 (0.9,6.4)</td></tr><tr><td> Severely (WAZ < −3)</td><td>15</td><td>44</td><td>6.8 (3.01, 15.2)</td><td>1.3 (0.5, 3.6)</td></tr><tr><td colspan="5">Stunting</td></tr><tr><td> Normal</td><td>12</td><td>254</td><td>1</td><td>1</td></tr><tr><td> Moderate (HAZ < −2)</td><td>8</td><td>39</td><td>3.9 (1.6, 9.7)</td><td>2.3 (0.9, 6.29)</td></tr><tr><td> Severe (HAZ < −3)</td><td>18</td><td>59</td><td>6.1 (2.9, 12.9)</td><td>3.9 (1.7, 9.4)<sup>**</sup></td></tr><tr><td colspan="5">Wasting</td></tr><tr><td> Normal</td><td>18</td><td>269</td><td>1</td><td>1</td></tr><tr><td> Moderate (WHZ or BAZ < −2)</td><td>5</td><td>44</td><td>1.5 (0.5, 4.0)</td><td>1.2 (0.4, 3.6)</td></tr><tr><td> Severe (WHZ or BAZ < −3)</td><td>15</td><td>39</td><td>4.5 (2.2,9.0)</td><td>3.0 (1.3, 6.9)<sup>**</sup></td></tr></table> |
7bab35483ca1f611a848119abf63b3e17fa2fe395757a063b6e1815a8b6bb65b.png | complex | <table><tr><td colspan="2">Variables</td><td>Frequency</td><td>Percentage</td></tr><tr><td rowspan="4">Age</td><td>15-19 years</td><td>16</td><td>3.8</td></tr><tr><td>20-34 years</td><td>333</td><td>79.5</td></tr><tr><td>35-49 years</td><td>70</td><td>16.7</td></tr><tr><td>Mean ±SD</td><td> </td><td>(27.4 ± 6.1)</td></tr><tr><td rowspan="2">Literacy status</td><td>No schooling</td><td>134</td><td>32</td></tr><tr><td>Schooling</td><td>285</td><td>68</td></tr><tr><td rowspan="2">Occupation</td><td>House wife</td><td>240</td><td>57.3</td></tr><tr><td>Other*</td><td>179</td><td>42.7</td></tr><tr><td rowspan="4">Average monthly family income</td><td>below 401</td><td>134</td><td>31.7</td></tr><tr><td>401-1000</td><td>174</td><td>41.8</td></tr><tr><td>above 1000</td><td>111</td><td>26.5</td></tr><tr><td>Mean ±SD</td><td> </td><td>(797.3 ±669.9)</td></tr><tr><td rowspan="4">Family size</td><td>1-3</td><td>123</td><td>29.4</td></tr><tr><td>4-5</td><td>203</td><td>48.4</td></tr><tr><td>above 5</td><td>93</td><td>22.2</td></tr><tr><td>Mean ±SD</td><td> </td><td>(4.6±1.7)</td></tr><tr><td rowspan="2">Media exposure</td><td>No exposure</td><td>122</td><td>29.1</td></tr><tr><td>Radio or TV</td><td>150</td><td>35.8</td></tr><tr><td> </td><td>Radio and TV</td><td>147</td><td>35.1</td></tr></table> |
c98a319c803fc3636412f367d1d5ede9d81bd7996b7e3dd4862e54098fdfb32a.png | complex | <table><tr><td></td><td>Without MHC</td><td>With MHC</td><td><i>p</i>-value</td></tr><tr><td colspan="4">Patient mediated diagnostic delay (<i>N</i> = 368, %)</td></tr><tr><td> No</td><td>187 (80.26)</td><td>108 (80)</td><td rowspan="2">0.99</td></tr><tr><td> Yes</td><td>46 (19.74)</td><td>27 (20)</td></tr><tr><td colspan="4">Patient mediated treatment delay (<i>N</i> = 380, %)</td></tr><tr><td> No</td><td>205 (85.42)</td><td>117 (82.98)</td><td rowspan="2">0.7909</td></tr><tr><td> Yes</td><td>34 (14.58)</td><td>24 (17.02)</td></tr><tr><td colspan="4">Patient deviation from standard of care treatment (<i>N</i> = 389, %)</td></tr><tr><td> No</td><td>212 (86.18)</td><td>116 (81.82)</td><td rowspan="2">0.1857</td></tr><tr><td> Yes</td><td>34 (13.82)</td><td>27 (18.18)</td></tr></table> |
c4a67e3dd26d1aad9ad14d877a347fadf809fc0c805efe56649456349e78c4a5.png | complex | <table><tr><td rowspan="3">Nutrient Content</td><td colspan="5">Unweighted Estimates (<i>n</i> = 431 Products)</td><td colspan="5">Estimates Weighted by Household Purchase Volumes (<i>n</i> = 419 Products)</td></tr><tr><td>2014</td><td>2016</td><td rowspan="2">Mean Difference (95% CI)</td><td rowspan="2"><i>p</i>-Value *</td><td rowspan="2">% diff <sup>#</sup></td><td>2014</td><td>2016</td><td rowspan="2">Mean Difference (95% CI)</td><td rowspan="2"><i>p</i>-Value *</td><td rowspan="2">% diff <sup>#</sup></td></tr><tr><td colspan="2">Mean (SD)</td><td colspan="2">Mean (SD)</td></tr><tr><td>Energy, KJ/100 g</td><td>1028.8 (790.4)</td><td>1000.2 (782.0)</td><td>−28.6 (−46.5 to −10.6)</td><td>0.002</td><td>−1.5</td><td>1026.8 (794.6)</td><td>997.3 (785.8)</td><td>−29.5 (−48.0 to −11.0)</td><td>0.002</td><td>−1.5</td></tr><tr><td>Saturated fat, g/100 g</td><td>2.3 (3.7)</td><td>2.2 (3.7)</td><td>−0.1 (−0.2 to 0.01)</td><td>0.07</td><td>−3.7</td><td>2.3 (3.7)</td><td>2.2 (3.8)</td><td>−0.1 (−0.2 to 0.01)</td><td>0.07</td><td>−4.8</td></tr><tr><td>Total sugars, g/100 g</td><td>9.9 (11.7)</td><td>9.6 (11.3)</td><td>−0.3 (−0.7 to 0.1)</td><td>0.14</td><td>−4.6</td><td>9.8 (11.8)</td><td>9.5 (11.4)</td><td>−0.3 (−0.7 to 0.1)</td><td>0.18</td><td>−4.4</td></tr><tr><td>Sodium, mg/100 g</td><td>357.4 (627.7)</td><td>308.4 (441.7)</td><td>−49.0 (−93.0 to −5.0)</td><td>0.03</td><td>−6.7</td><td>363.2 (635.4)</td><td>312.7 (446.8)</td><td>−50.5 (−95.7 to −5.2)</td><td>0.03</td><td>−4.6</td></tr><tr><td>Protein, g/100 g</td><td>8.5 (8.7)</td><td>8.3 (8.6)</td><td>−0.2 (−0.9 to 0.4)</td><td>0.5</td><td>−1.9</td><td>8.2 (8.3)</td><td>8.0 (8.2)</td><td>−0.2 (−0.9 to 0.4)</td><td>0.48</td><td>−1.9</td></tr><tr><td>Fibre, g/100 g</td><td>4.9 (5.4)</td><td>5.4 (5.2)</td><td>0.5 (0.2 to 0.8)</td><td>0.001</td><td>5.3</td><td>4.6 (4.9)</td><td>5.1 (4.7)</td><td>0.5 (0.2 to 0.9)</td><td>0.001</td><td>6.0</td></tr></table> |
14bb9a9b227fde1f5959c89c3987f7fd0723965b9d0fecd02df5d23dfc2791cb.png | complex | <table><tr><td></td><td colspan="2">Forensic autopsy</td></tr><tr><td>Molecular autopsy</td><td>+ (<i>n</i> = 26)</td><td>− (<i>n</i> = 24)</td></tr><tr><td>+ (<i>n</i> = 14)</td><td>9</td><td>5</td></tr><tr><td>− (<i>n</i> = 36)</td><td>17</td><td>19</td></tr></table> |
dc27e7a0ad3c9465375d2dbd56a61c9ac334ca26630aa5541da36e0e6b60e494.png | complex | <table><tr><td></td><td>Women screened N</td><td>Interval tumors N</td><td>Ratio/10000 (95% IC poisson)</td><td>Sensitivity (%)</td></tr><tr><td colspan="5">50-59 initial</td></tr><tr><td>Round 1</td><td>20221</td><td>17</td><td>8.41 (8.37-8.45)</td><td>104/121 (85.95)</td></tr><tr><td>Round 2</td><td>7675</td><td>4</td><td>5.21 (5.11-5.26)</td><td>36/40 (90.0)</td></tr><tr><td>50-59 succesive</td><td></td><td></td><td></td><td></td></tr><tr><td>Round 2</td><td>14811</td><td>9</td><td>6.08 (6.04-6.12)</td><td>47/56 (83.93)</td></tr><tr><td colspan="5">60-69 initial</td></tr><tr><td>Round 1</td><td>6953</td><td>4</td><td>5.75 (5.69-5.81)</td><td>53/57 (92.98)</td></tr><tr><td>Round 2</td><td>1837</td><td>3</td><td>16.33 (16.15-16.51)</td><td>17/20 (85.00)</td></tr><tr><td colspan="5">60-69 successive</td></tr><tr><td>Round 2</td><td>9449</td><td>6</td><td>6.35 (6.30-6.40)</td><td>42/48 (87.50)</td></tr></table> |
f2968efb656b97c1b684b832035b3015a7ff46b4b75e6df0550248351eb69aab.png | complex | <table><tr><td>Assembly names</td><td>A</td><td>B</td><td>C</td><td>D</td></tr><tr><td colspan="5">Assembly tools</td></tr><tr><td>Contig assembly tool</td><td><i>Fermi</i></td><td><i>Fermi</i></td><td><i>SOAPdenovo2</i></td><td><i>SOAPdenovo2</i></td></tr><tr><td>Scaffolding tool</td><td><i>SOAPdenovo2</i></td><td><i>SSPACE</i></td><td><i>SOAPdenovo2</i></td><td><i>SSPACE</i></td></tr><tr><td>Gap closing tool</td><td><i>GapCloser</i></td><td><i>GapCloser</i></td><td><i>GapCloser</i></td><td><i>GapCloser</i></td></tr><tr><td colspan="5">Assembly metrics</td></tr><tr><td>Total contigs (>1,000 bp)</td><td>71,429</td><td>71,429</td><td>189,566</td><td>189,566</td></tr><tr><td> Contig N50</td><td>54,944</td><td>54,944</td><td>4,048</td><td>4,048</td></tr><tr><td> Contig CEGMA (%)*</td><td>96.37(77.42)</td><td>96.37(77.42)</td><td>68.15(33.06)</td><td>68.15(33.06)</td></tr><tr><td> Contig BUSCO (%)</td><td>86(65)</td><td>86(65)</td><td>42(21)</td><td>42(21)</td></tr><tr><td>Total scaffolds (>1,000 bp)</td><td>14,417</td><td>40,372</td><td>20,466</td><td>-</td></tr><tr><td> Final N50</td><td>555,585</td><td>110,915</td><td>331,639</td><td>-</td></tr><tr><td> Final CEGMA (%)</td><td>95.56(81.85)</td><td>95.97(88.71)</td><td>95.97(90.73)</td><td>-</td></tr><tr><td> Final BUSCO (%)</td><td>91(74)</td><td>86(64)</td><td>94(80)</td><td>-</td></tr><tr><td colspan="5">Quality</td></tr><tr><td> Percentage of <i>N</i>s (%)</td><td>0.06322</td><td>0.0135</td><td>0.02622</td><td>-</td></tr><tr><td> REAPR error-free bases (%)</td><td>96.46</td><td>95.35</td><td>94.98</td><td>-</td></tr><tr><td> REAPR low-scoring regions</td><td>18</td><td>16</td><td>71</td><td>-</td></tr><tr><td> REAPR incorrectly oriented reads</td><td>11,543</td><td>5,329</td><td>28,964</td><td>-</td></tr></table> |
f7be6781076a90ed945058b0fb71e3d71c5cf3200e49cf4197e302a516c55574.png | simple | <table><tr><td>Group</td><td>No. oocytes</td><td>Survival rate</td><td>Cleavage rate</td><td>Blastocyst rate</td></tr><tr><td>Control</td><td>132</td><td>100% ± 0 (132/132)<sup>a</sup></td><td>84.21% ± 2% (111/132)<sup>a</sup></td><td>38.62% ± 0.75% (51/132)<sup>a</sup></td></tr><tr><td>Toxicity</td><td>103</td><td>93.22% ± 1.56% (96/103)<sup>b</sup></td><td>76.74% ± 2.27% (79/96)<sup>b</sup></td><td>35.93% ± 1.47% (37/96)<sup>a</sup></td></tr><tr><td>Vitrified</td><td>105</td><td>81.08% ± 2.86% (89/105)<sup>c</sup></td><td>63.49% ± 2.1% (66/105)<sup>c</sup></td><td>19.96% ± 1.06% (21/105)<sup>b</sup></td></tr></table> |
e0b34d0ee0bd17da3023be139d39dd5bd3ccddbd911abe2b6b4dbd18c4090cf6.png | complex | <table><tr><td>Project</td><td>Primer sequences</td><td>Amplified fragment length</td></tr><tr><td rowspan="2">GAPDH</td><td>F: 5′ GAAGAGTGGGTGTCGCTGTT 3′</td><td rowspan="2">141 bp</td></tr><tr><td>R: 5′ CTGCCGTCTGGAAAAACCT 3′</td></tr><tr><td rowspan="2">CREB</td><td>F: 5′ GTGCCAGCCTTTCCTTACAC 3′</td><td rowspan="2">109 bp</td></tr><tr><td>R: 5′ CACAAACCCACTGATGAACG 3′</td></tr></table> |
de94eb0125c4636b70a095e6ff5b0953cdeda15d89f12ffa1bc4b417ce96bf97.png | simple | <table><tr><td>Groups</td><td>Number of clusters</td><td>Number of clones</td><td>Clones/clusters</td><td>% of total</td><td>Putative identification</td></tr><tr><td>1</td><td>542</td><td>741</td><td>1.37</td><td>24.6</td><td>No Hit*</td></tr><tr><td>2</td><td>91</td><td>489</td><td>5.37</td><td>16.3</td><td>Sphingomyelinase D*</td></tr><tr><td>3</td><td>59</td><td>248</td><td>4.20</td><td>8.2</td><td>Metalloproteinase*</td></tr><tr><td>4</td><td>83</td><td>105</td><td>1.27</td><td>3.5</td><td>Unknown Function*</td></tr><tr><td>5</td><td>9</td><td>75</td><td>8.33</td><td>2.5</td><td>Troponin</td></tr><tr><td>6</td><td>4</td><td>55</td><td>13.75</td><td>1.8</td><td>Actin</td></tr><tr><td>7</td><td>14</td><td>46</td><td>3.29</td><td>1.5</td><td>Hsp*</td></tr><tr><td>8</td><td>7</td><td>43</td><td>6.14</td><td>1.4</td><td>Elongation Factor</td></tr><tr><td>9</td><td>7</td><td>41</td><td>5.86</td><td>1.4</td><td>Salivary protein*</td></tr><tr><td>10</td><td>3</td><td>38</td><td>12.67</td><td>1.3</td><td>5'-nucleotidase*</td></tr><tr><td>11</td><td>7</td><td>36</td><td>5.14</td><td>1.2</td><td>Myosin</td></tr><tr><td>12</td><td>5</td><td>26</td><td>5.20</td><td>0.9</td><td>Chitinase*</td></tr><tr><td>13</td><td>4</td><td>23</td><td>5.75</td><td>0.8</td><td>Tubulin</td></tr><tr><td>14</td><td>2</td><td>23</td><td>11.50</td><td>0.8</td><td>LIM protein</td></tr><tr><td>15</td><td>6</td><td>22</td><td>3.67</td><td>0.7</td><td>PDI*</td></tr><tr><td>16</td><td>2</td><td>18</td><td>9.00</td><td>0.6</td><td>Venom allergen III*</td></tr><tr><td>17</td><td>6</td><td>15</td><td>2.50</td><td>0.5</td><td>Lectin*</td></tr><tr><td>18</td><td>12</td><td>14</td><td>1.17</td><td>0.5</td><td>Serine Protease*</td></tr><tr><td>19</td><td>2</td><td>13</td><td>6.50</td><td>0.4</td><td>ATP-binding</td></tr><tr><td>20</td><td>9</td><td>12</td><td>1.33</td><td>0.4</td><td>Ubiquitin</td></tr></table> |
f029606f25d21d2462425d221094ace0e39d473654f6e2e2dafd1673adcaeabf.png | simple | <table><tr><td>r<sub>A </sub>- r<sub>a</sub></td><td>Number of generations needed for the relative proportion of a clone to change from 1% to 99%</td></tr><tr><td>0.01</td><td>919</td></tr><tr><td>0.05</td><td>184</td></tr><tr><td>0.10</td><td>92</td></tr><tr><td>0.50</td><td>18</td></tr><tr><td>0.75</td><td>12</td></tr><tr><td>1.00</td><td>9</td></tr><tr><td>2.00</td><td>5</td></tr><tr><td>5.00</td><td>2</td></tr></table> |
0c44cb56cc92e4d246e9b0fa49f4237eca6e10ab725b78035e03dc895e24210a.png | simple | <table><tr><td>Sample type</td><td>Origin</td><td>Origin</td><td>Period/yearsbefore present</td><td>Numberof samples</td><td>Reference</td><td>PUBMED ID</td><td>SRA accession</td></tr><tr><td>Completeground teeth</td><td>Published works</td><td>England</td><td>750–650</td><td>6</td><td>Adler et al.<sup>9</sup></td><td>23416520</td><td>ERP002107</td></tr><tr><td></td><td></td><td>Germany</td><td>1000–400</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>7400–6725</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4150–3600</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Germany</td><td>800–1100</td><td>14</td><td>Warinner et al.<sup>8</sup></td><td>24562188</td><td>SRP029257</td></tr><tr><td>Dental root canal</td><td></td><td>Brazil</td><td>Modern</td><td>17</td><td>Santos et al.<sup>10</sup></td><td>22132218</td><td>ERP000669</td></tr><tr><td>Dental pulp</td><td>This study</td><td>France</td><td>First World War (WWI)</td><td>6</td><td>N/A</td><td>N/A</td><td>SRP068830</td></tr><tr><td></td><td></td><td>Nigeria</td><td>500</td><td>15</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>France</td><td>Modern</td><td>2</td><td></td><td></td><td></td></tr><tr><td>Dental calculus</td><td>Published works</td><td>England</td><td>750–650</td><td>55</td><td>Adler et al.<sup>9</sup></td><td>23416520</td><td>ERP002107</td></tr><tr><td></td><td></td><td>Germany</td><td>1000–400</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>1100–850 4100–2800</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4150–3600 4450–4000</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>7400–6725 7550–5450</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Germany</td><td>800–1100</td><td>4</td><td>Warinner et al.<sup>8</sup></td><td>24562188</td><td>SRP029257</td></tr><tr><td>Saliva</td><td></td><td>US</td><td>Modern</td><td>29</td><td>Pride et al.<sup>11</sup></td><td>22158393</td><td>SRA024393</td></tr><tr><td></td><td></td><td>US</td><td>Modern</td><td>9</td><td>The HMP (Gevers et al.)<sup>12</sup></td><td>22904687</td><td>SRP002395</td></tr><tr><td>Oral cavity (diverse regions)</td><td></td><td>US</td><td>Modern</td><td>68</td><td>The HMP (Gevers et al.)<sup>12</sup></td><td>22904687</td><td>SRP002395</td></tr><tr><td>Soil</td><td></td><td>Germany</td><td>Modern</td><td>18</td><td>Will et al.<sup>13</sup></td><td>20729324</td><td>SRA020168</td></tr><tr><td></td><td></td><td>Different environments</td><td>Modern</td><td>151</td><td>Bates et al.<sup>14</sup></td><td>21085198</td><td>N/A</td></tr></table> |
96eb74c8d117eec69f471a5dd7c5e83ad28f9c0d75a8abe4f1df21facd9388ec.png | complex | <table><tr><td rowspan="2">Value</td><td colspan="2">GENIA</td><td colspan="2">ST</td><td rowspan="2">ST(%)/GENIA(%)</td></tr><tr><td>frequency</td><td>%</td><td>frequency</td><td>%</td></tr><tr><td>Investigation</td><td>1,914</td><td>5.3</td><td>520</td><td>5.5</td><td>1.03</td></tr><tr><td>Analysis</td><td>6,412</td><td>17.8</td><td>1,448</td><td>15.3</td><td>0.86</td></tr><tr><td>Observation</td><td>12,479</td><td>34.7</td><td>3,892</td><td>41.0</td><td>1.18</td></tr><tr><td>Fact</td><td>2,900</td><td>8.1</td><td>570</td><td>6.0</td><td>0.75</td></tr><tr><td>Method</td><td>973</td><td>2.7</td><td>40</td><td>0.4</td><td>0.16</td></tr><tr><td>Other</td><td>11,309</td><td>31.4</td><td>3,024</td><td>31.9</td><td>1.01</td></tr><tr><td>L3</td><td>33,090</td><td>91.9</td><td>8,921</td><td>94.0</td><td>1.02</td></tr><tr><td>L2</td><td>2,148</td><td>6.0</td><td>485</td><td>5.1</td><td>0.86</td></tr><tr><td>L1</td><td>749</td><td>2.1</td><td>88</td><td>0.9</td><td>0.45</td></tr><tr><td>Positive</td><td>33,779</td><td>93.9</td><td>8,939</td><td>94.2</td><td>1.00</td></tr><tr><td>Negative</td><td>2,208</td><td>6.1</td><td>555</td><td>5.8</td><td>0.95</td></tr><tr><td>High</td><td>1,381</td><td>3.8</td><td>466</td><td>4.9</td><td>1.28</td></tr><tr><td>Low</td><td>322</td><td>0.9</td><td>112</td><td>1.2</td><td>1.32</td></tr><tr><td>Neutral</td><td>34,284</td><td>95.3</td><td>8,916</td><td>93.9</td><td>0.99</td></tr><tr><td>Current</td><td>35,447</td><td>98.5</td><td>9,370</td><td>98.7</td><td>1.00</td></tr><tr><td>Other</td><td>540</td><td>1.5</td><td>124</td><td>1.3</td><td>0.87</td></tr><tr><td>Event Total</td><td>35,987</td><td>100.0</td><td>9,494</td><td>100.0</td><td>1.00</td></tr></table> |
1f21feb8551aaf3728536a9f3a0d1cdc37ad31259fa932b837be473e8921665c.png | simple | <table><tr><td>Disease</td><td>Cell surface DAF deficiency</td><td>Citation</td></tr><tr><td>Immune dysregulation</td><td> </td><td> </td></tr><tr><td> Sjogren's Syndrome</td><td>T-lymphocytes</td><td>[36]</td></tr><tr><td> SLE with lymphopenia and anemia</td><td>T-lymphocytes (CD8+), endothelium, lymphocytes, and anemia</td><td>[38, 41, 73]</td></tr><tr><td> Psoriatic skin</td><td>Epithelium and endothelium</td><td>[39]</td></tr><tr><td> Systemic sclerosis</td><td>Endothelium</td><td>[37]</td></tr><tr><td> Vasculitic skin lesions</td><td>Endothelium</td><td>[35]</td></tr><tr><td> Recurrent pregnancy loss in aPL</td><td>Endometrium</td><td>[42]</td></tr><tr><td> Autoimmune hemocytopenia</td><td>Platelets, lymphocytes, and RBC</td><td>[43, 44]</td></tr><tr><td> Rheumatoid arthritis</td><td>Neutrophils and RBC</td><td>[45, 46]</td></tr><tr><td> Myasthenia gravis</td><td>SNP with decreased expression</td><td>[47]</td></tr><tr><td> Vitiligo</td><td>Whole epidermis</td><td>[48]</td></tr><tr><td> Asthma</td><td>Bronchial epithelial cells and SNP</td><td>[49, 50]</td></tr><tr><td>Proliferative disorders</td><td> </td><td> </td></tr><tr><td> Myelodysplastic syndrome</td><td>Granulocytes and RBC</td><td>[51, 52]</td></tr><tr><td> Plasma cell dyscrasias</td><td>RBC</td><td>[53]</td></tr><tr><td> Lymphoproliferative disorders</td><td>RBC</td><td>[54]</td></tr><tr><td>Anemias</td><td> </td><td> </td></tr><tr><td> Anemia of malaria</td><td>RBC</td><td>[55–59]</td></tr><tr><td> Aplastic anemia</td><td>RBC</td><td>[51]</td></tr><tr><td> HIV</td><td>RBC, lymphocytes, and PBMC</td><td>[60, 61]</td></tr></table> |
a5bbc5bbdf3040b58b6ad90d87d81c5b1c25781cca30b21d1071fc9bbaccc3cc.png | simple | <table><tr><td>Authors</td><td>Study subjects</td><td>Substances</td><td>Insults</td><td>Results</td></tr><tr><td>Broekhuizen [67]</td><td>Patients</td><td>Sulodexide</td><td>Diabetes mellitus type 2</td><td>GCX thickness increased</td></tr><tr><td>Gao [71]</td><td>Rats</td><td>Hydrocortisone</td><td>Pancreatitis</td><td>Improved intestinal perfusionAttenuation of Syn-1 and HA release</td></tr><tr><td>Nordling [72]</td><td>Endothelial cells</td><td>Immobilized heparin conjugate</td><td>IRI</td><td>Attenuation of thrombotic disorder</td></tr><tr><td>Strunden [75]</td><td>Isolated mouse lung</td><td>HES</td><td>Heparinase</td><td>HES attenuated interstitial edema, increased pulmonary arterial pressure</td></tr><tr><td>Chappell [70]</td><td>Isolated guinea pig heart</td><td>Corticosteroid</td><td>IRI</td><td>Increase in Syn-1 and reduction in HS</td></tr><tr><td>Chappell [79]</td><td>Isolated guinea pig heart</td><td>Sevoflurane</td><td>IRI</td><td>Increase in Syn-1 and reduction in HS</td></tr></table> |
aa391d1f14c228095c2cf23038ad0c3163c5fec8c467d396b8d54a5c4e4f9d2b.png | complex | <table><tr><td>Region</td><td>Number tested</td><td colspan="4">Blood slide microscopy</td><td colspan="3">Rapid diagnostic test (ParaScreen)</td></tr><tr><td></td><td></td><td>Pf %</td><td>Pv %</td><td>Pf & Pv %</td><td>Total % (95%CI)</td><td>Pan/Pf %</td><td>Pan %</td><td>Total % (95%CI)</td></tr><tr><td>Amhara</td><td>7,664</td><td>2.4</td><td>1.9</td><td>0.4</td><td>4.6 (3.8–5.7)</td><td>2.0</td><td>1.1</td><td>3.1 (2.4–3.9)</td></tr><tr><td>Oromia</td><td>1,982</td><td>0.7</td><td>0.1</td><td>0</td><td>0.9 (0.5–1.6)</td><td>1.5</td><td>1.2</td><td>2.6 (1.1–6.5)</td></tr><tr><td>SNNP</td><td>1,858</td><td>3.6</td><td>1.8</td><td>0</td><td>5.4 (3.4–8.5)</td><td>4.5</td><td>1.7</td><td>6.2 (3.6–10.2)</td></tr><tr><td>Total</td><td>11,504</td><td>2.2</td><td>1.6</td><td>0.3</td><td>4.1 (3.4–5.0)</td><td>2.1</td><td>1.1</td><td>3.3 (2.6–4.1)</td></tr></table> |
c456051695c5eb65c17789e8de0c941459e52263f609e06da9839ed3a77cb461.png | complex | <table><tr><td>Lipid profile</td><td>Case Number (%)</td><td>Control Number (%)</td><td>Total subjects Number (%)</td><td><i>P</i> value<sup><i>∗</i></sup></td></tr><tr><td>Dyslipidemia</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>22 (18)</td><td>29 (23.8)</td><td>51 (20.9)</td><td rowspan="2">0.27</td></tr><tr><td> Yes</td><td>100 (82)</td><td>93 (76.2)</td><td>193 (79.1)</td></tr><tr><td>Hypertriglyceridemia</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>61 (50)</td><td>82 (67.2)</td><td>143 (58.6)</td><td rowspan="2">0.006</td></tr><tr><td> Yes</td><td>61 (50)</td><td>40 (32.8)</td><td>101 (41.4)</td></tr><tr><td>Hypercholesterolemia</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>70 (57.4)</td><td>91 (74.6)</td><td>161 (66)</td><td rowspan="2">0.005</td></tr><tr><td> Yes</td><td>52 (42.6)</td><td>31 (25.4)</td><td>83 (34)</td></tr><tr><td>High LDL</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>86 (70.5)</td><td>103 (84.4)</td><td>189 (77.5)</td><td rowspan="2">0.009</td></tr><tr><td> Yes</td><td>36 (29.5)</td><td>19 (15.6)</td><td>55 (22.5)</td></tr><tr><td>Low HDL</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>60 (49.2)</td><td>52 (42.6)</td><td>112 (45.9)</td><td rowspan="2">0.304</td></tr><tr><td> Yes</td><td>62 (50.8)</td><td>70 (57.4)</td><td>132 (54.1)</td></tr></table> |
10f524fbefb61ee61d63b1678fb58629319ce2a465f2e6efa7558e4c76f18bd8.png | simple | <table><tr><td>Area</td><td>Example</td><td>Potential utility</td><td>Limitations</td></tr><tr><td>Risk prediction</td><td>Predict new-onset AF or AF-related morbidity (stroke, heart failure, mortality risk)</td><td>Benchmark for clinical trial development</td><td>Absence of known preventive strategies for AF</td></tr><tr><td></td><td></td><td>Facilitate AF and clinical outcome prevention</td><td>Cohorts for genetic risk score derivation predominantly of European ancestry</td></tr><tr><td></td><td></td><td></td><td>Small relative risks of discovered variants</td></tr><tr><td></td><td></td><td></td><td>Complexity of incorporation into clinical practice</td></tr><tr><td></td><td></td><td></td><td>Cost</td></tr><tr><td></td><td></td><td></td><td>Untested</td></tr><tr><td></td><td>Predict AF progression</td><td>Early antiarrhythmic or ablation intervention</td><td>Unclear relations between AF progression and morbidity and mortality</td></tr><tr><td></td><td></td><td></td><td>Untested</td></tr><tr><td>Patient management</td><td>Pharmacogenetics</td><td>Maximize efficacy, minimize adverse effects</td><td>Development of novel agents with wide therapeutic margins</td></tr><tr><td></td><td></td><td>Thromboembolism prophylaxis</td><td>Ablation and mechanical interventions as alternatives</td></tr><tr><td></td><td></td><td>Antiarrhythmic therapy</td><td>Complexity of incorporation into clinical practice</td></tr><tr><td></td><td></td><td></td><td>Cost</td></tr><tr><td></td><td></td><td></td><td>Untested</td></tr></table> |
d76ea110d1784f4fd2adfc7eba7394e82caa4a78deae77b0e2957fdab26fc273.png | simple | <table><tr><td>Group</td><td>Number of Subjects</td><td>Average Age (Range)</td><td>Average Height, cm</td><td>Average Mass kg</td><td>Average Vital Capacity, L</td></tr><tr><td>Females</td><td>29</td><td>25.5 ± 3.7 (18 to 31)</td><td>164 ± 6</td><td>60.5 ± 13.3</td><td>3.58 ± 0.63</td></tr><tr><td>Males</td><td>19</td><td>26.5 ± 4.3 (19 to 34)</td><td>177 ± 7</td><td>74.1 ± 8.8</td><td>4.72 ± 8.4</td></tr></table> |
209ec9b494804583e41d0512ccd1aba043202dc2dede5ab0527130c1c6b37fa7.png | simple | <table><tr><td>History</td><td> No abnormality on IPS</td><td>Abnormality on IPS</td><td>Total</td></tr><tr><td>Family history of epilepsy</td><td>16</td><td>0</td><td>16</td></tr><tr><td>Consanguinity</td><td>14</td><td>1</td><td>15</td></tr><tr><td>No family history</td><td>94</td><td>12</td><td>106</td></tr><tr><td>Total</td><td>124</td><td>13</td><td>137</td></tr></table> |
e54cfd6bef0b8bad80e6e43edb2287175aa3a2018289adb32ebbf1a5d636fc53.png | complex | <table><tr><td colspan="4">(−592 C/A) (rs1800872)</td><td colspan="4">(−819 C/T) (rs1800871)</td></tr><tr><td>Genotype</td><td>n(%)SICL/(%)NCL (n = 204/166)</td><td>ORa (IC95%)</td><td>p Value*</td><td>Genotype</td><td>n(%)SICL/(%)NCL (n = 204/166)</td><td>ORa (IC95%)</td><td>p Value*</td></tr><tr><td colspan="4">Codominant Model</td><td colspan="4">Codominant Model</td></tr><tr><td>C/C</td><td>50(24.5)/66(40)</td><td colspan="2">1</td><td>C/C</td><td>64(31.4)/57(34.3)</td><td colspan="2">1</td></tr><tr><td>C/A</td><td>105(52)/70(42)</td><td>2.0(1.21-3.32)</td><td>0.007</td><td>C/T</td><td>94(46)/75(45.2)</td><td>1.16(0.71-1.92)</td><td>0.53</td></tr><tr><td>A/A</td><td>49(24)/30(18)</td><td>2.07(1.10-3.89)</td><td>0.02</td><td>T/T</td><td>46(22.6)/34(20.5)</td><td>1.15(0.62-2.12)</td><td>0.64</td></tr><tr><td colspan="4">Dominant Model</td><td colspan="4">Dominant Model</td></tr><tr><td>C/C</td><td>50(24.5)/66(40)</td><td colspan="2">1</td><td>C/C</td><td>64(31.4)/57(34.3)</td><td colspan="2">1</td></tr><tr><td>C/A + A/A</td><td>154(76)/100(60)</td><td>2.02(1.26-3.25)</td><td>0.003</td><td>C/T + T/T</td><td>140(68.5)/109(65.7)</td><td>1.16(0.73-1.84)</td><td>0.51</td></tr><tr><td colspan="4">Recessive Model</td><td colspan="4">Recessive Model</td></tr><tr><td>C/C + C/A</td><td>155(76)/136(82)</td><td colspan="2">1</td><td>C/C + C/T</td><td>158(77.4)/132(79.5)</td><td colspan="2">1</td></tr><tr><td>A/A</td><td>49(24)/30(18)</td><td>1.37(0.79-2.39)</td><td>0.25</td><td>T/T</td><td>46(22.6)/34(20.5)</td><td>1.05(0.61-1.81)</td><td>0.84</td></tr><tr><td colspan="4"><i>Alleles</i></td><td colspan="4"><i>Alleles</i></td></tr><tr><td>C</td><td>205(51)/202(60)</td><td colspan="2">1</td><td>C</td><td>222(54)/189(57)</td><td colspan="2">1</td></tr><tr><td>A</td><td>203(49)/130(40)</td><td>1.32 (0.97-1.81)</td><td>0.07</td><td>T</td><td>186(46)/143(43)</td><td>1.10(0.80-1.50)</td><td>0.53</td></tr><tr><td colspan="3">p HWE**</td><td>0.13</td><td colspan="3">p HWE**</td><td>0.31</td></tr><tr><td colspan="4">(−1082 A/G) (rs1800872)</td><td colspan="4">(−1352 G/A) (rs1800893)</td></tr><tr><td>Genotype</td><td>n(%)SICL/(%)NCL (n = 204/166)</td><td>ORa (IC95%)</td><td>p Value*</td><td>Genotype</td><td>n(%)SICL/(%)NCL (n = 204/166)</td><td>ORa (IC95%)</td><td>p Value*</td></tr><tr><td colspan="4">Codominant Model</td><td colspan="4">Codominant Model</td></tr><tr><td>A/A</td><td>125(61.3)/92(55.4)</td><td colspan="2">1</td><td>G/G</td><td>130(63.72)/102(61.44)</td><td colspan="2">1</td></tr><tr><td>A/G</td><td>66(32.3)/62(37.3)</td><td>0.95(0.59-1.52)</td><td>0.84</td><td>G/A</td><td>64(31.37)/53(31.94)</td><td>1.28(0.78-2.07)</td><td>0.31</td></tr><tr><td>G/G</td><td>13(6.4/12(7.3)</td><td>1.02(0.42-2.44)</td><td>0.96</td><td>A/A</td><td>10(4.9)/11(6.62)</td><td>0.85(0.33-2.22)</td><td>0.75</td></tr><tr><td colspan="4">Dominant Model</td><td colspan="4">Dominant Model</td></tr><tr><td>A/A</td><td>125(61.3)/92(55.4)</td><td colspan="2">1</td><td>G/G</td><td>130(63.72)/102(61.44)</td><td colspan="2">1</td></tr><tr><td>A/G + G/G</td><td>79(38.7)/74(44.6)</td><td>0.96(0.61-1.50)</td><td>0.87</td><td>G/A + A/A</td><td>74(36.27)/64(38.56)</td><td>1.20(0.76-1.90)</td><td>0.42</td></tr><tr><td colspan="4">Recessive Model</td><td colspan="4">Recessive Model</td></tr><tr><td>A/A + A/G</td><td>191(93.6)/154(92.7)</td><td colspan="2">1</td><td>G/G + G/A</td><td>194(95)/155(93.38)</td><td colspan="2">1</td></tr><tr><td>G/G</td><td>13(6.4/12(7.3)</td><td>1.04(0.44-2.44)</td><td>0.92</td><td>A/A</td><td>10(4.9)/11(6.62)</td><td>0.78(0.30-1.99)</td><td>0.6</td></tr><tr><td colspan="4"><i>Alleles</i></td><td colspan="4"><i>Alleles</i></td></tr><tr><td>A</td><td>316(77)/246(74)</td><td colspan="2">1</td><td>G</td><td>324(79)/257(77)</td><td colspan="2">1</td></tr><tr><td>G</td><td>92(23)/86(26)</td><td>1.01(0.71-1.45)</td><td>0.92</td><td>A</td><td>84(21)/75(23)</td><td>1.08(0.74-1.58)</td><td>0.65</td></tr><tr><td colspan="3">p HWE**</td><td>0.72</td><td colspan="3">p HWE**</td><td>0.26</td></tr></table> |
df296075d5730a102e8f1adb674fd064a5d59190eef8378d5a6e95e3a223fdf5.png | simple | <table><tr><td>Locus</td><td>SNP</td><td>Gene</td><td>eQTL <i>P</i><sub>all</sub></td><td>eQTL <i>P</i><sub>ER+</sub></td><td>DSS <i>P</i><sub>ER+</sub></td><td>727 cancer genes source</td></tr><tr><td>2q31.1</td><td>rs1550623</td><td><i>CDCA7</i></td><td>0.007 (0.09)</td><td>0.51 (0.67)</td><td>4 × 10<sup>−7</sup></td><td></td></tr><tr><td>11q13.1</td><td>rs3903072</td><td><i>FADD</i></td><td>0.04 (0.28)</td><td>0.01* (0.17)</td><td>0.0009</td><td>Cancer related genes panel</td></tr><tr><td>12q24.21</td><td>rs1292011</td><td><i>TBX3</i></td><td>0.28 (0.50)</td><td>0.21 (0.52)</td><td>0.012</td><td>Cancer gene census</td></tr><tr><td>14q13.3</td><td>rs2236007</td><td><i>PAX9</i></td><td>0.003 (0.07)</td><td>0.05 (0.32)</td><td>0.20</td><td>Cancer related genes panel</td></tr><tr><td>14q24.1</td><td>rs2588809</td><td><i>ZFP36L1</i></td><td>0.08 (0.38)</td><td>0.004 (0.09)</td><td>0.09</td><td>Identified in Nik-Zainal et al 2016</td></tr><tr><td>19p13.11</td><td>rs8170</td><td><i>MRPL34</i></td><td>0.001 (0.06)</td><td>0.01 (0.17)</td><td>0.004</td><td></td></tr></table> |
39f5b281fa945d5e76c5e2add2c8b38c138b833ef4e093c181f1dc2aa2f1d96b.png | simple | <table><tr><td>Group</td><td>Number</td><td>Age, years</td><td>Years of education</td><td>MMSE</td><td>ACE-R</td><td>PSP-RS</td></tr><tr><td>Alzheimer’s disease</td><td>17</td><td>71 (9)</td><td>14 (3)</td><td>25 (4)</td><td>72 (14)</td><td>-</td></tr><tr><td>PSP</td><td>17</td><td>69 (6)</td><td>12 (2)</td><td>27 (4)</td><td>83 (14)</td><td>41 (14)</td></tr><tr><td>Controls</td><td>12</td><td>67 (8)</td><td>16 (2)</td><td>29 (1)</td><td>96 (3)</td><td>-</td></tr></table> |
95725e8be5fdbb6ff1dd28a179b73e18b894a74b7c1f8956934a5ab55fb19676.png | simple | <table><tr><td>Types of substance</td><td>Frequency </td><td>Percent </td></tr><tr><td>Alcohol use (<i>n</i> = 489)</td><td> </td><td> </td></tr><tr><td> Yes</td><td>42</td><td>8.6</td></tr><tr><td> No</td><td>447</td><td>91.4</td></tr><tr><td>Period of alcohol use (<i>n</i> = 42)</td><td> </td><td> </td></tr><tr><td> ≤5 years</td><td>20</td><td>47.6</td></tr><tr><td> 6–10 years</td><td>12</td><td>28.6</td></tr><tr><td> ≥11 years</td><td>10</td><td>23.8</td></tr><tr><td>Cigarette smoking (<i>n</i> = 489)</td><td> </td><td> </td></tr><tr><td> Yes</td><td>55</td><td>11.2</td></tr><tr><td> No</td><td>434</td><td>88.8</td></tr><tr><td>Period of cigarette smoking (<i>n</i> = 55)</td><td> </td><td> </td></tr><tr><td> ≤5 years</td><td>10</td><td>18.2</td></tr><tr><td> 6–10 years</td><td>24</td><td>43.6</td></tr><tr><td> ≥11 years</td><td>21</td><td>38.2</td></tr><tr><td>Psychoactive drugs use (<i>n</i> = 489)</td><td> </td><td> </td></tr><tr><td> Yes</td><td>96</td><td>19.6</td></tr><tr><td> No</td><td>393</td><td>80.4</td></tr><tr><td>Type of psychoactive drugs used (<i>n</i> = 96)</td><td> </td><td> </td></tr><tr><td> Shisha</td><td>7</td><td>7.3</td></tr><tr><td> Khat</td><td>89</td><td>92.7</td></tr></table> |
fa2cddfbb245fa8ededf7b3b167989ed35f18eb2916ce0422d39b1a7448d3839.png | simple | <table><tr><td>Food group</td><td>Items awarded 1 point</td><td>ARFS</td></tr><tr><td>Vegetables</td><td>>4 vegetables per day; potatoes cooked without fat; tomatoes fresh/canned; lettuce/endive/salad greens; carrots; cabbage/brussels sprouts; cauliflower; broccoli; celery; silver beet or spinach; peas; green beans; bean sprout or alfalfa sprout; pumpkin; onion or leeks; sweet corn; sweet potato; coleslaw; mushrooms; zucchini</td><td>20</td></tr><tr><td>Fruits</td><td>2 pieces of fruit/day; 1/week of each of fruit or vegetable juice; canned or frozen fruit; oranges or other citrus; apples; pears; bananas; melons (water, rock, honeydew); pineapple; strawberries; apricots; peach/nectarines; mango/pawpaw; avocado</td><td>14</td></tr><tr><td>Protein foods</td><td>Nuts; peanut butter or peanut paste; 1–4/week of each of beef, lamb, pork, chicken, fish (steamed, baked, or grilled fish/canned (salmon, tuna, sardines)); ≥1/week of each of baked beans, soya beans/soy beans and tofu; use up to 2 eggs per week</td><td>11</td></tr><tr><td>Grains</td><td>≥1/week of each of the following bread types with high fibre, wholemeal; ≥4 slices bread per day; ≥1/week All-Bran, Sultana bran, FibrePlus, Branflakes, Weetbix, VitaBrits, Weeties; rice; pasta/noodles</td><td>12</td></tr><tr><td>Dairy</td><td>Reduced fat or skim; 500 mL/day; cheese 1/week; ice-cream; yoghurt 1/week; use ricotta/cottage cheese; use low-fat cheese</td><td>7</td></tr><tr><td>Fats</td><td>Use nil/polyunsaturated/monounsaturated margarine</td><td>1</td></tr><tr><td>Alcohol</td><td>Drink beer/wine/spirits 1/month up to 4 days/week; or 2 glasses maximum/day</td><td>2</td></tr></table> |
f08b4256d9bd125a5daf31dbddb4ab32ec802d846974ae4be4108dc9fc603161.png | complex | <table><tr><td>Dimension</td><td>Value</td><td>Count</td><td>R / P / F</td><td>+GENIA (R/P/F)</td><td>Majority (R/P/F)</td></tr><tr><td rowspan="6">KT</td><td>Investigation</td><td>38</td><td>76.3 / 67.4 / 71.6</td><td>68.4 / 65.0 / 66.7</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td>Analysis</td><td>132</td><td>70.5 / 69.9 / 70.2</td><td>72.7 / 73.3 / 73.0</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td>Observation</td><td>412</td><td>80.6 / 77.4 / 79.0</td><td>78.6 / 75.2 / 76.9</td><td>100.0 / 40.5 / 57.7</td></tr><tr><td>Fact</td><td>59</td><td>33.9 / 76.9 / 47.1</td><td>40.7 / 70.6 / 51.6</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td>Method</td><td>8</td><td>0.0 / 0.0 / 0.0</td><td>0.0 / 0.0 / 0.0</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td>Other</td><td>368</td><td>77.4 / 73.8 / 75.6</td><td>76.6 / 74.0 / 75.3</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td> </td><td>Macro Average</td><td>1,017</td><td>56.5 / 60.9 / 57.3</td><td>56.2 / 59.7 / 57.3</td><td>16.7 / 6.8 / 9.6</td></tr><tr><td> </td><td>Micro Average</td><td>1,017</td><td>74.6 / 74.6 / 74.6</td><td>73.9 / 73.9 / 73.9</td><td>40.5 / 40.5 / 40.5</td></tr><tr><td rowspan="3">CL</td><td>L3</td><td>983</td><td>97.7 / 98.9 / 98.3</td><td>98.6 / 99.0 / 98.8</td><td>100.0 / 96.7 / 98.3</td></tr><tr><td>L2</td><td>30</td><td>73.3 / 48.9 / 58.7</td><td>76.7 / 62.2 / 68.7</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td>L1</td><td>4</td><td>0.0 / 0.0 / 0.0</td><td>25.0 / 100.0 / 40.0</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td> </td><td>Macro Average</td><td>1,017</td><td>57.0 / 49.3 / 52.3</td><td>66.8 / 87.1 / 69.2</td><td>33.3 / 32.2 / 32.8</td></tr><tr><td> </td><td>Micro Average</td><td>1,017</td><td>96.6 / 96.6 / 96.6</td><td>97.7 / 97.7 / 97.7</td><td>96.7 / 96.7 / 96.7</td></tr><tr><td rowspan="2">Polarity</td><td>Positive</td><td>975</td><td>97.5 / 98.8 / 98.1</td><td>98.2 / 98.6 / 98.4</td><td>100.0 / 95.9 / 97.9</td></tr><tr><td>Negative</td><td>42</td><td>71.4 / 55.6 / 62.5</td><td>66.7 / 60.9 / 63.6</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td> </td><td>Macro Average</td><td>1,017</td><td>84.5 / 77.2 / 80.3</td><td>82.5 / 79.8 / 81.0</td><td>50.0 / 47.9 / 48.9</td></tr><tr><td> </td><td>Micro Average</td><td>1,017</td><td>96.4 / 96.4 / 96.4</td><td>96.9 / 96.9 / 96.9</td><td>95.9 / 95.9 / 95.9</td></tr><tr><td rowspan="3">Manner</td><td>High</td><td>56</td><td>78.6 / 63.8 / 70.4</td><td>76.8 / 65.2 / 70.5</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td>Low</td><td>4</td><td>100.0 / 66.7 / 80.0</td><td>100.0 / 66.7 / 80.0</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td>Neutral</td><td>957</td><td>97.2 / 98.7 / 97.9</td><td>97.4 / 98.6 / 98.0</td><td>100.0 / 94.1 / 97.0</td></tr><tr><td> </td><td>Macro Average</td><td>1,017</td><td>91.9 / 76.4 / 82.8</td><td>91.4 / 76.8 / 82.8</td><td>33.3 / 31.4 / 32.3</td></tr><tr><td> </td><td>Micro Average</td><td>1,017</td><td>96.2 / 96.2 / 96.2</td><td>96.3 / 96.3 / 96.3</td><td>94.1 / 94.1 / 94.1</td></tr><tr><td rowspan="2">Source</td><td>Current</td><td>1,003</td><td>99.8 / 99.5 / 99.7</td><td>99.9 / 99.5 / 99.7</td><td>100.0 / 98.6 / 99.3</td></tr><tr><td>Other</td><td>14</td><td>64.3 / 81.8 / 72.0</td><td>64.3 / 90.0 / 75.0</td><td>0.0 / 0.0 / 0.0</td></tr><tr><td> </td><td>Macro Average</td><td>1,017</td><td>82.1 / 90.7 / 85.9</td><td>82.1 / 94.8 / 87.4</td><td>50.0 / 49.3 / 49.7</td></tr><tr><td> </td><td>Micro Average</td><td>1,017</td><td>99.3 / 99.3 / 99.3</td><td>99.4 / 99.4 / 99.4</td><td>98.6 / 98.6 / 98.6</td></tr><tr><td colspan="2">Event (Task 1)</td><td>1,789</td><td colspan="3">55.1 / 61.7 / 58.2</td></tr><tr><td colspan="2">Event (Task 2)</td><td>1,795</td><td colspan="3">54.1 / 60.8 / 57.2</td></tr><tr><td> </td><td colspan="2">Event (Task 3)</td><td>1,997</td><td colspan="3">51.6 / 59.4 / 55.3</td></tr></table> |
0f20c607b048be823259ea733a2612dcccdbe4973703faf0c194d04994b06564.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2">Sex</td><td rowspan="2">Age</td><td colspan="2">Pressure (mmHg)</td><td colspan="2">Echo Vol (ml)</td><td rowspan="2">Echo EF (%)</td><td rowspan="2">Patient MI and catheter information</td></tr><tr><td>Min</td><td>Max</td><td>Min</td><td>Max</td></tr><tr><td colspan="9">Infarct Group</td></tr><tr><td> P1</td><td>M</td><td>60</td><td>10</td><td>121</td><td>103</td><td>176</td><td>41.48</td><td>Inferior and posterior MI, 90 % stenosis LAD; 80 % stenosis LCX, 100 % stenosis mid MCA</td></tr><tr><td> P2</td><td>F</td><td>72</td><td>8</td><td>96</td><td>50</td><td>98</td><td>48.98</td><td>Anterior myocardial infarction, 30 % stenosis proximal LAD,100 % in the proximal-mid LAD, LCX, RCA</td></tr><tr><td> P3</td><td>M</td><td>73</td><td>9</td><td>105</td><td>115</td><td>193</td><td>40.41</td><td>Inferior and posterior MI, 90 % stenosis proximal and distal LAD; 90 % stenosis proximal LCX, 99 % stenosis in mid LCX, 50 % stenosis in the mid RCA, total occlusion of distal RCA</td></tr><tr><td> P4</td><td>M</td><td>71</td><td>10</td><td>120</td><td>134</td><td>228</td><td>41.23</td><td>Anterior myocardial infarction, apical left ventricular aneurysm;), 100 % stenosis proximal LAD, 40 % stenosis proximal-mid LCX, 40 % stenosis in the mid RCA</td></tr><tr><td> P5</td><td>M</td><td>58</td><td>9</td><td>110</td><td>70</td><td>147</td><td>52.38</td><td>anterior myocardial infarction, 40 % stenosis in LM, total occlusion of proximal LAD, 80 % stenosis mid LCX, 40 % stenosis mid RCA, total occlusion distal RCA</td></tr><tr><td colspan="2"> Mean ± SD</td><td>66.8 ± 7.19</td><td>9.2 ± 0.84</td><td>110.4 ± 10.5</td><td>94.4 ± 34.0</td><td>168.4 ± 49.1</td><td>44.9 ± 5.4</td><td></td></tr><tr><td colspan="9">Non-Infarcted Group</td></tr><tr><td> P6</td><td>M</td><td>48</td><td>9</td><td>115</td><td>46</td><td>116</td><td>60.34</td><td></td></tr><tr><td> P7</td><td>F</td><td>43</td><td>10</td><td>130</td><td>46</td><td>120</td><td>61.67</td><td></td></tr><tr><td> P8</td><td>M</td><td>59</td><td>10</td><td>118</td><td>33</td><td>79</td><td>58.23</td><td></td></tr><tr><td> P9</td><td>M</td><td>43</td><td>9</td><td>115</td><td>51</td><td>120</td><td>57.5</td><td></td></tr><tr><td> P10</td><td>M</td><td>56</td><td>10</td><td>138</td><td>46</td><td>121</td><td>61.98</td><td></td></tr><tr><td colspan="2"> Mean ± SD</td><td>49.8 ± 7.40</td><td>9.6 ± 0.55</td><td>123.2 ± 10.3</td><td>44.4 ± 6.7</td><td>111.2 ± 18.1</td><td>59.9 ± 0.02</td><td></td></tr><tr><td colspan="2"> P value*</td><td>0.06</td><td>0.40</td><td>0.09</td><td>0.01</td><td>0.04</td><td>0.0004</td><td></td></tr></table> |
9487418d76b5d2fab7be6b633bc1c0fdd379ae7d98baeff1110905fd7864d3e0.png | complex | <table><tr><td rowspan="2">Clinicopathologic features</td><td rowspan="2">Cases<i>N</i> (%)</td><td colspan="2">miR‐133b expression</td><td rowspan="2"><i>P</i></td></tr><tr><td>Low (%)</td><td>High (%)</td></tr><tr><td colspan="5">Gender</td></tr><tr><td>Male</td><td>94 (64.4)</td><td>42 (44.7)</td><td>52 (55.3)</td><td>0.467</td></tr><tr><td>Female</td><td>52 (35.6)</td><td>20 (38.5)</td><td>32 (61.5)</td><td></td></tr><tr><td colspan="5">Age (years)</td></tr><tr><td><60</td><td>70 (47.9)</td><td>27 (38.6)</td><td>43 (61.4)</td><td>0.361</td></tr><tr><td>≥60</td><td>76 (52.1)</td><td>35 (46.1)</td><td>41 (53.9)</td><td></td></tr><tr><td colspan="5">ECOG</td></tr><tr><td>≤1</td><td>127 (87.0)</td><td>49 (38.6)</td><td>78 (61.4)</td><td>0.014a</td></tr><tr><td>≥2</td><td>19 (13.0)</td><td>13 (68.4)</td><td>6 (31.6)</td><td></td></tr><tr><td colspan="5">T stage</td></tr><tr><td>Ta</td><td>52 (35.6)</td><td>16 (30.8)</td><td>36 (69.2)</td><td>0.013a</td></tr><tr><td>T1</td><td>70 (47.9)</td><td>30 (42.9)</td><td>40 (57.1)</td><td></td></tr><tr><td>≥T2</td><td>24 (16.4)</td><td>16 (66.7)</td><td>8 (33.3)</td><td></td></tr><tr><td colspan="5">Histological grade</td></tr><tr><td>PUNLMP</td><td>33 (22.6)</td><td>8 (24.2)</td><td>25 (75.8)</td><td><0.001a</td></tr><tr><td>LG</td><td>80 (54.8)</td><td>27 (33.8)</td><td>53 (66.3)</td><td></td></tr><tr><td>HG</td><td>33 (22.6)</td><td>27 (81.8)</td><td>6 (18.2)</td><td></td></tr><tr><td colspan="5">Surgery</td></tr><tr><td>Transurethral resection (TUR)</td><td>117 (80.1)</td><td>41 (35.0)</td><td>76 (65.0)</td><td><0.001a</td></tr><tr><td>Cystectomy</td><td>29 (19.9)</td><td>21 (72.4)</td><td>8 (27.6)</td><td></td></tr><tr><td colspan="5">Recurrence or progression (postoperative)</td></tr><tr><td>Yes</td><td>58 (39.7)</td><td>44 (75.9)</td><td>14 (24.1)</td><td><0.001a</td></tr><tr><td>No</td><td>88 (60.3)</td><td>18 (20.5)</td><td>70 (79.5)</td><td></td></tr><tr><td colspan="5">Past history of urothelial carcinoma of the bladder (UCB)</td></tr><tr><td>Yes</td><td>44 (30.1)</td><td>21 (47.7)</td><td>23 (52.3)</td><td>0.398</td></tr><tr><td>No</td><td>102 (69.9)</td><td>41 (40.2)</td><td>61 (59.8)</td><td></td></tr><tr><td colspan="5">Multifocality</td></tr><tr><td>Single tumor</td><td>91 (62.3)</td><td>32 (23.8)</td><td>59 (76.3)</td><td>0.022a</td></tr><tr><td>Multiple tumor</td><td>55 (37.7)</td><td>30 (65.2)</td><td>25 (34.8)</td><td></td></tr><tr><td colspan="4">Death</td><td></td></tr><tr><td>Yes</td><td>33 (22.6)</td><td>28 (84.8)</td><td>5 (15.2)</td><td><0.001a</td></tr><tr><td>No</td><td>113 (77.4)</td><td>34 (30.1)</td><td>79 (69.9)</td><td></td></tr></table> |
b3bf438ec2d4665c75f25b276918e2c1a12c80ad2832a74b310230a2c306e2d6.png | simple | <table><tr><td>Group</td><td>DEG</td><td>Fold change (log2,</td></tr><tr><td></td><td></td><td><i>vs.</i> Model)</td></tr><tr><td>Martynoside</td><td><i>Rny1</i> (RNA, Y1 small cytoplasmic, Ro-associated)</td><td>-7.74</td></tr><tr><td></td><td><i>Hist1h4a</i> (histone cluster 1, H4a)</td><td>-1.85</td></tr><tr><td></td><td><i>Opn3</i> (RNA, Y1 small cytoplasmic, Ro-associated)</td><td>1.29</td></tr><tr><td></td><td><i>Supt4b</i> (suppressor of Ty 4B)</td><td>-1.21</td></tr><tr><td></td><td><i>Tnnt3</i> (troponin T3, skeletal, fast)</td><td>-1.15</td></tr><tr><td>R2</td><td><i>Egr4</i> (early growth response 4)</td><td>-6.85</td></tr><tr><td></td><td><i>Cdkn1a</i> [cyclin-dependent kinase inhibitor 1A (P21)]</td><td>-3.33</td></tr><tr><td></td><td><i>Ets2</i> (E26 avian leukemia oncogene 2, 3′ domain)</td><td>-3.18</td></tr><tr><td></td><td><i>Sap25</i> (sin3 associated polypeptide)</td><td>2.98</td></tr><tr><td></td><td><i>Il4i1</i> (interleukin 4 induced 1)</td><td>2.93</td></tr><tr><td>Rg2</td><td><i>Tnnc2</i> (troponin C2, fast)</td><td>2.75</td></tr><tr><td></td><td><i>Amigo2</i> (adhesion molecule with Ig like domain 2)</td><td>2.07</td></tr><tr><td></td><td><i>Col8a1</i> (collagen, type VIII, alpha 1)</td><td>-1.95</td></tr><tr><td></td><td><i>Map7</i> (microtubule-associated protein 7)</td><td>1.92</td></tr><tr><td></td><td><i>Car3</i> (carbonic anhydrase 3)</td><td>-1.70</td></tr></table> |
1d67670b4c85b35b27671818384316e439b8c9456105da77514fcc76b1fb7fbd.png | simple | <table><tr><td>IPTG μM</td><td>OD620</td><td>Isopentenol mg/L</td></tr><tr><td>0.01</td><td>0.014</td><td>3.6</td></tr><tr><td>0.05</td><td>0.079</td><td>5.9</td></tr><tr><td>0.1</td><td>0.127</td><td>8.45</td></tr><tr><td>0.2</td><td>0.179</td><td>12.5</td></tr><tr><td>0.5</td><td>0.456</td><td>98.1</td></tr><tr><td>1</td><td>0.506</td><td>142</td></tr></table> |
794fc17b99ebf0e06561ef940ca30b2020d5e30b54be9e3aaffabd65a50c589d.png | simple | <table><tr><td>Radiologic Impression/Technique</td><td>Patient</td><td>BI-RADS Category</td><td>Needle Gauge (G)</td><td>Pieces of tissue in specimen</td><td>Pieces of tissue imaged</td><td>Pathologic diagnosis</td></tr><tr><td>Calcium positive/mammogram</td><td>1</td><td>4</td><td>11</td><td>7</td><td>1</td><td>Fibrocystic changes with calcifications</td></tr><tr><td>mass/mammogram, ultrasound</td><td>2</td><td>4</td><td>14</td><td>4</td><td>1</td><td>Fibrocystic changes with calcifications</td></tr><tr><td>mass/sonogram</td><td>3</td><td>3</td><td>14</td><td>3</td><td>1</td><td>Fibrocystic changes with apocrine metaplasia</td></tr><tr><td>Calcium positive/mammogram</td><td>4</td><td>4</td><td>11</td><td>5</td><td>1</td><td>Ductal carcinoma in situ</td></tr><tr><td>Speculated mass/Mammogram, sonogram</td><td>5</td><td>4</td><td>14</td><td>3</td><td>1</td><td>Infiltrating ductal carcinoma</td></tr><tr><td>Mass/mammogram, ultrasound</td><td>6</td><td>5</td><td>14</td><td>2</td><td>1</td><td>Infiltrating lobular carcinoma</td></tr><tr><td>Palpable mass/ultrasound</td><td>7</td><td>5</td><td>14</td><td>5</td><td>1</td><td>Poorly differentiated infiltrating ductal carcinoma</td></tr></table> |
4ed42ef01caef0a6f9ca06b8309f7e8aa15989ead63752becc6ca51a4ca531a7.png | simple | <table><tr><td>Studies</td><td>Patients</td><td>Inter- ventions</td><td>Relevant outcomes</td><td>Size of effect</td><td>Benefits and harms</td><td>Factors influencing the clinical relevance</td></tr><tr><td>Barker et al. (2008) [15]</td><td>YES</td><td>NO</td><td>NO</td><td>NO</td><td>YES</td><td>Patients: Pre-treatment surgery is poorly described. Intervention is poorly described. Results 6 weeks and 12 weeks post-treatment are not integrated.</td></tr><tr><td>Hohmann et al. (2012) [20]</td><td>NO</td><td>NO</td><td>YES</td><td>NO</td><td>YES</td><td>Patients: Pregnancy is poorly described, although 15 patients out of 21 were women. Intervention is poorly described.</td></tr><tr><td>Morone et al. (2011) [16]</td><td>YES</td><td>YES</td><td>YES</td><td>YES</td><td>YES</td><td>Patients: Pre-treatment surgery is poorly described.</td></tr><tr><td>Paolucci et al. (2012) [37]</td><td>YES</td><td>YES</td><td>NO</td><td>NO</td><td>YES</td><td>Patients: Pre-treatment surgery is poorly described. Function is no outcome measure.</td></tr><tr><td>Ryan et al. (2014) [38]</td><td>NO</td><td>YES</td><td>YES</td><td>NO</td><td>YES</td><td>Patients: Pre-treatment surgery or pregnancies are poorly described. Ratio men / women is not documented.</td></tr><tr><td>Vetrano et al. (2013) [39]</td><td>YES</td><td>YES</td><td>YES</td><td>YES</td><td>YES</td><td>There have been remarkably more women included in this study than men. Intervention 2 (Control group) received also a SFT.</td></tr></table> |
a889f29cdf6cfa6f86a2cd474f8390a37d03874c80e50eea9333f245715caebb.png | complex | <table><tr><td></td><td colspan="2">IORT</td><td colspan="2">APBI</td><td colspan="2">EBRT</td></tr><tr><td></td><td>%Vol > 0.1 Gy</td><td>%Vol > 4 Gy</td><td>%Vol > 0.1 Gy</td><td>%Vol > 4 Gy</td><td>%Vol > 0.1 Gy</td><td>%Vol > 4 Gy</td></tr><tr><td>Ipsilateral Breast</td><td>84.5</td><td>18.1</td><td>88.2</td><td>54.4</td><td>99.9</td><td>99.9</td></tr><tr><td>Contralateral breast</td><td>< 1</td><td>0</td><td>< 1</td><td>0</td><td>97.7</td><td>1.3</td></tr><tr><td>Ipsilateral Lung</td><td>4.5</td><td>0</td><td>5.0</td><td>1.3</td><td>98.8</td><td>10.1</td></tr><tr><td>Contralateral lung</td><td>< 1</td><td>0</td><td>< 1</td><td>0</td><td>87</td><td>0</td></tr><tr><td>Heart</td><td>1.8</td><td>0</td><td>4.2</td><td>0</td><td>98</td><td>0</td></tr><tr><td>Spine</td><td>< 1</td><td>0</td><td>< 1</td><td>0</td><td>92</td><td>0</td></tr></table> |
11e3f02e6a4cfd3f4d24306c65fe92556b0d7edefe7561d2a797ef6aba5a62d3.png | complex | <table><tr><td rowspan="2">Variable</td><td rowspan="2">Treatment</td><td colspan="2">Time (h)</td><td rowspan="2">p-level</td></tr><tr><td>0</td><td>2</td></tr><tr><td>Cholesterol</td><td>PLA</td><td>170.6 ± 34.6</td><td>182.8 ± 35.1</td><td rowspan="3">0.006</td></tr><tr><td rowspan="2">(mg/dl)</td><td>PWS</td><td>187.3 ± 46.6 <sup>a</sup></td><td>180.2 ± 36.9</td></tr><tr><td>PWS + S</td><td>161.7 ± 29.8 <sup>a,b</sup></td><td>174.0 ± 33.5 <sup>a</sup></td></tr><tr><td>HDL-c</td><td>PLA</td><td>54.9 ± 13.3</td><td>60.1 ± 16.0</td><td rowspan="3">0.57</td></tr><tr><td rowspan="2">(mg/dl)</td><td>PWS</td><td>52.2 ± 13.9</td><td>58.9 ± 14.6</td></tr><tr><td>PWS + S</td><td>54.2 ± 16.2</td><td>60.1 ± 18.1</td></tr><tr><td rowspan="3">CHOL: HDL-c</td><td>PLA</td><td>3.2 ± 0.9 <sup>b</sup></td><td>3.2 ± 0.9</td><td rowspan="3">0.001</td></tr><tr><td>PWS</td><td>3.8 ± 1.3 <sup>a,c</sup></td><td>3.2 ± 1.0 *</td></tr><tr><td>PWS + S</td><td>3.2 ± 1.0 <sup>b</sup></td><td>3.1 ± 1.0</td></tr><tr><td>LDL-c</td><td>PLA</td><td>104.3 ± 36.7</td><td>109.6 ± 41.2</td><td rowspan="3">0.55</td></tr><tr><td rowspan="2">(mg/dl)</td><td>PWS</td><td>96.9 ± 31.9</td><td>104.5 ± 36.0</td></tr><tr><td>PWS + S</td><td>99.8 ± 41.2</td><td>104.6 ± 40.7</td></tr><tr><td>Triglycerides</td><td>PLA</td><td>98.0 ± 58.6</td><td>89.3 ± 38.3</td><td rowspan="3">0.14</td></tr><tr><td rowspan="2">(mg/dl)</td><td>PWS</td><td>109.5 ± 56.8</td><td>100.3 ± 47.5</td></tr><tr><td>PWS + S</td><td>88.3 ± 42.2</td><td>92.8 ± 54.6</td></tr><tr><td>Glucose</td><td>PLA</td><td>90.2 ± 9.7</td><td>101.5 ± 14.4 *</td><td rowspan="3">0.03</td></tr><tr><td rowspan="2">(mg/dl)</td><td>PWS</td><td>100.1 ± 16.0 <sup>a,c</sup></td><td>114.4 ± 12.6 *<sup>a</sup></td></tr><tr><td>PWS + S</td><td>90.4 ± 7.3</td><td>113.8 ± 15.0 *<sup>a</sup></td></tr></table> |
b56a59af1752b98e4cc16a4838bb537bdfe6b881cdeda90c08551df9ef98eb5d.png | complex | <table><tr><td>Cox model*</td><td>Factors</td><td>HR (95% CI)</td><td><i>P</i></td></tr><tr><td colspan="4">TTP</td></tr><tr><td>Gabor filter 0 Subgroups</td><td>TACE+sorafenib</td><td></td><td>0.002</td></tr><tr><td></td><td>Gabor-1-90 ≤3.6190</td><td>0.802 (0.505–1.274)</td><td></td></tr><tr><td></td><td>Gabor-1-90 > 3.6190</td><td>2.184 (1.190–4.007)</td><td></td></tr><tr><td>Gabor filter 1. 0 Subgroups</td><td>TACE+sorafenib</td><td></td><td>0.004</td></tr><tr><td></td><td>Gabor-1-135 ≤1.3995</td><td>0.455 (0.231–0.898)</td><td></td></tr><tr><td></td><td>Gabor-1-135 > 1.3995</td><td>1.298 (0.827–2.036)</td><td></td></tr><tr><td>Gabor filter 1.5 Subgroups</td><td>TACE+sorafenib</td><td></td><td>0.008</td></tr><tr><td></td><td>Gabor-1-135 ≤0.5175</td><td>0.665 (0.390–1.137)</td><td></td></tr><tr><td></td><td>Gabor-1-135 > 0.5175</td><td>1.503 (0.930–2.431)</td><td></td></tr><tr><td>Wavelet Transform filter 1.0 Subgroups</td><td>TACE+sorafenib</td><td></td><td>0.007</td></tr><tr><td></td><td>Wavelet-2-D ≤18.3585</td><td>0.663 (0.393–1.118)</td><td></td></tr><tr><td></td><td>Wavelet-2-D > 18.3585</td><td>1.486 (0.912–2.422)</td><td></td></tr><tr><td>Wavelet Transform filter 1.5</td><td></td><td>None identified</td><td></td></tr><tr><td colspan="4">OS</td></tr><tr><td>Wavelet Transform filter 1.0 Subgroups</td><td>TACE+sorafenib</td><td></td><td>0.005</td></tr><tr><td></td><td>Wavelet-3-D < 12.2620</td><td>0.759 (0.465–1.239)</td><td></td></tr><tr><td></td><td>Wavelet-3-D > 12.2620</td><td>2.115 (1.101–4.062)</td><td></td></tr></table> |
3f730661c8490efbdf72595f197b2a2815626ba4b15ab3b5fd7476df292d2422.png | simple | <table><tr><td>Sections</td><td>Multidisciplinary expertise</td><td>Hardware</td><td>Software</td></tr><tr><td>2.1: Fluorescent protein behavior</td><td>Molecular biology, biochemistry</td><td>n.a.</td><td>n.a.</td></tr><tr><td>2.2–2.4: Microscopy</td><td>Cell biology, biophysics, optics</td><td>Microscope control system</td><td>Time series, stage control, autofocus</td></tr><tr><td>2.5: Cell physiology</td><td>Cell biology</td><td>Incubation control system</td><td>n.a.</td></tr><tr><td>2.6: Image analysis</td><td>Math/physics</td><td>High performance computer</td><td>Image segmentation, tracking</td></tr><tr><td>2.7: Population sampling</td><td>Statistics</td><td>High performance computer</td><td>Statistical analysis</td></tr><tr><td>2.8: Network modeling</td><td>Math/physics/engineering</td><td>High performance computer</td><td>Mathematical modeling</td></tr></table> |
559a899448f508bf7f95ec43672876c38c20a1d5f40c63fe84f7a9260e45dd7c.png | complex | <table><tr><td> </td><td>Total n</td><td>Ate fish (%)</td><td>Mean ounces of fish consumed in last month of pregnancy (+/- SD)</td><td>MeHg concentration in cord blood ≥5 μg/L</td></tr><tr><td>Total</td><td>100</td><td>86.0 (86)</td><td>19.8 (3.7)</td><td>44.0 (44)</td></tr><tr><td>Race**</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Hispanic</td><td>18</td><td>88.9 (16)</td><td>18.8 (15.0)</td><td>33.3 (6)</td></tr><tr><td>Caucasian</td><td>42</td><td>88.1 (37)</td><td>18.3 (18.8)</td><td>42.9 (18)</td></tr><tr><td>Japanese</td><td>23</td><td>91.3 (21)</td><td>9.6 (7.4)</td><td>56.5 (13)</td></tr><tr><td>Chinese</td><td>23</td><td>82.6 (19)</td><td>16.2 (20.0)</td><td>34.8 (8)</td></tr><tr><td>Filipino</td><td>32</td><td>75.0 (24)*</td><td>13.7 (15.0)</td><td>28.1 (9)*</td></tr><tr><td>Pacific Islander¶</td><td>48</td><td>87.5 (42)</td><td>25.7 (34.8)*</td><td>43.8 (21)</td></tr><tr><td>Birthplace</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>United States</td><td>65</td><td>81.5 (53)</td><td>17.4 (20.7)</td><td>38.5 (25)</td></tr><tr><td>Outside of United States</td><td>34</td><td>94.1 (32)</td><td>23.5 (37.9)</td><td>52.9 (18)</td></tr><tr><td>Income</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Less than $22,000</td><td>20</td><td>95.0 (19)*</td><td>38.0 (47.7)*</td><td>50.0 (10)</td></tr><tr><td>$22,000–$47,600</td><td>21</td><td>71.4 (15)</td><td>12.2 (18.5)</td><td>38.1 (8)</td></tr><tr><td>$47,600–$80,100</td><td>22</td><td>86.4 (19)</td><td>22.5 (23.0)</td><td>36.4 (8)</td></tr><tr><td>Greater than $80,100</td><td>19</td><td>89.5 (17)</td><td>13.3 (11.1)</td><td>47.4 (9)</td></tr><tr><td>Missing</td><td>18</td><td>88.9 (16)</td><td>11.9 (13.3)</td><td>50.0 (9)</td></tr><tr><td colspan="3">Highest education level achieved</td><td> </td><td> </td></tr><tr><td>Less than high school</td><td>9</td><td>88.9 (8)</td><td>32.8 (35.8)</td><td>55.6 (5)</td></tr><tr><td>High school diploma</td><td>39</td><td>84.6 (33)</td><td>22.8 (36.2)</td><td>46.2 (18)</td></tr><tr><td>Any college</td><td>52</td><td>86.5 (45)</td><td>15.2 (16.1)</td><td>40.4 (21)</td></tr><tr><td>Mother’s age</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Less than 23 years</td><td>27</td><td>77.8 (21)</td><td>18.3 (21.9)</td><td>33.3 (9)</td></tr><tr><td>23 – 27.5 years</td><td>23</td><td>87.0 (20)</td><td>24.7 (31.7)</td><td>47.8 (11)</td></tr><tr><td>27.5 – 33 years</td><td>26</td><td>92.3 (24)</td><td>19.0 (35.6)</td><td>38.5 (10)</td></tr><tr><td>Over 33 years</td><td>24</td><td>87.5 (21)</td><td>17.6 (20.2)</td><td>58.3 (14)</td></tr></table> |
42f058d6ffac9e220005ba77e491fe7eb0702686f28ebbafb88b68818a98f61a.png | complex | <table><tr><td>Marker alleles</td><td>Chromosome (linked genes)</td><td>Position</td><td colspan="6">Alleles belong to the</td></tr><tr><td></td><td></td><td></td><td>20 best</td><td>10 best</td><td>5 best</td><td>20 worst</td><td>10 worst</td><td>5 worst</td></tr><tr><td>GWM1130_109bp<sup>*</sup></td><td>1B</td><td>0</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>GWM1130_115bp<sup>*</sup></td><td>1B</td><td>0</td><td></td><td></td><td></td><td>x</td><td>x</td><td>x</td></tr><tr><td>BARC0240_231bp</td><td>1B</td><td>36.1</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>GWM3166_153bp</td><td>1B</td><td>175.7</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WMC0732c_295bp</td><td>1D</td><td>132.4</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WMC0522_200bp</td><td>2A (<i>Ppd-A1</i>)</td><td>88.3</td><td>x</td><td>x</td><td></td><td></td><td></td><td></td></tr><tr><td>GWM4167_217bp</td><td>2B (<i>Ppd-B1</i>)</td><td>40</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>BARC0160_111bp</td><td>2B</td><td>80.4</td><td></td><td></td><td></td><td>x</td><td>x</td><td></td></tr><tr><td>CFD0056c_250bp</td><td>2D</td><td>20.2</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>GWM0988_180bp</td><td>2D</td><td>84.5</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>CFD0168_256bp</td><td>2D</td><td>160.3</td><td></td><td></td><td></td><td>x</td><td>x</td><td>x</td></tr><tr><td>Ppd_insensitive</td><td>2D</td><td>unm.</td><td>x</td><td>x</td><td>x</td><td></td><td></td><td></td></tr><tr><td>Ppd_sensitive</td><td>2D</td><td>unm.</td><td></td><td></td><td></td><td>x</td><td>x</td><td>x</td></tr><tr><td>WMC0264_141bp<sup>*</sup></td><td>3A<sup>1</sup></td><td>131.3</td><td>x</td><td>x</td><td></td><td></td><td></td><td></td></tr><tr><td>WMC0264_148bp<sup>*</sup></td><td>3A<sup>1</sup></td><td>131.3</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>WMC0808_147bp</td><td>3B<sup>1</sup></td><td>67.5</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>GWM0160a_181bp</td><td>4A</td><td>186.4</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>GWM4636_233bp</td><td>4B<sup>1</sup></td><td>59.4</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WMC0285_293bp</td><td>4D</td><td>0</td><td>x</td><td>x</td><td></td><td></td><td></td><td></td></tr><tr><td>GWM0291_176bp</td><td>5A (<i>Vrn-A2</i>)</td><td>231</td><td>x</td><td>x</td><td>x</td><td></td><td></td><td></td></tr><tr><td>WMC0160b_137bp</td><td>5B<sup>1</sup> (Hd6-related gene)</td><td>158.4</td><td></td><td></td><td></td><td>x</td><td>x</td><td></td></tr><tr><td>WMC0783_179bp</td><td>5B</td><td>219.8</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>WMC0215_208bp</td><td>5D</td><td>200.5</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>GDM0063_147bp</td><td>5D</td><td>265.4</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>WMC0161b_184bp</td><td>5D</td><td>301.3</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>GWM4047_194bp</td><td>6B</td><td>0</td><td></td><td></td><td></td><td>x</td><td>x</td><td></td></tr><tr><td>GWM0825b_122bp</td><td>6B</td><td>34.3</td><td></td><td></td><td></td><td>x</td><td>x</td><td></td></tr><tr><td>GWM1391_158bp<sup>*</sup></td><td>6D</td><td>0</td><td></td><td></td><td></td><td>x</td><td>x</td><td>x</td></tr><tr><td>GWM1391_160bp<sup>*</sup></td><td>6D</td><td>0</td><td>x</td><td>x</td><td>x</td><td></td><td></td><td></td></tr><tr><td>CFD0019c_313bp</td><td>6D</td><td>130.9</td><td>x</td><td>x</td><td>x</td><td></td><td></td><td></td></tr><tr><td>BARC0204b_500bp</td><td>6D</td><td>194</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>GWM0983b_130bp<sup>*</sup></td><td>7B</td><td>54</td><td></td><td></td><td></td><td>x</td><td>x</td><td>x</td></tr><tr><td>GWM0983b_133bp<sup>*</sup></td><td>7B</td><td>54</td><td>x</td><td>x</td><td></td><td></td><td></td><td></td></tr><tr><td>BARC0182_118bp</td><td>7B</td><td>176</td><td></td><td></td><td></td><td>x</td><td>x</td><td></td></tr><tr><td>GWM0428_145bp</td><td>7D</td><td>228.2</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>WMC0014_267bp</td><td>7D</td><td>274.2</td><td></td><td></td><td></td><td>x</td><td></td><td></td></tr><tr><td>BARC0261_170bp</td><td>Unmapped</td><td>–</td><td>x</td><td>x</td><td>x</td><td></td><td></td><td></td></tr><tr><td>CFA2263_123bp</td><td>Unmapped</td><td>–</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WMC0327_209bp</td><td>Unmapped</td><td>–</td><td>x</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WMC0349_118</td><td>Unmapped</td><td>–</td><td>x</td><td>x</td><td></td><td></td><td></td><td></td></tr></table> |
48ab92437e6dbdfc204c72ab9bb93898984c46560142a2389aa33cf08704e21f.png | complex | <table><tr><td>Organ</td><td colspan="2">REP1 expression</td><td>Total (<i>N</i>)</td><td><i>P</i>-value</td></tr><tr><td> </td><td>−/+ <i>N</i> (%)</td><td>++/+++ <i>N</i> (%)</td><td> </td><td> </td></tr><tr><td colspan="5"><i>Cervical</i></td></tr><tr><td> Normal</td><td>4 (100.0%)</td><td>0 (0.0%)</td><td>4</td><td>0.0000</td></tr><tr><td> Cancer</td><td>6 (12.0%)</td><td>44 (88.0%)</td><td>50</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="5"><i>Lung</i></td></tr><tr><td> Normal</td><td>9 (100%)</td><td>0 (0.0%)</td><td>9</td><td>0.0000</td></tr><tr><td> Cancer</td><td>12 (30.0%)</td><td>28 (70.0%)</td><td>40</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="5"><i>Colorectal</i></td></tr><tr><td> Normal</td><td>8 (88.9%)</td><td>1 (11.1%)</td><td>9</td><td>0.0002</td></tr><tr><td> Cancer</td><td>10 (25%)</td><td>30 (75%)</td><td>40</td><td> </td></tr></table> |
5ccf9563d17b8ea04d7e0ab7a5339a458184a0782690e353e30970e5920aa4eb.png | simple | <table><tr><td>Site</td><td>Number</td><td>Morphology</td><td>Number</td><td>Comorbid diseases</td><td>Number</td></tr><tr><td>Local recurrence alone</td><td>4 (12.9%)</td><td>Adenocarcinoma</td><td>4 (12.9%)</td><td>Hypertension Diabetes</td><td>2 (6.4%) 2 (6.4%)</td></tr><tr><td>Pelvic lymph node</td><td>3 (9.6%)</td><td>Adenocarcinoma</td><td>3 (9.6%)</td><td>Diabetes COPD</td><td>2 (6.4%) 1 (3.2%)</td></tr><tr><td>Persistent</td><td>2 (6.4%)</td><td>Adenocarcinoma Clear cell carcinoma</td><td>1 (3.2%) 1 (3.2%)</td><td>Diabetes</td><td>2 (6.4%)</td></tr><tr><td>Distant</td><td>5 (16.1%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Lung</td><td>2 (6.4%)</td><td>Adenocarcinoma</td><td>2 (6.4%)</td><td>Hypertension Diabetes</td><td>1 (3.2%) 1 (3.2%)</td></tr><tr><td>Multi-organ</td><td>2 (6.4%)</td><td>Adenocarcinoma</td><td>2 (6.4%)</td><td>Hypertension SLE</td><td>1 (3.2%) 1 (3.2%)</td></tr><tr><td>Bone</td><td>1 (3.2%)</td><td>Adenocarcinoma</td><td>1 (3.2%)</td><td>Diabetes</td><td>1 (3.2%)</td></tr></table> |
24843d2c74a6d1519ff05ca03bd25c29e452f4dda938c138bb4cc9facc467a44.png | simple | <table><tr><td>Patient</td><td>Target lesion</td><td>SUV<sub>max</sub> pre<sup>a</sup></td><td>SUV<sub>max</sub> post<sup>b</sup></td><td>ΔSUV<sub>max</sub><sup>c</sup> (%)</td><td>RECIST<sup>d</sup></td></tr><tr><td>1</td><td>Mediastinal mass</td><td>10.00</td><td>7.50</td><td>−25</td><td>PR</td></tr><tr><td>2</td><td>Mediastinal mass</td><td>6.60</td><td>3.50</td><td>−47</td><td>PR</td></tr><tr><td>3</td><td>Mediastinal mass</td><td>13.00</td><td>6.20</td><td>−52</td><td>SD</td></tr><tr><td>4</td><td>Pleural implant</td><td>9.23</td><td>0.00</td><td>−100</td><td>CR</td></tr><tr><td>5</td><td>Mediastinal mass</td><td>4.10</td><td>3.00</td><td>−27</td><td>PR</td></tr><tr><td>6</td><td>Lung lesion</td><td>18.70</td><td>17.00</td><td>−9</td><td>SD</td></tr><tr><td>7</td><td>Lymph node</td><td>12.00</td><td>11.50</td><td>−4</td><td>SD</td></tr><tr><td>8</td><td>Pleural implant</td><td>5.80</td><td>2.10</td><td>−64</td><td>PR</td></tr><tr><td>9</td><td>Pleural implant</td><td>7.60</td><td>1.70</td><td>−78</td><td>PR</td></tr><tr><td>10</td><td>Lymph node</td><td>3.70</td><td>8.20</td><td>120</td><td>PD</td></tr><tr><td>11</td><td>Mediastinal mass</td><td>4.19</td><td>5.30</td><td>26</td><td>SD</td></tr><tr><td>12</td><td>Mediastinal mass</td><td>8.40</td><td>11.30</td><td>35</td><td>SD</td></tr><tr><td>13</td><td>Lung lesion</td><td>19.70</td><td>5.70</td><td>−71</td><td>PR</td></tr><tr><td>14</td><td>Mediastinal mass</td><td>4.20</td><td>4.60</td><td>10</td><td>PR</td></tr><tr><td>15</td><td>Mediastinal mass</td><td>5.00</td><td>3.00</td><td>−40</td><td>PR</td></tr><tr><td>16</td><td>Mediastinal mass</td><td>8.40</td><td>0.00</td><td>−100</td><td>CR</td></tr><tr><td>17</td><td>Pleural implant</td><td>4.00</td><td>4.80</td><td>20</td><td>PD</td></tr><tr><td>18</td><td>Mediastinal mass</td><td>15.60</td><td>18.5</td><td>19</td><td>PR</td></tr><tr><td>19</td><td>Mediastinal mass</td><td>7.70</td><td>2.20</td><td>−71</td><td>PR</td></tr><tr><td>20</td><td>Lung lesion</td><td>8.80</td><td>14.40</td><td>64</td><td>SD</td></tr><tr><td>21</td><td>Mediastinal mass</td><td>8.30</td><td>5.70</td><td>−31</td><td>PR</td></tr><tr><td>22</td><td>Lymph node</td><td>8.50</td><td>5.40</td><td>−36</td><td>PR</td></tr><tr><td>23</td><td>Pleural implant</td><td>3.30</td><td>1.90</td><td>−42</td><td>PR</td></tr><tr><td>24</td><td>Mediastinal mass</td><td>7.00</td><td>4.50</td><td>−36</td><td>SD</td></tr><tr><td>25</td><td>Mediastinal mass</td><td>5.60</td><td>1.80</td><td>−68</td><td>PR</td></tr><tr><td>26</td><td>Mediastinal mass</td><td>20.00</td><td>15.00</td><td>−25</td><td>PR</td></tr><tr><td>27</td><td>Mediastinal mass</td><td>4.80</td><td>6.70</td><td>40</td><td>SD</td></tr></table> |
907cb99698f5a340a33dd54fefed33d036eb83b121ea650a6027e301757f7f72.png | complex | <table><tr><td rowspan="2">Protocol</td><td colspan="4">Contig assembly</td><td colspan="4">Scaffolding</td></tr><tr><td>Unamplified</td><td>Phi</td><td>Tre</td><td>Rap</td><td>Unamplified</td><td>Phi</td><td>Tre</td><td>Rap</td></tr><tr><td>Assembly size (bp)</td><td>94 641 187</td><td>94 028 877</td><td>94 541 978</td><td>88 411 985</td><td>96 571 590</td><td>96 849 620</td><td>96 382 191</td><td>96 869 541</td></tr><tr><td>contig number</td><td>13 386</td><td>14 661</td><td>21 721</td><td>34 073</td><td>9415</td><td>8744</td><td>9068</td><td>9247</td></tr><tr><td>contig average (kb)</td><td>7.1</td><td>6.4</td><td>4.4</td><td>2.6</td><td>10.3</td><td>11.1</td><td>10.6</td><td>10.5</td></tr><tr><td>largest contig (kb)</td><td>167.7</td><td>147.8</td><td>116.8</td><td>41.8</td><td>167.7</td><td>187.5</td><td>167.7</td><td>167.7</td></tr><tr><td>N50 (kb)</td><td>16.6</td><td>15.7</td><td>10.8</td><td>4.2</td><td>17.6</td><td>24.1</td><td>20.7</td><td>18.4</td></tr><tr><td>N50 (number)</td><td>1525</td><td>1597</td><td>2109</td><td>5897</td><td>1533</td><td>1067</td><td>1258</td><td>1482</td></tr><tr><td colspan="9">GAGE assessment</td></tr><tr><td>Corrected N50 (kb)</td><td>15.1</td><td>14.1</td><td>9.5</td><td>3.5</td><td>16.8</td><td>22.7</td><td>19.7</td><td>17.7</td></tr><tr><td>Corrected N50 (number)</td><td>1721</td><td>1825</td><td>2431</td><td>7493</td><td>1642</td><td>1141</td><td>1354</td><td>1577</td></tr><tr><td>Missing reference (%)</td><td>0.09</td><td>0.09</td><td>4.43</td><td>0.14</td><td>0.09</td><td>0.09</td><td>0.09</td><td>0.09</td></tr><tr><td>Inversion</td><td>13</td><td>21</td><td>38</td><td>50</td><td>12 (−1)</td><td>17 (+4)</td><td>13</td><td>15 (+2)</td></tr><tr><td>Relocation</td><td>7</td><td>7</td><td>11</td><td>22</td><td>17 (+10)</td><td>13 (+6)</td><td>19 (+12)</td><td>11 (+4)</td></tr><tr><td>Translocation</td><td>12</td><td>16</td><td>37</td><td>30</td><td>12</td><td>12</td><td>12</td><td>11 (−1)</td></tr></table> |
10c6dfc86fa045616aa433dd0b5aad76dc619ac29c4b271c0a4f147eba97128d.png | complex | <table><tr><td>No.</td><td>Location</td><td colspan="2">RT-PCR</td><td colspan="2">Single RT-qPCR</td><td colspan="2">Duplex RT-qPCR</td></tr><tr><td> </td><td> </td><td>ACLSV</td><td>CGRMV</td><td>ACLSV</td><td>CGRMV</td><td>ACLSV</td><td>CGRMV</td></tr><tr><td>1</td><td>Qingdao</td><td> </td><td>+</td><td> </td><td>+</td><td> </td><td>+</td></tr><tr><td>2</td><td>Qingdao</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3</td><td>Qingdao</td><td> </td><td> </td><td>+</td><td> </td><td>+</td><td> </td></tr><tr><td>4</td><td>Qingdao</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>5</td><td>Qingdao</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>6</td><td>Qingdao</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>7</td><td>Qingdao</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>8</td><td>Qingdao</td><td> </td><td> </td><td> </td><td>+</td><td> </td><td>+</td></tr><tr><td>9</td><td>Qingdao</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>10</td><td>Qingdao</td><td>+</td><td> </td><td>+</td><td> </td><td>+</td><td> </td></tr><tr><td>11</td><td>Qingdao</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>12</td><td>Qingdao</td><td> </td><td> </td><td>+</td><td> </td><td>+</td><td> </td></tr><tr><td>13</td><td>Qingdao</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>14</td><td>Shijiazhuang</td><td>+</td><td> </td><td>+</td><td> </td><td>+</td><td> </td></tr><tr><td>15</td><td>Shijiazhuang</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>16</td><td>Shijiazhuang</td><td>+</td><td> </td><td>+</td><td> </td><td>+</td><td> </td></tr><tr><td>17</td><td>Shijiazhuang</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>18</td><td>Shijiazhuang</td><td> </td><td>+</td><td> </td><td>+</td><td> </td><td>+</td></tr><tr><td>19</td><td>Shijiazhuang</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>20</td><td>Shijiazhuang</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>21</td><td>Shijiazhuang</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>22</td><td>Shijiazhuang</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>23</td><td>Taian</td><td>+</td><td> </td><td>+</td><td> </td><td>+</td><td> </td></tr><tr><td>24</td><td>Taian</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>25</td><td>Taian</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>26</td><td>Taian</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>27</td><td>Taian</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>28</td><td>Taian</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>29</td><td>Taian</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>30</td><td>Taian</td><td>+</td><td> </td><td>+</td><td> </td><td>+</td><td> </td></tr><tr><td>31</td><td>Taian</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>32</td><td>Taian</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>33</td><td>Taian</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>34</td><td>Taian</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Total</td><td> </td><td>8</td><td>5</td><td>10</td><td>6</td><td>10</td><td>6</td></tr></table> |
59aa406c8f288761baacf466dabac9c58ae465a97b09cf98ff1b3ab96d086671.png | simple | <table><tr><td>Region</td><td>County</td><td>Number of sites</td><td>Number of patients enrolled</td></tr><tr><td>Global <i>(total)</i></td><td> </td><td>114</td><td>1931</td></tr><tr><td>WEC <i>(total)</i></td><td> </td><td>74</td><td>760</td></tr><tr><td> </td><td>Austria</td><td>3</td><td>18</td></tr><tr><td> </td><td>Canada</td><td>6</td><td>72</td></tr><tr><td> </td><td>France</td><td>8</td><td>82</td></tr><tr><td> </td><td>Germany</td><td>4</td><td>70</td></tr><tr><td> </td><td>Greece</td><td>4</td><td>40</td></tr><tr><td> </td><td>Ireland</td><td>1</td><td>20</td></tr><tr><td> </td><td>Israel</td><td>3</td><td>37</td></tr><tr><td> </td><td>Italy</td><td>6</td><td>99</td></tr><tr><td> </td><td>Netherlands</td><td>1</td><td>25</td></tr><tr><td> </td><td>Norway</td><td>3</td><td>21</td></tr><tr><td> </td><td>Portugal</td><td>6</td><td>93</td></tr><tr><td> </td><td>Spain</td><td>16</td><td>87</td></tr><tr><td> </td><td>Sweden</td><td>4</td><td>25</td></tr><tr><td> </td><td>Switzerland</td><td>2</td><td>27</td></tr><tr><td> </td><td>UK</td><td>7</td><td>44</td></tr><tr><td>CEE <i>(total)</i></td><td> </td><td>20</td><td>532</td></tr><tr><td> </td><td>Czech Republic</td><td>3</td><td>20</td></tr><tr><td> </td><td>Estonia</td><td>3</td><td>99</td></tr><tr><td> </td><td>Romania</td><td>8</td><td>200</td></tr><tr><td> </td><td>Russia</td><td>5</td><td>171</td></tr><tr><td> </td><td>Slovenia</td><td>1</td><td>42</td></tr><tr><td>LA <i>(total)</i></td><td> </td><td>17</td><td>519</td></tr><tr><td> </td><td>Argentina</td><td>3</td><td>101</td></tr><tr><td> </td><td>Brazil</td><td>1</td><td>90</td></tr><tr><td> </td><td>Chile</td><td>1</td><td>50</td></tr><tr><td> </td><td>Columbia</td><td>6</td><td>84</td></tr><tr><td> </td><td>Mexico</td><td>2</td><td>115</td></tr><tr><td> </td><td>Venezuela</td><td>4</td><td>79</td></tr><tr><td>Asia <i>(total)</i></td><td> </td><td>3</td><td>120</td></tr><tr><td> </td><td>China</td><td>3</td><td>120</td></tr></table> |
7ecc356ace59aafec7237246e8ecc4fd07662fc0500bb4807748bb0ad32f3e22.png | simple | <table><tr><td>Characteristic</td><td>Overall<i>n</i>=92 (%)</td><td>Culture methods 41 (%)</td><td>Molecular diagnosis 51 (%)</td></tr><tr><td>Treatment with first-line drug regimen (%)</td><td>92 (100)</td><td>41 (100)</td><td>51 (100)</td></tr><tr><td>Mean days on first-line drug (range) (<i>n</i>=92)</td><td>81 (14–434)</td><td>154 (73–434)</td><td>22 (14–36)</td></tr><tr><td>Mean days until starting MDR-TB treatment using second-line drug (range) (<i>n</i>=92)</td><td>44 (6–85)</td><td>73 (54–102)</td><td>5 (2–6)</td></tr><tr><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>Required surgery (%)</i></td><td>87 (95)</td><td>41 (100)</td><td>46 (90)</td></tr><tr><td> Recovered without need for surgery</td><td>5</td><td>0</td><td>5</td></tr></table> |
500bf9f109dc4bda9efd14682f2185ef58eb6f3fe191f89769c67e157dda186b.png | complex | <table><tr><td><i>Patient</i></td><td colspan="3"><i>JAK2 p.V617F allele burden (%)</i>a</td><td colspan="3"><i>MPL p.W515L allele burden (%)</i></td><td><i>Additional mutations by NGS in DNA from GR (allele burden)</i></td><td><i>HUMARA</i></td></tr><tr><td> </td><td><i>RNA platelets</i></td><td><i>RNA GR</i></td><td><i>DNA GR</i></td><td><i>RNA platelets</i>b</td><td><i>RNA GR</i>b</td><td><i>DNA GR</i>c</td><td> </td><td> </td></tr><tr><td>1</td><td>20</td><td>0</td><td>1.85</td><td>2.16</td><td>0</td><td>0</td><td>ND</td><td>Clonal</td></tr><tr><td>2</td><td>16</td><td>10</td><td>1.8</td><td>12</td><td>33</td><td>Positive</td><td>ND</td><td>NA</td></tr><tr><td>3</td><td>0</td><td> </td><td> </td><td>26</td><td>15</td><td>Positive</td><td>ND</td><td>NA</td></tr><tr><td>4</td><td>0</td><td> </td><td> </td><td>0</td><td> </td><td> </td><td><i>MPL</i> p.Pro222Ser (42.32%)</td><td>Clonal</td></tr><tr><td>5</td><td>0</td><td> </td><td> </td><td>0</td><td> </td><td> </td><td><i>MPL</i> p.Ser204Pro (46.94%)</td><td>Clonal</td></tr><tr><td>6</td><td>0</td><td> </td><td> </td><td>0</td><td> </td><td> </td><td><i>TET2</i> p.Gln958Ter (20.17%)</td><td>Clonal</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td><i>TET2</i> p.Leu1880Pro1 (15.2%)</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td><i>CBL</i> p.Leu380Pro (2.79%)</td><td> </td></tr><tr><td>7</td><td>0</td><td> </td><td> </td><td>0</td><td> </td><td> </td><td><i>MPL</i> p.Ser204Phe (25.69%)</td><td>Clonal</td></tr><tr><td>8</td><td>0</td><td> </td><td> </td><td>0</td><td> </td><td> </td><td><i>MPL</i> p.Ser204Pro (37.45%)</td><td>Clonal</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td><i>MPL</i> p.Arg592Gln (30.56%)</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td><i>SF3B1</i> p.His662Asp (3.44%)</td><td> </td></tr><tr><td>9</td><td>0</td><td> </td><td> </td><td>0</td><td> </td><td> </td><td><i>TET2</i> p.Gln790Ter (20%)</td><td>No clonal</td></tr><tr><td>10</td><td>0</td><td> </td><td> </td><td>0</td><td> </td><td> </td><td><i>TET2</i> p.Ser1848Ter (44.74%)</td><td>NA</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td><i>SH2B3</i> p.Trp364Ter (41.47%)</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td><i>CBL</i> p.Val363Gly (3.69%)</td><td> </td></tr><tr><td>11</td><td>0</td><td> </td><td> </td><td>0</td><td> </td><td> </td><td><i>TET2</i> p.Ala1196Asp (2.41%)</td><td>NA</td></tr></table> |
277411e601ee3ec9bf65911ba060e456b92d82df3d9028b6bc764c27550038eb.png | simple | <table><tr><td>Patient no.</td><td>Age (years)</td><td>Diagnosis</td><td>Stage</td><td>Therapy</td></tr><tr><td>1</td><td>29</td><td>HD, MC</td><td>IIA</td><td>MOPP × 6, Mantle 36 Gy</td></tr><tr><td>2</td><td>28</td><td>HD, NS</td><td>IIB</td><td>MOPP × 4, ABVD × 4, Mantle 20 Gy</td></tr><tr><td>3</td><td>42</td><td>Had</td><td>IIB</td><td>ABVD × 3, Mantle 40 Gy</td></tr><tr><td>4</td><td>38</td><td>HD, MC</td><td>IIA</td><td>MOPP × 6, Mantle 40 Gy</td></tr><tr><td>5</td><td>24</td><td>HD, NS</td><td>IIB</td><td>MOPP × 6, Mantle 40 Gy</td></tr><tr><td>6</td><td>30</td><td>HD, NS</td><td>IIA</td><td>MOPP × 4, ABVD × 4, Mantle 36 Gy</td></tr></table> |
527f3a2fd9e88950326b32cb388836ca798185c4c8be6e17c3a1914803cafcba.png | simple | <table><tr><td>Characteristics</td><td>N (%)</td></tr><tr><td>Low back pain, spine or joint disorders</td><td></td></tr><tr><td>No</td><td>315 (39.6)</td></tr><tr><td>Yes</td><td>481 (60.4)</td></tr><tr><td>Non-ischemic heart disease</td><td></td></tr><tr><td>No</td><td>433 (54.4)</td></tr><tr><td>Yes</td><td>363 (45.6)</td></tr><tr><td>Musculoskeletal disorders</td><td></td></tr><tr><td>No</td><td>501 (62.9)</td></tr><tr><td>Yes</td><td>295 (37.1)</td></tr><tr><td>Neurological disease</td><td></td></tr><tr><td>No</td><td>514 (64.6)</td></tr><tr><td>Yes</td><td>282 (35.4)</td></tr><tr><td>Hematological disease</td><td></td></tr><tr><td>No</td><td>606 (76.1)</td></tr><tr><td>Yes</td><td>190 (23.9)</td></tr><tr><td>Chronic respiratory disease</td><td></td></tr><tr><td>No</td><td>620 (77.9)</td></tr><tr><td>Yes</td><td>176 (22.1)</td></tr><tr><td>Visual impairment</td><td></td></tr><tr><td>No</td><td>623 (78.3)</td></tr><tr><td>Yes</td><td>173 (21.7)</td></tr><tr><td>Infections</td><td></td></tr><tr><td>No</td><td>644 (80.9)</td></tr><tr><td>Yes</td><td>152 (19.1)</td></tr><tr><td>Urology diseases</td><td></td></tr><tr><td>No</td><td>647 (81.3)</td></tr><tr><td>Yes</td><td>149 (18.7)</td></tr><tr><td>Liver, pancreas or biliary disease</td><td></td></tr><tr><td>No</td><td>701 (88.1)</td></tr><tr><td>Yes</td><td>95 (11.9)</td></tr><tr><td>Peripheral vascular</td><td></td></tr><tr><td>No</td><td>778 (97.7)</td></tr><tr><td>Yes</td><td>18 (2.3)</td></tr></table> |
a2425626e1347e7528e748076b8d46767134c078dd1438a6310ca0573714f9c6.png | complex | <table><tr><td rowspan="2">Feature</td><td rowspan="2"><i>F-score</i></td><td colspan="4">Correlation, <i>r</i></td></tr><tr><td>ss_Abs_dSize</td><td>zsEntropy21</td><td>predRSA</td><td>varPredRSA21</td></tr><tr><td>Abs_dSS</td><td>0.73</td><td>0.73</td><td>−0.72</td><td>−0.38</td><td>−0.32</td></tr><tr><td>ss_Abs_dSize</td><td>0.61</td><td> </td><td>−0.50</td><td>−0.28</td><td>−0.31</td></tr><tr><td>zsEntropy21</td><td>0.49</td><td> </td><td> </td><td>0.39</td><td>0.14</td></tr><tr><td>predRSA</td><td>0.47</td><td> </td><td> </td><td> </td><td>0.42</td></tr><tr><td>varPredRSA21</td><td>0.45</td><td> </td><td> </td><td> </td><td> </td></tr></table> |
a047ac80fbdabcb8fcee582a6d5a13c0c072c888902dbf1256d2f55afdf9f20c.png | complex | <table><tr><td></td><td colspan="3">27 April 2007, end of bloom</td><td colspan="3">27 April 2008, full bloom</td><td colspan="3">9 May 2008, end of bloom</td></tr><tr><td></td><td><i>n</i></td><td>mean (<i>μ</i>L)</td><td>std</td><td><i>n</i></td><td>mean (<i>μ</i>L)</td><td>std</td><td><i>n</i></td><td>mean (<i>μ</i>L)</td><td>std</td></tr><tr><td>Site 1</td><td>33</td><td>1.339*</td><td> 0.549</td><td>50</td><td>1.516</td><td> 0.807</td><td>50</td><td>1.162*</td><td> 0.549</td></tr><tr><td>Site 2</td><td>31</td><td>0.936*</td><td> 0.526</td><td>50</td><td>1.422</td><td> 0.772</td><td>50</td><td>0.732*</td><td> 0.568</td></tr><tr><td>Site 3</td><td></td><td></td><td></td><td>49</td><td>1.318</td><td> 0.677</td><td>50</td><td>0.104*</td><td> 0.185</td></tr><tr><td>method</td><td colspan="3"><i>t</i>-test, <i>P</i> = 0.0039</td><td colspan="3">ANOVA, <i>P</i> = 0.4298</td><td colspan="3">Kruskal-Wallis test, <i>P</i> < 0.0001</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.